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ABSTRACT 
COMPARISON OF AN ANKLE-FOOT-ORTHOSIS AND NEUROPROSTHESIS 
DURING LEVEL AND NON-LEVEL WALKING 
FOR INDIVIDUALS POST-STROKE 
 
 
Michelle B. Gunther Gallagher, B.S. 
 
Marquette University, 2011 
This study used gait analysis to compare the efficacy of the two foot drop treatments 
(ankle-foot-orthosis and neuroprosthesis) and to contrast the stimulation control of the two 
different neuroprosthesis sensors during level and non-level ambulation of post-stroke 
individuals. 
Eight subjects completed two gait analysis sessions, once while using a study-provided 
articulated AFO and the other while using a WalkAide. After four weeks of acclimation to the 
device, each subject performed two minute walking trials on a level, inclined and declined 
treadmill. Kinematic and heart rate data were collected for all sessions. Plantar pressure and 
WalkAide tilt, heel loading, and stimulation timing data were collected during WalkAide 
sessions. Temporal parameters, kinematic gait asymmetry (GA), toe clearance, as well as 
WalkAide stimulation reliability (StR) and stimulation timing, were computed from Vicon and 
WalkAide data. Wilcoxon signed rank and Friedman tests were conducted to identify significant 
differences between treatments and amongst treadmill orientations, respectively. 
Significantly greater minimum and mean ankle GA during initial swing was observed 
during AFO versus WalkAide ambulation for all treadmill orientations. Further analysis revealed 
that the ankle range of motion between affected and unaffected limbs was significantly different 
for the AFO, but not the WalkAide. Review of functional assessments indicated that these 
differences in ankle GA during initial swing may be attributed to the rigidity of the AFO, not 
functional gains with the WalkAide.  
Comparison of the two sensor control options yielded mixed results.  More optimal StR 
values were observed during heel sensor-based stimulation by 25% of the post-stroke subjects.  
Changes in StI on non-level surfaces occurred with the tilt sensor, but not the heel sensor. 
However, progressively delayed StI timing from declined to inclined walking with the tilt sensor 
may result in increased ankle plantar flexion during PS, providing beneficial during inclined 
ambulation.  
 
Improved kinematic gait symmetry and StI changes on inclined surfaces with the 
WalkAide may be beneficial for community stroke ambulators on inclined surfaces; however, the 
lower StR and increased stimulating timing variability raise concerns about safety of the 
WalkAide while using tilt sensor controlled stimulation. The WalkAide heel sensor may provide 
a consistent, safer substitute. 
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CHAPTER 1: INTRODUCTION AND MOTIVATION 
It is estimated that 6,400,000 stroke survivors are alive today, and that approximately 
795,000 people experience a new or recurrent stroke each year [1]. A stroke, sometimes referred 
to as a “brain attack”, can have a large impact on a person’s ability to function and participate in 
activities of daily life; stroke is considered the leading cause of serious, long term disability in the 
United States [1]. One area that is often affected by stroke is a person’s mobility. A common gait 
impairment for stroke survivors is the inability to dorsiflex the ankle during the swing phase of 
walking. Without compensation, this impairment causes the foot to drag along the floor (i.e. foot 
drop) during swing. An estimated 20% of stroke survivors suffer from foot drop [2]. This 
impairment limits mobility, increases instability and increases the risk of tripping or falling [3].  
The traditional form of treatment for foot drop is an ankle-foot-orthosis or AFO. The 
AFO holds the ankle in a neutral position during swing, preventing the toe from dragging along 
the ground. However, the AFO may decrease the range of motion at the ankle, so gait pathologies 
may still exist when wearing an AFO. An alternative treatment is a neuroprosthesis that 
electrically stimulates the common peroneal nerve thereby activating the ankle dorsiflexors 
during swing. Since the neuroprosthesis potentially increases ankle range of motion, the use of a 
neuroprosthesis for post-stroke individuals with drop foot is hypothesized to improve gait 
symmetry and efficacy on both level and inclined/declined surfaces when compared to 
ambulation with an AFO. Improvement in symmetry and efficacy, as well as the ability to walk 
on inclined/declined surfaces, enhances a person’s mobility and safety inside and outside the 
home.  
Although neuroprostheses have been available for 10 years, insurance reimbursement for 
neuroprostheses such as the WalkAide is often denied; insurance companies claim that these 
devices are still considered experimental. Research that quantifies the benefits of the 
2 
 
neuroprosthesis over an AFO in terms of improving safety and facilitating community ambulation 
may therefore increase the accessibility of these devices. 
In addition to insurance reimbursement, this research study may provide insight into 
design improvements of neuroprostheses during inclined and declined walking. The WalkAide, 
the neuroprosthesis used in this study, uses an accelerometer to measure the angle of the tibia (i.e. 
tilt sensor). During initial fitting, the tibial angles that correspond to “toe off” and “heel strike” 
during level walking are determined. During subsequent ambulation, the WalkAide initiates 
stimulation to the common peroneal nerve at this “toe off” angle and ceases stimulation when the 
“heel strike” angle is reached [4]. However, as the fitting is performed during ambulation on a 
level surface, changes in these swing event identifiers for inclined and declined surfaces are not 
commonly assessed. In addition to the tilt sensor, clinicians may alternatively program the 
WalkAide using a heel sensor, where stimulation is based on the force under the heel [4]. The 
WalkAide can currently be programmed using either the tilt accelerometer or heel sensor. During 
inclined and declined ambulation, the heel sensor-based programming may be less affected by 
treadmill orientation. Therefore, it may result in a more accurate detection of the swing phase, the 
period in which peroneal nerve stimulation is needed to assist in foot clearance.  
The goals of this study are to compare the gait of individuals with foot drop due to stroke 
during level and non-level walking, while using a WalkAide (Innovative Neurotronics; Austin, 
TX) and an ankle-foot-orthosis (produced by Tom Current CPO, Hanger Prosthetics and 
Orthotics, Milwaukee, WI) and to evaluate the control sensors for peroneal nerve stimulation 
currently used for WalkAide programming. Measures of lower extremity joint kinematics (e.g. 
maximum ankle dorsiflexion during swing) and temporal parameters (e.g. cadence) will be 
calculated from gait analysis data and used to contrast gait symmetry between two treatments for 
level and non-level ambulation. Toe clearance will be determined from gait analysis data and 
used to evaluate treatment efficacy on level and non-level surfaces. WalkAide stimulation 
reliability and stimulation initiation and termination timing will be calculated using gait analysis 
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data and WalkAide tilt sensor and heel sensor data will be compared with stimulation data using 
Matlab; these measures were used for the evaluation of the current control sensors of WalkAide 
stimulation. 
The three primary research hypotheses contrasting treatments and WalkAide sensors are: 
1) The use of a neuroprosthesis for post-stroke individuals with drop foot will:  
a) improve temporal and kinematic gait symmetry on both level and non-level surfaces 
compared to an AFO and  
b) improve treatment efficacy (toe clearance) on both level and non-level surfaces compared 
to an AFO.   
2) Non-level walking will adversely affect the WalkAide tilt sensor-based stimulation reliability 
and timing resulting in:  
a) missed or extraneous stimulations during ambulation on non-level surfaces and 
b) changes in stimulation initiation and termination timing during non-level ambulation. 
3) The use of the WalkAide heel sensor versus tilt sensor for stimulation control will: 
a) improve stimulation reliability during ambulation on non-level and  
b) exhibit more consistent stimulation timing during ambulation on non-level surfaces. 
This investigation will provide quantitative data via gait analysis that may enhance the control of 
neuroprostheses and will help document the efficacy of AFOs and neuroprostheses for treatment 
of foot drop, potentially improving patient access to these devices. 
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CHAPTER 2: BACKGROUND AND LITERATURE REVIEW 
This section introduces background information relevant to the study motivation, 
research questions, project methodology and interpretation of the results of this study. Topics 
include: physiology and statistics on stroke, able-bodied gait, post-stroke gait, treatment of foot 
drop, previous studies investigating neuroprostheses, gait on non-level surfaces, and gait 
symmetry. 
2.1 INTRODUCTION TO STROKE  
2.1.1 Physiology of Stroke  
A stroke, also known as a cerebrovascular accident (CVA), occurs when blood flow to 
the brain is interrupted and brain cells in the immediate area die due to lack of oxygen and 
nutrients (e.g. ischemia). Ischemia leads to brain cell death (infarction) and a fluid filled cavity 
(an infarct) replaces the dead cells. A stroke can be caused by either an occlusion of cerebral 
blood vessels, called an ischemic stroke, or rupture of a cerebral blood vessel, called a 
hemorrhagic stroke [5].  During a hemorrhagic stroke, the blood irritates the brain tissue, causing 
swelling. Additionally the blood flowing into the brain collects into a mass called a hematoma. 
The combination of the swelling and hematoma compresses and displaces brain tissue. For this 
reason, the initial effects of a hemorrhagic stroke may be more severe. However, hemorrhagic 
strokes are less frequent than ischemic strokes, with only 20% of strokes being hemorrhagic [5]. 
Not all cells die immediately.  Many surrounding cells are left in a compromised state and so the 
time between onset and treatment for a stroke is critical in determining the level of disability 
caused by the stroke [5].  
The immediate symptoms of stroke include: sudden onset of numbness or weakness, 
confusion or trouble speaking or understanding speech, difficulty seeing in one or both eyes, 
difficulty walking, dizziness, loss of balance or coordination, and/or severe headache with no 
5 
 
known cause [5]. Although many of these symptoms improve after treatment, the location, 
severity and duration of symptoms before initial treatment determine the patient's long term 
disabilities. Infarction can result in disabilities such as sensory disturbances, language problems, 
emotional issues, thinking and memory problems, and paralysis or motor control problems. Since 
one side of the brain controls the opposite side of the body, neurological complications often arise 
on the opposite side of the body than where the stroke occurred in the brain [5, 6]. 
2.1.2 Stroke Incidence 
Stroke is the third leading cause of death and the leading cause of disability in the United 
States [7].  There are approximately 6.4 million stroke survivors in the U.S., and about 795,000 
people experience a new or recurrent stroke each year [1]. Approximately 10% of stroke 
survivors recover almost completely, 25% recover with minor impairments, 40% experience 
moderate to severe impairments that require special care, 10% require nursing home or long-term 
facility care, and 15% die shortly after the stroke [7]. Physical, occupational, and speech therapy, 
as well as long-term care expenses, cost Americans billions of dollars each year. In 2010, 
Americans paid about $73.7 billion in stroke-related medical costs and disability        
rehabilitation [8].  
Of the disabilities requiring rehabilitation, gait deviations occur in approximately 70% of 
people following a stroke, with up to 86% of patients admitted to rehabilitation unable to 
ambulate independently [2, 9]. Even after therapy, only 50% of stroke survivors manage to walk 
in the community [10] and two-thirds of those do so with limitations (e.g. cannot walk 
independently in a crowded shopping center) [11].  
Many stroke survivors must overcome the challenges of paralysis and motor control 
complications to walk around the house or in the community.  As a result, there are some distinct 
differences between able-bodied ambulation and post-stroke gait. General gait changes in terms 
of temporal and stride parameters, as well as energy cost, have been observed.  
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2.2 ABLE-BODIED GAIT 
 Before examining the gait complications caused by the occurrence of one or more 
strokes, it is necessary to review the gait of able-bodied individuals, particularly the phases of the 
gait cycle, temporal and stride parameters, and lower extremity joint kinematics. 
2.2.1 Phases of the Gait Cycle 
 A gait cycle is defined by the successive recurrence of events; able-bodied gait is 
typically defined by consecutive heel strikes. The gait cycle can be broadly divided into two main 
phases, stance and swing. Stance phase is defined as the period between initial foot contact (heel 
strike) and ipsilateral toe off. For unimpaired ambulators, the stance phase is approximately 62% 
of the gait cycle. The swing phase is defined as the period between ipsilateral toe off and the 
ipsilateral heel strike, when the foot is not in contact with the ground; this phase continues for the 
remaining 38% of the gait cycle. These stance and swing phases can be further divided into 8 
functional phases (Figure 1): stance: initial contact, loading response, mid-stance, terminal stance, 
pre-swing and swing: initial swing, mid-swing, and terminal swing [12, 13]. 
 
Figure 1: Functional phases of the gait cycle (adapted from [14]). 
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 Initial contact, the first 2 % of the gait cycle, is defined by the instant when the foot first 
touches the floor [12, 13]. Although short, this phase is important because joint orientations  
during initial contact have a direct effect on the limb’s loading response. The objective of this 
phase is to position the limb for stance or load-bearing. For unimpaired ambulators, the heel 
contacts the ground first, creating a rocker in which the heel acts as a fulcrum. The heel rocker 
continues into the next phase, loading response [12]. 
 Loading response begins with heel strike and continues until the contralateral foot is 
lifted off the ground (e.g. contralateral toe off); the loading response duration for able-bodied 
individuals is 2-10% of the gait cycle. This phase is considered the first period of double limb 
support [12]. During this period, several key events occur to accomplish three main objectives: 
preservation of progression, shock absorption, and weight bearing stability [12, 13].  As stated 
previously, when the heel first contacts the floor, it acts as a fulcrum, allowing the foot to rotate at 
the ankle. The rapid loading of 60% body weight onto the stance limb creates an external plantar 
flexion torque. The tibialis anterior (dorsiflexor) contracts eccentrically, controlling the foot as it 
is lowered to the ground, preventing foot slap and prolonging heel support.  Both the 
advancement of the tibia and the prolonged heel support preserve forward progression. Another 
benefit of the dorsiflexor muscle activity is shock absorption, since some of the body’s downward 
motion is absorbed by the tibialis anterior as it resists the external plantar flexion torque [12]. 
Knee flexion during this initial loading response provides additional shock absorption, 
transmitting some of the energy to the eccentrically contracting quadriceps. The quadriceps are 
also responsible for weight bearing stability, resisting internal rotation of the tibia, the external 
adduction torque caused by limb loading, and preventing knee buckling (external knee flexion 
torque) [12]. 
 Mid-stance, which occurs during the first half of single limb support (approximately 10-
30% of the gait cycle), begins when the contralateral foot is lifted off the ground and continues 
until the body is aligned over the ipsilateral forefoot. Momentum from the contralateral limb, 
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which has just entered swing, and the forward fall of the body results in passive ankle 
dorsiflexion. This dorsiflexion allows the tibia to rotate over the foot (second rocker), 
contributing to further forward progression. To control the rate of dorsiflexion and stabilize the 
ankle, the soleus (plantar flexor) contracts eccentrically [12]. 
 The latter half of single limb support is referred to as terminal stance phase; it occurs 
from approximately 30- 50% of the gait cycle. For unimpaired ambulators, this phase begins with 
ipsilateral heel rise and ends when the contralateral foot strikes the ground [12]. During terminal 
stance, the body advances beyond the supporting foot. The gastrocnemius and soleus muscles 
contract to stabilize heel rise, allowing the body to roll forward over the forefoot (3rd rocker) [12, 
13]. 
 The final phase of stance is the pre-swing phase which begins with contralateral heel 
strike and ends with ipsilateral toe off (approximately 50-60% of the gait cycle). This is the 
second interval of double limb support.  During this period, weight is transferred to the 
contralateral limb in preparation for ipsilateral swing. The decreased load on the limb results in 
rapid plantar flexion (approximately 20°).  This plantar flexion causes the tibia to rotate 
anteriorly; as the toe is stabilized on the ground, knee flexion results. At the end of pre-swing, the 
tibialis anterior and toe extensor muscles are active in preparation for swing [12]. 
 Initial swing phase (approximately 60-73% of the gait cycle) starts when the foot is lifted 
off the floor (ipsilateral toe off) and ends when the ipsilateral foot is opposite the contralateral 
stance foot [12](Figure 2). The main objective of this phase is toe clearance. To achieve toe 
clearance, the ankle dorsiflexes from its initial 20° plantar flexion to a more neutral position, due 
to tibialis anterior and toe extensor activity. Toe clearance is achieved by both this ankle 
dorsiflexion and knee flexion (nearly 60°) [12, 13]. 
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Figure 2: Functional phases of swing, illustrating both limb orientation at both initiation 
and termination of the respective phase (adapted from [12]).  
 The second phase of swing (mid-swing; approximately 73-87% of the gait cycle) begins 
when the ipsilateral swinging foot is next to the contralateral stance foot, and ends when the 
ipsilateral tibia is vertical  (Figure 2). As the tibia approaches a vertical position, the mass of the 
foot places a greater demand on the ankle, and the activity of the tibialis anterior and extensor 
hallucis longus increase [12].  
 The final phase of the gait cycle (approximately 87-100%) is terminal swing. This phase 
begins when the ipsilateral tibia is vertical and ends when the ipsilateral foot strikes the ground 
(Figure 2). During terminal swing, the limb prepares for initial contact. Pretibial muscle action, 
especially tibialis anterior contraction, increases to counteract the inertia of the swinging leg, 
ensuring that the ankle will be neutrally positioned for subsequent heel contact. The knee extends 
in preparation for this initial contact [12]. 
2.2.2 Temporal and Stride Parameters 
 To evaluate timing of specific events and phase durations in the gait cycle, common 
temporal and stride parameters are used. The primary temporal parameters are cadence, stance 
and swing duration, as well as the duration of single limb and double limb support [14]. Cadence 
is the number of steps taken per unit time (steps/minute). As stated previously, for able-bodied 
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individuals, stance duration is approximately 62% of the gait cycle, while swing phase accounts 
for the remaining 38% [12-14]. These percentages and relative phase durations vary between 
individuals and with velocity [12].   
 The stance phase consists of two periods of double limb support, separated by a period of 
single limb support; swing phase occurs during single limb support, as shown in Figure 3. Single 
limb support defines the period in which only one limb is in contact with the ground; during 
double limb support, both feet are in contact with the ground. For normal, able-bodied gait, the 
first 12% of the gait cycle, from ipsilateral initial contact to contralateral toe off (loading 
response), defines the initial period of double limb support. This is followed by single limb 
support over the subsequent 38% of the gait cycle until contralateral heel strike (mid- and 
terminal stance). Late stance phase includes a second period of double limb support (50-62% of 
the gait cycle), from contralateral heel strike through ipsilateral toe off (pre-swing).  The final 
single limb support period spans the entire swing phase (initial, mid-, and terminal swing), from 
ipsilateral toe-off through ipsilateral heel strike [12, 14]. 
 
Figure 3: Temporal (stance, swing, single and double support duration) and stride 
parameters of gait (adapted from [14]). 
 The most common stride parameters examined during gait are step length, stride length, 
and velocity.  Step length refers to the distance between heel strike of one limb and heel strike of 
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the contralateral limb, while stride length is the distance between subsequent heel strikes of the 
same limb (Figure 3). Velocity is defined as the distance traveled per period of time 
(meters/second) [12, 14]. 
2.2.3 Kinematic Parameters 
 Gait kinematics describe the movement of the lower extremities during walking; these 
kinematic measures are typically presented in terms of lower extremity joint (i.e. hip, knee and 
ankle) angles in the three respective planes of motion. During gait, the largest ranges  of motion 
are observed in the sagittal plane. Therefore only sagittal plane kinematics are reviewed in this 
section.  
 
Figure 4: Sagittal plane motion of the hip (top), knee (middle) and ankle (bottom) during 
level walking for able-bodied subjects (adapted from [12]). 
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 During able-bodied gait, each lower extremity joint displays a characteristic wave-form 
in the sagittal plane, as seen in Figure 4. Joint transitions occur between periods of flexion and 
extension throughout the gait cycle [14].  
 The normal range of motion of the hip during self-selected walking is 40°. At heel strike, 
the hip is flexed about 30°. The hip extends until the contralateral foot contacts the ground. As 
body weight is transferred to the contralateral limb during pre-swing, the ipsilateral hip then 
flexes in preparation for swing. Throughout swing the hip continues to flex, until terminal swing 
when the ipsilateral hip extensor muscles decelerate the limb in preparation for weight acceptance 
[12, 14]. 
 As seen in Figure 4, the knee has the largest range of motion of the lower extremity joints 
(approximately 60°), and displays two periods of flexion. The initial knee flexion period occurs 
during early stance, with peak knee flexion (20°) occurring at the transition between loading 
response and mid-stance; this initial knee flexion reflects shock absorption that aids weight 
acceptance.  During single limb support, the knee slowly extends to approximately 5° flexion 
during terminal stance. Knee flexion then rapidly increases following contralateral heel strike. 
Maximum knee flexion (approximately 60°) occurs during initial swing, allowing the limb to 
shorten and facilitate toe clearance. The combination of the inertial forces of the shank/foot and 
activation of the quadriceps muscles then results in rapid knee extension. Full knee extension is 
achieved just prior to heel strike [12, 14]. 
 In contrast, sagittal plane motion of the ankle includes four inflection periods which 
relate to the three ankle rockers; ankle range of motion is approximately 25°.  During weight 
acceptance, the neutral position of the ankle allows the heel contact with the floor. The foot uses 
the heel as a fulcrum, rotating to achieve foot flat (heel rocker). To provide both shock absorption 
and deceleration of the tibia, the ankle plantar flexes about 5°. After the forefoot contacts the 
floor, the tibia rotates about the ankle (ankle rocker), resulting in passive dorsiflexion. 
Dorsiflexion continues through single limb support (maximum dorsiflexion of approximately 
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10°). After contralateral heel strike, the center of mass of the body is over the metatarsal heads 
causing the ipsilateral heel to rise. The foot then rotates over the metatarsal-phalangeal joint 
(forefoot rocker), transitioning from 10° dorsiflexion to 15° plantar flexion.  Finally, during 
swing the ankle rapidly dorsiflexes to provide foot and toe clearance. At the end of swing, the 
ankle is in a neutral position in preparation for heel strike [12, 14]. 
2.2.4 Ankle Muscle Activation 
 The major muscles controlling ankle motion are the dorsiflexors (tibialis anterior, 
extensor digitorum longus and extensor hallucis longus) and plantar flexors (soleus and 
gastrocnemius). Although the tibialis anterior, extensor digitorum longus and extensor hallucis 
longus all dorsiflex the ankle, the tibialis anterior is the primary dorsiflexor (60% of overall 
dorsiflexor muscle mass). The dorsiflexors are active during both swing and stance, in a biphasic 
fashion, with peak activation during initial swing (toe clearance) and loading response (prevent 
foot slap), as seen in Figure 5. In contrast, the plantar flexors are active during stance only, 
controlling the forward motion of the tibia via eccentric contraction and providing push off during 
mid- to terminal stance via concentric contraction [12]. 
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Figure 5: Activation of the ankle muscles during normal walking (adapted from [12]). 
2.3 POST-STROKE GAIT 
2.3.1 General Changes in Gait  
Depending on the location and severity, a stroke may cause hemiparesis which results in 
the weakness and loss of some function on one side of the body, or hemiplegia which results in 
total paralysis of an arm, leg, and trunk on one side of the body. Hemiparesis and hemiplegia can 
affect an individual’s gait. There is large inter-individual variability in temporal, kinematic and 
kinetic parameters of gait for post-stroke individuals [15] due to variations in the site, size, and 
type of lesion [9], as well as the time elapsed since the stroke [9, 16]. Without treatment, gait 
pathologies may contribute to reduced physical activity, impaired mental health, falls, fear of 
falling, frailty, and loss of independence [13]. 
2.3.2 Temporal and Stride Parameters  
Many gait deviations following stroke result from the inability to generate muscle 
contractions [13], the inability to coordinate muscle contractions [13], and spasticity and joint 
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contractures that restrict joint mobility [17]. Studies have shown that post-stroke individuals 
generally have slower walking speeds [17-22] and reduced cadence [18, 21, 22]. In addition to 
decreases in velocity and cadence, post-stroke individuals have shorter stride and step length [ 13, 
16, 21, 22], spend extended time in double limb support, and exhibit decreased step duration [16, 
18, 21, 23] on the affected side. Due to muscle weakness and poor balance of the affected side, 
the swing time of the paretic (i.e. affected) limb is typically prolonged, with the non-paretic (i.e. 
unaffected) limb exhibiting prolonged stance duration and single limb support duration with 
respect to the paretic limb [13]. Post-stroke patients also require more energy to ambulate the 
same distance when compared to age-matched, healthy subjects [24-25]. The differences in step 
length, swing time, muscle strength, and range of motion between the affected and unaffected 
limbs result in an asymmetric gait pattern [16, 20] and increased energy consumption [26]. 
2.3.3 Gait Kinematics and Foot Drop 
In addition to temporal gait parameters, changes in lower extremity joint kinematics are 
also observed in post-stroke individuals.  Post-stroke individuals walking at slow, medium and 
fast speeds exhibited decreased range of motion of the affected hip, knee and ankle compared to 
the unaffected limb [23]. Specific changes in joint kinematics were dependent on muscle 
weakness and/or spasticity and joint contractures specific to the individual. Kinematic changes 
included: increased/reduced hip flexion at initial contact [27], knee hyperextension during stance 
[27-28], increased plantar flexion at initial contact (foot flat) [27-29], reduced ankle plantar 
flexion at toe off [29], reduced dorsiflexion or continuous ankle plantar flexion during swing [28-
29], and reduced knee flexion during swing [27-29].   
One of the more common changes in joint kinematics during gait for individuals post-
stroke is foot drop (the inability to dorsiflex the ankle during the swing phase of walking). 
Without compensation, this impairment causes the foot to drag along the floor. There are three 
common compensatory gait patterns for post-stroke individuals with foot drop:  1)  steppage gait, 
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2) vaulting, and/or 3) circumduction. Increasing knee and hip flexion to facilitate toe clearance is 
effective when there is sufficient muscle strength on the affected side. Insufficient hip and/or 
knee muscle strength may cause the individual to vault or circumduct the lower limb to assist 
contralateral foot clearance during swing. These compensatory gait mechanisms result in joint 
kinematic asymmetry and require more energy for each step. Additionally, these compensatory 
methods may not consistently yield sufficient toe clearance, and may increase the risk of falling 
[30, 31]. Therefore, patients with foot drop require some form of treatment to improve foot 
clearance and decrease their risk of falling. 
2.4 TREATMENTS FOR POST-STROKE INDIVIDUALS WITH FOOT DROP 
2.4.1 Ankle-Foot-Orthosis 
Ankle-foot-orthoses (AFOs) are among the most commonly prescribed lower extremity 
limb orthoses [31] and are the primary treatment for foot drop [32]. Thermoplastic AFOs are 
more common than metal AFOs due to decreased mass, lower cost, and increased durability. 
These AFOs incorporate a three-point loading configuration to encourage dorsiflexion and 
minimize plantar flexion during swing (Figure 6). This is accomplished with either a solid (fixed 
ankle) or articulated (ankle motion permitted) AFO.  
 
Figure 6: Three-point force system for an AFO [31] 
Forces R1 and R2 are provided by the foot shell and proximal strap; force R3is provided by the shoe and/or 
anterior strap. 
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An articulated AFO (Figure 7) may also incorporate dorsiflexion assist bands or springs, 
as well as plantar flexor stops. Although the articulated AFOs permit greater movement of the 
ankle than a solid AFO, they may still limit the full range of ankle motion [31]. 
 
Figure 7: Sample thermoplastic articulated AFO [31]. 
2.4.2 Neuroprostheses 
In 1961, Liberson and colleagues proposed an alternative treatment for foot drop, a Drop 
Foot Stimulator [33], or neuroprosthesis that stimulates the common peroneal nerve to activate 
the anterior tibialis and dorsiflex the ankle. This technology has since been further developed and 
today there are three FDA approved neuroprostheses: the Odstock Dropped Foot Stimulator 
(Department of Medical Physics and Biomedical Engineering, Salisbury District Hospital, 
Salisbury, UK), the NESS L300 (Bioness Inc.,  Valencia, CA), and the WalkAide (Hanger 
Orthopedic Group/Innovative Neurotronics, Bethesda, MD) [34].   
2.4.3 The WalkAide 
Both the Odstock Dropped Foot Stimulator and the NESS L300 incorporate a foot switch 
placed in the shoe to determine the stimulation periods for peroneal nerve stimulation during gait 
[34].  In contrast, the WalkAide uses an accelerometer to measure the angle of the tibia of the 
affected limb (e.g.  tilt sensor) and define the stimulation timing [4]. During initial fitting, the 
clinician uses the WalkLink, a WalkAide programming interface, to manually initiate peroneal 
nerve stimulation as the patient is walking. The manual stimulation allows the patient to walk 
18 
 
with the WalkAide before it has been programmed and allows the clinician to acquire tibial angle 
data from the accelerometer.  (Heel sensor data from the optional WalkAide heel sensor placed in 
the shoe can be similarly acquired.)  This manual stimulation allows the clinician to determine the 
tibial angles that correspond to “toe off” and “heel strike” during level walking. During 
subsequent ambulation, the stimulation of the common peroneal nerve is initiated at this “toe off” 
angle and ceases when the “heel strike” angle is reached [4]. 
2.5 INVESTIGATION OF POST-STROKE GAIT WITH NEUROPROSTHESES 
Prior studies of various neuroprostheses for the treatment of foot drop have shown that 
these devices improve gait. Improvements are most often quantified in terms of increased walking 
speed and stride length [32, 35-39], as well as decreased physiological cost index (PCI) which 
reflects energy consumption and effort [37- 38]. Although walking speed, stride length and 
energy are important measurements for rehabilitation, they are limited in their ability to identify 
functional changes, such as increased joint motion, which may facilitate additional activities of 
daily living (e.g. stair ascent). Therefore studies have also investigated changes in functional 
ambulation scale scores [40], gait asymmetry index (i.e. comparison of affected and unaffected 
swing times) [38-39], and stride time variability [38-39]. Most studies have examined changes 
before and during use of the neuroprosthesis, with only two studies comparing gait parameters 
between the neuroprosthesis and the traditional AFO treatment [39-40].  
Scheffer et al. compared functional ambulation scale scores during ambulation with no 
treatment, neuroprosthetic treatment (Odstock Dropped-Foot Stimulator) and a previously issued 
articulated AFO (with dorsiflexion assist and plantar flexion stop) for 14 chronic post-stroke 
individuals [40]. Although significant differences in functional ambulation scores were observed 
between no treatment versus each treatment, differences in scores between the two treatments 
were not significant.  However, subjects in this study had only two days to acclimate to the 
neuroprosthesis prior to evaluation.  In a similar study, Ring et al. noted that 8 weeks (versus 4 
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weeks) acclimation was necessary to observe significant differences in stride time, gait symmetry, 
and swing time variability between neuroprosthesis and AFO treatments; no significant 
differences in walking speed were observed for these 15 chronic post-stroke subjects, regardless 
of acclimation period [39].  Given sufficient acclimation, Ring et al. concluded that a 
neuroprosthesis can enhance balance control and manage foot drop more effectively than an AFO 
for chronic post-stroke individuals with foot drop [39]. 
2.6 LIMITATIONS OF PREVIOUS POST-STROKE GAIT STUDIES 
2.6.1 Walking Surface 
One limitation of prior neuroprosthesis studies is that only level walking trials were 
conducted, although non-level walking surfaces are routinely encountered during household and 
community ambulation. Gait kinematics and kinetics for unimpaired ambulators have been found 
to vary during ambulation on inclined (5o, 8o, 10o) and declined surfaces (5o, 8o, 10o), as shown in 
Figure 8 [41]. Significant increases in hip flexion at heel strike, knee flexion at heel strike and 
during early stance, ankle dorsiflexion at heel strike and during stance, and plantar flexion during 
toe off were observed for inclined walking trials. Significant increases in peak knee flexion and 
decreases in minimum knee flexion during stance, increases in maximum knee flexion during 
swing, and increases in ankle dorsiflexion during stance were observed for declined walking 
trials.  
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Figure 8: Lower extremity sagittal plane joint kinematics of normal subjects during 
walking on non-level surfaces (adapted from [41]). 
Accommodation to non-level walking surfaces may be problematic for individuals post-
stroke with limitations in lower extremity range of motion; these non-level surfaces may be 
particularly problematic for post-stroke individuals with foot drop who have difficulty with foot 
clearance and are at risk of falling.  For post-stroke individuals using the WalkAide, these non-
level surfaces may affect the angle of the tibia at heel strike and toe off, adversely affecting 
neuroprosthesis stimulation. 
2.6.2 Measurement Parameters  
Previous studies involving neuroprostheses to treat post-stroke individuals with foot drop 
have focused on walking speed and PCI as primary functional measures. However, measures such 
as walking speed provide limited insight into the control of walking. Additionally, walking speed 
is only one measure of clinical relevance regarding rehabilitation progress. For example, 
rehabilitative functional goals may also include symmetric weight bearing and improved weight 
transfer between the affected and unaffected limbs during gait [42]. Further quantification of gait 
has potential clinical value and may provide direction for future care or therapy. 
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2.6.2.1 Significance of Gait Symmetry 
Quantifying gait symmetry may provide enhanced understanding of rehabilitation 
progress and functional recovery. Kim et al. have shown that normal gait is symmetric both 
spatially and temporally [42]. Therefore, if the goal of rehabilitation programs is continual 
progress toward normal ambulation, then gait symmetry is a more descriptive clinical functional 
measure than walking speed or PCI. Gait symmetry is also linked to energy expenditure with 
greater symmetry associated with greater energy efficiency [26]. Patterson et al. have suggested 
that the increased energy cost during ambulation for post-stroke individuals can be attributed to 
their asymmetric gait [26]. Gait asymmetry may also reflect balance instability, risk of 
musculoskeletal injury to the unaffected lower limb, and loss of bone mass in the affected lower 
limb [43]. Comparison of gait asymmetry may therefore assist in differentiating the efficacy of 
various treatment methods.  
2.6.2.2 Measures of Gait Symmetry 
Gait symmetry investigations have focused on temporal and stride parameters. Both a 
symmetry ratio (SR) and a symmetry index (SI) have been proposed as measures with which to 
assess symmetry during gait. The SR is defined as: 
𝑆𝑅 =  𝑠𝑦𝑚𝑚𝑒𝑡𝑟𝑦 𝑟𝑎𝑡𝑖𝑜 = 𝑉𝑎𝑓𝑓𝑒𝑐𝑡𝑒𝑑
𝑉𝑢𝑛𝑎𝑓𝑓𝑒𝑐𝑡𝑒𝑑
  (Eq 1) 
where vaffected is the value of the respective gait parameter on the affected side and vunaffected is the 
value of the gait parameter on the unaffected side. Patterson et al. recommended use of the SR for 
standardization of temporal and stride parameters, such as step length, swing and stance times and 
double limb support time [43]. However, for kinematic parameters, the SR does not account for 
sign changes in joint angle (e.g. flexion versus extension).  The SR magnitude also fails to 
account for differences in range of motion that may occur between subjects or joints. 
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 An alternative measure of symmetry, the SI, is defined as: 
𝑆𝐼 = 𝑠𝑦𝑚𝑚𝑒𝑡𝑟𝑦 𝑖𝑛𝑑𝑒𝑥 = 𝑉𝑎𝑓𝑓𝑒𝑐𝑡𝑒𝑑−𝑉𝑢𝑛𝑎𝑓𝑓𝑒𝑐𝑡𝑒𝑑
0.5 (𝑉𝑎𝑓𝑓𝑒𝑐𝑡𝑒𝑑+𝑉𝑢𝑛𝑎𝑓𝑓𝑒𝑐𝑡𝑒𝑑)𝑋 100    (Eq 2) 
where vaffected is the value of the respective gait parameter on the affected side and vunaffected is the 
value of the respective gait parameter on the unaffected side. The SI has also been used to 
examine temporal and stride parameter symmetry; and to investigate neuroprosthesis treatment of 
post-stroke subjects with drop foot [38]. However, like the SR, the SI fails to capture sign 
differences in joint kinematics. While normalized to facilitate potential inter-subject and/or inter-
joint comparisons, both the unaffected and affected limb parameters are incorporated into the 
normalization. As such, the SI may be more appropriate for symmetry investigations of able-
bodied individuals. Even for able-bodied subjects, the SI does not provide sufficient resolution to 
examine small inter-limb differences and cannot differentiate the performance of each limb with 
large versus modest asymmetries [44]. 
 Other symmetry measures used in gait analysis of able-bodied and post-stroke subjects 
(see Table 1) include: the non-normalized arithmetic difference between parameters, a 
logarithmic measure of gait asymmetry (GA), symmetry angle (SA), and two measures that 
include comparison of constrained versus free joint data (via joint bracing) with able-bodied data 
[symmetry rejoins of deviation (SROD) and individual rejoins of deviation (IROD)]. None of 
these measures, however, appear viable for symmetry investigations of treatment options of 
pathologic populations, kinematic analysis with potential variations in sign, and scaling or 
normalization to facilitate inter-subject and inter-joint comparison. 
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Table 1: Review of measures used to quantify gait symmetry 
Reference Symmetry Measure Population 
Parameters 
Investigated 
Brouwer et. 
al.,2009 [45] Vaffected-Vunaffected Post-stroke 
Spatiotemporal 
joint angles 
and ground 
reaction forces 
Patterson et. 
al., 2009 [43] 
SR =Vaffected /Vunaffected;                                                                                      
SI=( Vaffected- Vunaffected)/0.5(Vaffected +Vunaffected) X 100%; 
GA=|100 X [ln(Vaffected/ Vunaffected)]|;                                  
SA=[(450-arctan(Vaffected/ Vunaffected))x 100%]/90 
Post-stroke 
and 
able-bodied 
Spatiotemporal 
Robinson et. 
al., 1987 [46] SI=( Vaffected- Vunaffected)/0.5(Vaffected+ Vunaffected) X 100% Able-bodied 
Ground 
reaction forces 
Patterson et. 
al., 2008 [26] SR = Vaffected/ Vunaffected                                                                                       Post-stroke Spatiotemporal 
Herzog et. al. 
1989 [47] SI=( Vaffected- Vunaffected)/0.5(Vaffected+ Vunaffected) X 100% Able-bodied 
Ground 
reaction forces 
Shorter et. al., 
2008 [48] SROD and IROD Able-bodied Joint angles 
SR=symmetry ratio, SI= symmetry index, GA=gait asymmetry, SA=symmetry angle, 
SROD=symmetry regions of deviation, IROD=individual regions of deviation. 
2.7 SUMMARY 
 Stroke, the leading cause of long term disability in the United States, affects 6.4 million 
people in the United States alone, with approximately 795,000 new strokes each year. Stroke can 
have a large affect on the ambulation of individuals, with gait deviations occurring in 
approximately 70% of the post-stroke population.   
 Changes in gait are often caused by the inability to generate muscle contractions, the 
inability to coordinate muscle contractions, and spasticity and joint contractures that restrict joint 
mobility. Foot drop is a neurological problem in which the ability to dorsiflex the ankle is 
restricted or diminished. Two treatments currently used for foot drop are an AFO, a plastic brace 
which restricts the range of motion around the ankle, and a neuroprosthesis which electronically 
stimulates the nerve causing ankle dorsiflexion. 
 Prior research has shown that both AFO and neuroprostheses can improve gait in terms of 
walking speed, energy consumption, spatiotemporal gait symmetry and functional ambulation 
scale scores. This research, however, has been limited to ambulation on level surfaces and 
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investigation of spatiotemporal measures. More thorough analysis of ambulation on level and 
non-level surfaces, including measures of kinematic symmetry, may further quantify treatment 
efficacy.   
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CHAPTER 3: METHODS AND DATA PROCESSING 
Due to limitations in prior research involving neuroprostheses to treat foot drop in post 
stroke individuals, the goal of this research study was to conduct more thorough analyses of post-
stroke ambulation, contrasting AFO and neuroprosthesis treatments, on level and non-level 
surfaces. The specific hypotheses of the study were to determine if 1) use of a neuroprosthesis for 
post-stroke individuals with foot drop improves temporal and kinematic gait symmetry and 
treatment efficacy on level and inclined/declined surfaces when compared to an AFO, 2) non-
level surfaces cause missed or extraneous stimulations or changes in the stimulation timing while 
using the WalkAide tilt sensor, and 3) use of heel sensor-based versus tilt sensor-based 
stimulation leads to improved stimulation reliability and more consistent stimulation timing  in 
neuroprosthetic control for ambulation over non-level surfaces.  To achieve these research 
objectives, gait analysis trials were conducted.  Specific measures of interest included: temporal 
parameters, gait symmetry and asymmetry, and toe clearance (objective 1), as well as stimulation 
reliability and timing (objective 2 and 3). 
This chapter summarizes these gait analysis procedures, including subject selection, 
experimental groups and treatments, and gait analysis protocol, as well as the data processing 
procedures for kinematic, gait parameter, WalkAide , and F-scan data.  The statistical analysis 
procedures are also summarized.  
3.1 SUBJECT SELECTION 
3.1.1 Inclusion and Exclusion Criteria 
Eight post-stroke individuals with the ability to actively ambulate within the community 
were selected from the greater Milwaukee area for participation in this study. This study was 
approved by the Institutional Review Boards (IRB) of Marquette University and the Medical 
College of Wisconsin. The following criteria were used to determine participant eligibility:  
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Inclusion Criteria: 
• Hemiplegia due to stroke  
• At least 6 months post stroke 
• Passive ankle range of motion to neutral position 
• No prior use of a neuroprosthesis other than evaluation or trial use 
• Capable of walking 30 meters without stopping to rest and without the use of a cane or 
walker 
Exclusion Criteria: 
• Lower limb Botox injection within the past 6 months 
• History of falls in the last 3 months while walking on level ground 
• Pacemaker, defibrillator, or any electrical or metallic implant 
• Cognitive disability due to stroke 
• Prior history of seizures 
• Peripheral nerve disease or Guillian Barre syndrome 
• Fractures, dislocations or cancers of the affected lower limb 
• Pregnancy 
3.1.2 Subject Recruitment 
Recruitment took place through fliers distributed at stroke support groups and in clinics1, 
referrals by physicians2 and professors3, and by word of mouth via research subjects and 
clinicians4 directly involved in the study.  Referrals and individuals recruited by word of mouth 
gave written or verbal permission to forward their contact information to research staff. Interested 
parties were then contacted by phone, screened to determine if he or she met the inclusion 
criteria, and given a more detailed explanation of the study and study procedures. Informed 
consent was solicited prior to participation in any research activities. 
 
                                                     
1 Department of Physical Medicine and Rehabilitation at Froedtert Memorial Lutheran Hospital, Sacred Heart 
Rehabilitation Institute at Columbia St. Mary's Hospital, Speech Pathology Department at Marquette University, 
Therapy Services at the Milwaukee Center for Independence. 
2 John McGuire, MD, Physical Medicine & Rehabilitation, Medical College of Wisconsin. 
3Tina Stoeckmann, Ph.D. and Sheila Schindler-Ivens, Ph.D., Physical Therapy, Marquette University.  
4 Tom Current ,CPO (Hanger Prosthetics & Orthotics) and Craig Peters, DPT (Innovative Neurotronics) 
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3.2 EXPERIMENTAL GROUPS AND TREATMENTS 
The study involved testing two treatment options for foot drop, a study provided AFO 
and a WalkAide neuroprosthesis. The treatment order was random, e.g. subjects were randomly 
assigned to an experimental group (Group 1 was tested with the AFO first; Group 2 was tested 
with the WalkAide first). 
The first research visit for subjects in Group 1 (AFO, then WalkAide) consisted of 
casting and fitting the AFO by the study orthotist (Tom Current, CPO). After acclimating to the 
study-provided AFO for four weeks, the subject completed gait analysis in that AFO. Within a 
week of this gait session, the subject was fitted with the WalkAide by the study physical therapist 
or PT (Craig Peters, DPT). After four weeks of acclimating to the WalkAide, a second gait 
analysis session was completed using the WalkAide.  
The first research visit for Group 2 (WalkAide, then AFO) subjects was the WalkAide 
fitting by the PT. During the next four weeks, the subject acclimated to the WalkAide and met 
with the orthotist for AFO casting. At the end of this period, the subject completed gait analysis 
with the WalkAide. Within a week of this gait session, the subject visited the orthotist for AFO 
fitting. After four weeks of acclimating to the study-provided AFO, the subject completed their 
final gait analysis session in the AFO.  
3.2.1 AFO Fabrication and Fitting  
The subject was casted for AFO fabrication by the study orthotist. The orthotist wrapped 
fiberglass casting material around the subject’s affected lower leg from just distal to the knee 
down to the subject’s toes. Before the casting material hardened, the leg was positioned such that 
the ankle was neutral (90o); the ankle was held in this position until the cast set. This cast served 
as a negative mold of the subject’s affected lower leg. The orthotist then filled this negative mold 
with plaster to produce a positive mold of the subject’s lower leg. A thermoplastic (3/16 inch 
28 
 
polypropylene) articulated AFO was vacuum-formed over the positive mold.  Ankle joints 
(Tamarack Flexure Joints, Model #740-M, Becker Orthopedic, Troy, MI) and a plantar flexion 
stop (TC Ankle Stop, Model #101TCA,Creative Adaptations, Milton, NH) were positioned on the 
articulated thermoplastic AFO, see Figure 9. The plantar flexion stop was set so that the tibia was 
vertical while standing.  The foot plate was trimmed at the level of the toe sulcus; the proximal 
AFO trimline was no less than 2 cm inferior to the fibular head and no greater than the level of 
the fibular head.  
After fabrication, the subject met with the orthotist for a second time. During this 
meeting, the subject ambulated within parallel bars with the study-provided AFO. Adjustments 
were made to the AFO as needed to improve comfort.  
 
Figure 9: Study-provided AFO. 
3.2.2 WalkAide Fitting and Programming 
At the first visit for the WalkAide, the PT fit and programmed the WalkAide using the 
Walklink and WalkAnalysis software. Using a peripheral nerve stimulator (Innovative 
Neurotronics, Bethesda, MD; Figure 10), the PT stimulated the peroneal nerve at locations on the 
proximal leg, noting the resultant ankle dorsiflexion. The WalkAide electrodes were positioned 
over the stimulation site that resulted in ‘balanced’ eversion and dorsiflexion. The subject then 
walked within the parallel bars while the PT manually stimulated the peroneal nerve using the 
WalkLink. The manual stimulation allowed the subject to walk with the WalkAide before it was 
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programmed, facilitating tibial angle and heel sensor data acquisition from the WalkAide prior to 
programming. With these data, the PT determined the tibial angle thresholds for stimulation 
initiation/termination; these threshold angles were adjusted as needed to optimize gait. Each 
subject was instructed to slowly acclimate to the WalkAide, ramping up from 2 to 8 hours of use 
per day over a 1 week acclimation period.  The subject then returned to the Hanger office for 
potential adjustments; further WalkAide adjustment visits were scheduled as needed.  
 
Figure 10: Testing of the common peroneal nerve (left) using the peroneal nerve stimulator 
(right), adapted from [4]. 
3.2.3 Functional Assessment 
  To quantify subject functionality and level of impairment, several common clinical 
assessments [Fugl-Meyer, Modified Ashworth Scale, strength and range of motion (ROM)] were 
performed.  For Fugl-Meyer assessment, subjects were asked to complete five tasks (Appendix 
A) and were scored based on their level of completion of each task [49]. Subjects’ Achilles and 
patellar tendon reflexes were also assessed.  Spasticity of the affected lower leg was evaluated 
using the five point Modified Ashworth Scale (Table 2).  
Manual Muscle Testing (MMT) was completed at the hip, knee and ankle joints to 
evaluate muscle strength using a five-point scale, see Table 3. Flexion and extension strength 
were tested at the hip and knee joints. Plantar flexion, dorsiflexion, eversion and inversion 
strength were tested at the ankle joint.  
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Table 2: Modified Ashworth Scale [adapted from 50] 
Muscle Tone Score 
No increase in muscle tone 0 
Slight increase in  tone with a catch and release  1 
Minimal resistance at the end of the ROM 1+ 
Slight increase in tone with catch and minimal resistance 
through range following catch 
2 
More marked increase in tone through ROM 3 
Considerable increase in tone with passive movement 
difficult 
4 
Affected part rigid 5 
 
 
Table 3: Criteria for MMT Grades [adapted from 50] 
Muscle Contraction 
Against 
Gravity 
Range of motion 
completed Resistance added 
MMT 
Grade 
No palpable muscle contraction No None None 0 
Muscle contraction is palpable No None None 1 
Contraction produces movement No Partial to Full None 2 
Contraction produces movement Yes Partial None 3- 
Contraction produces movement Yes Full None 3 
Contraction produces movement Yes Full Minimal 3+ 
Contraction produces movement Yes Full 
Minimal to 
Moderate 
4- 
Contraction produces movement Yes Full Moderate 4 
Contraction produces movement Yes Full Almost Maximum 4+ 
Contraction produces movement Yes Full Maximum 5 
 
The  flexion and extension ROM was assessed at the hip and knee joints. Plantar flexion, 
dorsiflexion, eversion and inversion ROM of the ankle and subtalar joints were also assessed 
using a goniometer (see Table 4).  
The Modified Ashworth, strength and ROM measurements were evaluated at the end of 
the subject’s first research visit and at the beginning of each gait analysis session.  
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Table 4: Goniometer Placement for ROM Measurements (adapted from [50]) 
Joint Measurement 
Center of goniometer 
landmark 
Stationary arm 
landmark 
Moveable arm 
landmark 
Hip Flexion/   
Extension 
Greater trochanter Lateral pelvis midline Lateral epicondyle 
of the femur 
Knee Flexion/   
Extension 
Lateral epicondyle of the 
femur 
Greater trochanter Lateral malleolus 
Ankle Plantar flexion/ 
Dorsiflexion 
Approximately 1.5 cm 
inferior to the lateral 
malleolus 
Fibula head Longitudinal axis 
of the 5th 
metatarsal 
Ankle Inversion/  
Eversion 
Midpoint between medial 
and lateral malleolus 
Tibial crest 2nd metatarsal 
 
3.3 GAIT ANALYSIS PROTOCOL 
Gait analysis sessions were conducted at the Motion Analysis Laboratory (MAL) in the 
Department of Orthopedic Surgery at the Medical College of Wisconsin. This section reviews the 
test protocol for these sessions including reflective marker placement for kinematic analysis, 
subject instrumentation for kinematic, plantar pressure, EMG, and physiologic data monitoring, 
and test protocol during dynamic and static trials. Details regarding the specific equipment and 
data acquisition are outlined in Table 5.  
Table 5: Equipment overview 
Data System  Vendor Sampling 
Rate (Hz) 
Lower extremity 
kinematic data 
VICON 524 Motion 
Analysis  
VICON Motion Systems Inc.; 
Lake Forest, CA 
120 
Tibialis Anterior EMG 
data  
MA300 EMG  Motion Lab Systems, Inc.; Baton 
Rouge, LA 
1800 
Physiologic monitoring S610 Polar heart rate 
monitor  
Polar Electro Inc.; Lake Success, 
NY 
0.02 
Plantar/heel pressure 
data  
0.15 mm F-scan insole F-Scan VersaTek System, 
Tekscan, Inc.; South Boston, MA 
50 
Stimulation, heel 
loading, tibia tilt data 
WalkLink Innovative Neurotronics; Austin, 
TX 
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3.3.1 Marker Placement for Kinematic Analysis 
During each gait session, reflective markers were affixed with double sided adhesive tape on 
the following anatomical locations (see Figure 11) to facilitate lower extremity kinematic 
analysis:  
• anterior superior iliac spines, ASIS (if palpable, otherwise on the lateral pelvis) 
• sacrum (mid-way between the posterior superior iliac spines) 
• thigh (in line with the greater trochanter and lateral epicondyle of the femur) 
• lateral femoral epicondyle  
• tibia 
• lateral malleolus (medial malleolus if F-Scan sensors were used) 
• second metatarsal head (on shoe)  
• calcaneus (on shoe) 
 
Figure 11: Marker placement for lower limb gait analysis (adapted from [51]). 
Knee=lateral epicondyle Ankle=lateral malleolus  Heel=calcaneus 
During AFO testing, the lateral malleolus marker for the affected limb was affixed to the lateral 
AFO ankle joint. All other markers were placed as described above. 
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Virtual markers were created during data processing when the anatomical location was 
obscured by clothes or the body, or when the marker could not be consistently viewed during 
ambulation. Virtual markers were created for the ASIS and sacrum when body bulk or clothing 
obscured the marker location; these virtual markers were referenced to markers placed on the 
lateral pelvis. If the subject wore a knee brace that covered the lateral femoral epicondyle, the 
virtual knee marker was referenced to a marker triad placed on the thigh. Finally, when F-scan 
insoles were used to acquire plantar pressure data, a virtual ankle (lateral malleolus) marker was 
referenced to the medial malleolus.  For all subjects and trials, virtual markers were created for 
the tip of the shoe to assess toe clearance. 
3.3.2 Testing Protocol 
3.3.2.1 Subject Instrumentation 
Strength and joint ROM tests were conducted on both lower limbs before each gait 
analysis session (see 3.2.3: Functional Assessment). Anthropometric measurements including 
height, weight, and limb segment dimensions were acquired during the first gait session.  
Physiologic monitoring consisted of heart rate monitoring (see Table 5); a heart rate monitor was 
placed beneath the shirt directly over the heart. Kinematic analysis was based on the reflective 
markers affixed to the respective anatomical locations. 
 
Figure 12: F-scan insole (left) and sample plantar pressure data (right). 
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During WalkAide gait sessions, the WalkAide heel sensor (Table 5) was placed under the 
insole of the subject’s shoe on the affected side. An F-scan insole (Table 5) was trimmed to the 
subject’s shoe size and placed on top of the shoe insole on the affected side, see Figure 12. After 
the subject donned their shoes, the WalkAide neuroprosthesis was positioned and research staff 
manually stimulated the peroneal nerve to identify the tibialis anterior location for 
electromyographic monitoring.  
 
Figure 13: Tibialis anterior EMG differentiating voluntary contraction versus 
neuromuscular stimulation via the WalkAide. 
After cleansing the skin with an alcohol swab, a bipolar electromyographic (EMG) 
electrode, see Table 5, was placed on the skin over the tibialis anterior and affixed with 
hypoallergenic adhesive tape. The electrode position was confirmed by manual stimulation from 
the WalkAide, ensuring that neuromuscular stimulation by the WalkAide and voluntary tibialis 
anterior activity could be differentiated (Figure 13). The WalkLink was placed around the 
subject’s neck and connected to the WalkAide to acquire heel and tilt sensor data during 
ambulation. Finally, the F-scan insole was calibrated based on the subject’s body weight using 
Tekscan software. Figure 14 illustrates a subject instrumented for a WalkAide gait session. 
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Figure 14: Subject instrumented for WalkAide gait analysis session. 
3.3.2.2 Dynamic Gait Trials 
Gait analysis trials were conducted on a treadmill (Landice L8, Landice Inc.; Randolph, 
NJ), randomly oriented in level, inclined (+7°) and declined (-7°) orientations. As the treadmill 
only allows level and inclined ambulation, the treadmill was positioned on a 7° declined wooden 
ramp, thereby supporting all treadmill orientations.  For each treadmill orientation, the subject 
determined his/her comfortable walking speed; two minute walking trials were then conducted 
with 10 seconds of data acquired every 15 seconds. Kinematic and heart rate data were collected 
simultaneously. During WalkAide trials, tibialis anterior EMG data were acquired using a 
VICON analog channel, synchronizing the kinematic and EMG data.  Plantar pressure data (F-
scan insoles) were acquired on a separate computer.  Tilt and heel sensor data, as well as 
stimulation data, were acquired using the WalkLink on a third computer (see Table 5); these data 
were transmitted to the VICON workstation via Bluetooth. 
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3.3.2.3 Static Pointer Trials 
After completing the walking trials, static trials for virtual marker determination were 
conducted with the treadmill in the level orientation. The tip of the virtual marker wand was 
positioned over the respective anatomical location (e.g. ASIS, lateral malleolus, toe).  As the 
subject quietly stood, the wand was “poked”, pointing to the location of interest, thereby 
decreasing the distance between the wand’s two reflective markers (Figure 15) and creating a 
reference position for the virtual maker in relation to other lower extremity markers.  
 
Figure 15: Virtual marker wand positioned to create virtual toe marker. 
3.3.2.4 Static Knee Marker Trial 
A final static trial was conducted in which knee alignment devices (KADs) were placed 
over the medial and lateral epicondyles of both limbs to better define the knee joint axis (Figure 
16).  These KADs replaced the lateral femoral epicondyle markers.  
 
Figure 16: KAD (left) positioned over the femoral epicondyles during a static trial (right). 
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3.4   KINEMATIC DATA PROCESSING 
Upon completion of each gait analysis session, the subject’s data were first processed to 
obtain c3d kinematic data files.  Kinematic data processing was completed at the Motion Analysis 
Laboratory at the Medical College of Wisconsin using VICON Workstation software (version 
5.4) and MATLAB (R2010a, Mathworks; Natick, MA). This section summarizes raw marker data 
conversion to three-dimensional (3D) motion data, creation of virtual markers, and use of a 
PlugInGait model to integrate marker kinematic data, define lower extremity limb segments and 
calculate joint angles.  
3.4.1 Construction of 3D Motion Data 
Raw marker data from the 15 cameras were reconstructed using direct linear 
transformation to produce 3D marker position data. Each respective marker was manually 
labeled. Gaps (due to marker obstruction in the camera field of view) in marker data up to 10 
frames were filled by linear interpolation.  The marker motion data were filtered using a low pass 
quintic spline Woltring filter (mean square error of 20 corresponding to a noise tolerance of 20 
mm2) to smooth data.  These video data processing steps are summarized in Figure 17.
 
Figure 17: Flow chart illustrating conversion of raw video data to 3D marker data. 
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3.4.2 Creation of Virtual Markers 
Virtual markers for the ASIS, sacrum, knee, lateral malleoli, and toes were created as 
needed using MATLAB code (J. Long, Medical College of Wisconsin), the virtual marker wand 
data, and reference marker data; this procedure is summarized in Figure 18. The static virtual 
marker trial data files were opened and the individual camera views from the 15 cameras were 
reconstructed to produce the 3D motion data. The two markers on the wand and the three 
reference markers (see Table 6) were labeled. The position of the virtual maker during the static 
trial was determined and a vector relating the virtual marker to the reference markers was created. 
This vector was then used to create the virtual marker in all dynamic trial data files.  
Table 6: Virtual marker reference 
Virtual marker Reference markers 
Right/left ASIS 
Right pelvis  
Left pelvis 
Sacrum 
Sacrum 
Right pelvis  
Left pelvis 
Replacement sacral marker 
superior to anatomical location 
Knee 
Thigh plate marker 1 
Thigh plate marker 2 
Thigh plate marker 3 
Right/left lateral 
malleolus 
Right/left Toe  
Right/left medial malleolus 
Right/left heel   
Right/left toe marker 
for toe clearance 
Right/left toe  
Right/left medial or lateral 
malleolus 
Right/left heel   
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Open virtual marker 
static trial
Wand 
marker 1 
motion data
Wand 
marker 2 
motion data
Determine 
distance between 
wand markers
Wand dimensions
Create virtual 
marker position 
in static trial
References’ 
motion data in 
static trial
Compare position of virtual 
marker to reference markers 
Find point of 
minimum 
distance
Vector relating 
virtual marker to 
reference markers
References’ 
motion data in 
dynamic trial
Create virtual marker motion 
data for dynamic trial
Virtual 
marker  
Figure 18: Procedure for creation of virtual markers. 
3.4.3 Calculation of Lower Extremity Joint Angles 
The PlugInGait model used to label the markers also defines the respective limb 
segments (pelvis, right/left femur, right/left tibia, right/left foot) in terms of these markers. The 
segments (rigid bodies) were defined by three non-collinear markers as follows:  
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• pelvis: right and left ASIS markers and the sacral marker 
• femur: ASIS and knee markers, thigh wand 
• tibia: knee and ankle markers and the tibia wand 
• foot: heel, toe and ankle markers.  
The origin of each segment was located at the distal end of the respective segment. The first axis 
of each segment was defined by the line joining the distal and proximal joint centers of the 
segment, the second axis was defined by the main axis of rotation of the distal joint, and the third 
axis was perpendicular to the first two axes (Figure 19). 
 
Figure 19: Segment axes definition. 
Joint centers were calculated based on marker locations and anthropometric 
measurements. The hip joint centers were based on an offset applied to the ASIS markers; this 
offset calculation incorporated leg length (L), inter-ASIS distance (IAD), and pelvic geometry 
[51]. The knee joint centers were based on the hip joint center, the knee and thigh wand markers, 
and the knee offset (KAD static trials). The ankle joint center was determined using the knee joint 
center, the tibia marker, the ankle marker, and the ankle offset (half ankle width) [51].  Euler 
angles about these respective joint centers were calculated using VICON Workstation.  
All marker motion data, joint angles, and analog data were stored in binary c3d files.  
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3.5 GAIT PARAMETERS DATA PROCESSING 
The aforementioned c3d files were further manipulated using MATLAB code to identify 
gait events [toe off (TO) and heel strike (HS)] and quantify temporal parameters, gait asymmetry 
and toe clearance measures. 
3.5.1 Gait Events and Temporal Parameters 
The velocity of the toe and heel markers, calculated using the finite difference method, 
was used to identify HS and TO events – both of which occur at local minima.  HS occurred at 
the minimum velocity of the heel marker, immediately after the period of maximum heel marker 
velocity (i.e. swing phase) – see Figure 20. TO occurred at the minimum velocity of the toe 
marker, just prior maximum toe marker velocity or swing phase (Figure 21). The frame numbers 
corresponding to these HS and TO events were written to Excel files for use in subsequent 
algorithms. 
 
Figure 20: Heel marker velocity illustrating HS and swing. 
 
42 
 
 
Figure 21: Toe marker velocity illustrating TO and swing. 
Temporal parameters such as stance and swing duration, single limb support, and double 
limb support periods for both the affected and unaffected limbs were calculated based on these 
HS and TO events, see Figure 22 and Section 2.2.2. Cadence and gait cycle duration were 
similarly evaluated based on the HS events of both the affected and unaffected limbs. Cadence 
was defined as the number of gait cycles or steps (one less than the number of ipsilateral heel 
strikes) divided by the time elapsed between the first and last HS (in minutes). 
 
 
Figure 22: Temporal parameters based on gait events (adapted from [14]). 
Aff=affected limb and Unaff= unaffected limb  
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3.5.2 Functional Phased of Stance and Swing  
Each stance phase (ipsilateral HS to ipsilateral TO) was separated into four functional 
phases [loading response (LR), mid-stance (MSt), terminal stance (TSt) and pre-swing (PS),] see 
Section 2.2.1 and Table 7; this data processing procedure is summarized in Figure 23 (left).   
Table 7: Functional phases of stance  
Gait Phase Beginning End 
LR Ipsilateral HS Contralateral TO 
MSt Contralateral TO First 1/2 of the frames to contralateral HS 
TSt First 1/2 of the frames to contralateral HS Contralateral HS 
PS Contralateral HS Ipsilateral TO 
 
Similarly, each swing phase (ipsilateral TO to ipsilateral HS) was separated into three 
functional phases [initial (IS), mid (MS), and terminal swing (TS)], see Section 2.2.1 and Table 8.  
While the original swing phase durations were based on functional definitions of the phases 
described by Perry [12], the variability in these phases (per cent gait cycle) was substantial.  As 
such, the functional swing phases simply divided the swing phase into thirds, see flow chart in 
Figure 23 (right) and Table 8 (second row). 
Table 8: Functional phases of swing 
  
Gait 
Phase Beginning End 
Based on 
functional 
definition 
[12] 
IS Ipsilateral TO Ipsilateral toe crosses contralateral heel 
MS 
Ipsilateral toe crosses 
contralateral heel Vertical tibia 
TS Vertical tibia Ipsilateral HS 
Alternative 
definition: 
thirds 
IS Ipsilateral TO First 1/3 of the frames to  ipsilateral HS 
MS 
First 1/3 of the frames to 
ipsilateral HS Second 1/3 of the frames to ipsilateral HS 
TS 
Second 1/3 of the frames to 
ipsilateral HS  Ipsilateral HS 
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Open dynamic file
Import gait events: 
heel strikes (hs) 
and toe offs (to)
Determine number 
of gait cycles, N
n=1
Import joint  angles for loading 
response (LR) 
LR:  hs ipsilateral  => to contralateral 
Import joint  angles for MSt
Determine end of midstance (MSt)
MSt: to contralateral   => hs contralateral (1st ½)
Determine end of terminal stance (TSt)
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Figure 23: Flow chart summarizing the division of gait cycle data into stance (left) and 
swing (right) functional phases. 
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The hip, knee and ankle joint motion in the sagittal plane was divided into these 
functional phases of stance and swing for each gait cycle.  The mean, minimum, and 
maximum joint motion for each functional phase were quantified (Figure 24) and stored 
in a spreadsheet for each subject, joint and treadmill orientation for plotting and 
subsequent analysis.   
 
Figure 24: Sample ankle motion time series (left) and associated mean, minimum and 
maximum sagittal plane ankle angle for the affected and unaffected limbs for the functional 
phases of swing (right). 
3.5.3 Gait Asymmetry 
As discussed in Chapter 2, effective treatment of foot drop for post-stroke subjects is 
expected to result in improved gait symmetry. However, current measures of gait symmetry (or 
asymmetry) are limited since they incorporate the affected limb in the normalization, are unable 
to account for sign changes which occur in kinematic data and ROM differences between subjects 
or joints, and lack the resolution needed to observe small inter-limb differences. As such, a new 
parameter to quantify gait asymmetry for kinematic data was proposed.  
This new parameter, gait asymmetry (GA), was defined as the difference in the respective 
joint angle parameter between the affected and unaffected limbs normalized by the ROM of the 
unaffected limb joint: 
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𝐺𝐴 = �𝐾𝑎𝑓𝑓𝑒𝑐𝑡𝑒𝑑−𝐾𝑢𝑛𝑎𝑓𝑓𝑒𝑐𝑡𝑒𝑑
𝑅𝑂𝑀𝑢𝑛𝑎𝑓𝑓𝑒𝑐𝑡𝑒𝑑
𝑋 100�      (Eq 3) 
 
where K affected is the kinematic parameter of interest for the affected limb (e.g. minimum, 
maximum or mean sagittal plane joint motion during the various stance and swing functional 
phases), K unaffected  is the kinematic parameter of interest for the unaffected limb, and ROM unaffected 
is the mean range of motion of the specific joint (e.g. hip, knee or ankle) on the unaffected side 
for the  entire gait cycle. 
Unlike the various measures of gait asymmetry used previously in the literature to assess 
temporal gait asymmetry or asymmetry between the limbs in free versus constrained conditions 
(see Section 2.6.2.2), the above GA measure accounts for sign changes in the kinematic data as 
well as differences in ROM between subjects or joints. These advantages are illustrated in Figure 
25 which contrasts this asymmetry measure for minimum ankle joint motion during IS with 
alternative measures used previously in the literature. The difference in ankle joint minima 
between the affected  and unaffected limbs in both the top and bottom curves is 12°, although the 
top curves reflect a sign change (flexion=dorsiflexion=positive; extension=plantar 
flexion=negative).  The denominator for GA, 25° ROM for the unaffected limb, is based on that 
ROM of the entire gait cycle although only ankle motion during swing is shown in this figure.  
Since the relative difference between limbs is 12° for both graphs, the symmetry (or asymmetry) 
measure should be insensitive to the change in sign. Previously reported measures of symmetry, 
symmetry ratio (SR) and symmetry index (SI), demonstrate excessive sensitivity to these sign 
changes; the new GA measure is insensitive to this sign change. 
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Figure 25: Comparison of GA with prior symmetry measures reported in the literature for 
ankle kinematic data with (top) and without (bottom) a sign change (flexion = positive, 
extension = negative). Each parameter was evaluated for minimum ankle joint motion 
during IS. 
Figure 26 contrasts these measures for ankle versus knee kinematic data during mid-
stance, demonstrating that GA also facilitates comparison of gait asymmetry between joints.  The 
difference in mean joint motion between the affected and unaffected limbs during mid-stance was 
12° for both joints; however, the ROM of the unaffected knee differs from that of the ankle (55° 
versus 25°, respectively).  Only the GA measure accounts for the difference in joint ROM or 
scale. 
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Figure 26: Comparison of GA with prior symmetry measures reported in the literature for 
ankle versus knee motion during mid-stance. 
3.5.4 Toe Clearance 
To investigate the efficacy of the two treatments (AFO, WalkAide) and assess whether 
the treatment minimized the risk of falling, toe clearance was assessed. Increased toe clearance 
may reflect a decrease in the risk of stumbling or falling, although excessive toe clearance of the 
affected versus unaffected or “normal limb” may indicate unnecessary energy expenditure. 
Therefore, both the magnitude of toe clearance and the difference in toe clearance between the 
affected and unaffected sides were evaluated.    
To account for inclined and declined treadmill positions, three markers were placed on 
the treadmill to define the treadmill orientation (Figure 27). These three markers were used to 
determine the plane of the treadmill relative to the laboratory coordinate system. The distance 
between the virtual toe marker and the plane of the treadmill was calculated throughout swing. 
49 
 
Toe clearance was defined as the minimum distance between the virtual toe marker and the plane 
defined by the treadmill.  These procedures are summarized in Figure 28.  
 
Figure 27: Markers (TM0, TMX, TMY) used to define treadmill plane relative to the 
laboratory-based coordinate system (XYZ). 
3.6 WALKAIDE DATA PROCESSING 
As discussed in Chapter 2, the clinician programs the WalkAide using the tilt sensor and 
tibial angles during level walking. However, McIntosh et al. [41] observed that lower extremity 
joint kinematics change on inclined and declined surfaces. Therefore, if WalkAide programming 
is based solely on level walking, stimulations may be missed or occur at different times 
throughout the gait cycle during inclined and declined ambulation.   
In addition to the tilt sensor, the WalkAide system also includes a heel sensor. The 
clinician can program the WalkAide using either the tilt or the heel sensor.  The heel sensor data 
may not change as significantly during non-level walking and therefore heel sensor-based 
stimulation may be more reliable for ambulation on non-level surfaces. Theoretical stimulations 
based on the WalkAide heel sensor data were determined to investigate whether the heel sensor 
may be a more reliable control parameter for stimulation during non-level walking.  
To investigate potential missed and extraneous stimulations for both tilt and heel sensor-
based stimulation, WalkAide stimulation reliability was determined. WalkAide tilt and heel 
sensor-based stimulation initiation and termination timing were also investigated to determine 
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whether stimulation timing changes with inclined and/or declined walking with either WalkAide 
sensor. 
Open dynamic trial
Import motion data for 
TM0, TMX, and TMY
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Figure 28: Flow chart summarizing the procedures for determining toe clearance (left) and 
treadmill plane (right). 
3.6.1 Determination of Tilt Sensor-based Stimulation using EMG  
Anterior tibialis EMG data (sampled at 1800 Hz) were used to identify the specific 
initiation and termination frame of each stimulation (Figure 29). The EMG data were high pass 
filtered (250 Hz cut-off frequency, 10th order Butterworth) to eliminate 60 Hz noise and voluntary 
muscle activity and then rectified and low-pass filtered (8 Hz cut-off frequency, 8th order 
Butterworth) to produce a linear envelope – see Figure 30.  
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Threshold detection was then applied to the linear enveloped EMG to identify the on/off 
stimulation or stimulation initiation/termination periods.   Based on preliminary analysis of all 
EMG and WalkAide data files for the first four subjects, a threshold value of 37% mean peak 
EMG consistently differentiated these stimulation periods.  All frames in which the EMG 
magnitude exceeded the threshold were stored in a “stimulation on” array. The frame 
corresponding to the beginning of each “stimulation on” period was stored as the stimulation 
initiation; the final frame of each “stimulation on” period was stored as the corresponding 
stimulation termination. The stimulation initiation and termination frames determined from the 
EMG data were later used to determine if the reliability and timing of the tilt sensor-based 
programming changed with treadmill orientation. 
Import EMG data
High-pass filter EMG data
Take absolute value of EMG
Low-pass filter rectified EMG data
Find mean value of EMG peak 
amplitudes and determine threshold
EMG(n) > threshold
n=1
Store in stimulation array
 n=n+1
Determine 
beginning of 
stimulation periods
Determine end 
of stimulation 
periods
Stimulation 
initiation
Stimulation 
termination
Store stimulation initiation and 
termination to excel file
n=N?
yes
no
no
yes
 
Figure 29: Flow chart summarizing the procedure used to determine neuroprosthesis 
stimulation initiation and termination based on tibialis anterior EMG data. 
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Figure 30: EMG data processing contrasting raw tibialis anterior EMG (top), high pass 
filtering to remove 60 Hz noise and voluntary contraction (middle), and resultant linear 
envelope (bottom) illustrating the WalkAide stimulation periods. 
3.6.2 Clinical WalkAide Parameters and Programming 
 The WalkAide is typically programmed clinically using the tilt sensor since this sensor 
can be used without shoes. The tilt sensor measures the approximate angle of the tibia.  The 
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clinician controls the stimulation by setting and refining several parameters: stimulation 
initiation/termination thresholds, wait time, and minimum/maximum stimulation duration.  These 
control parameters are defined below. 
1) Stimulation initiation and stimulation termination thresholds: Tibial tilt increases as the knee 
flexes and decreases as the knee extends, see Figure 31. The stimulation initiation threshold is 
defined as the tilt threshold that will initiate a new stimulation.  The stimulation termination 
threshold is defined as the tilt threshold that will end or terminate the stimulation 
 
Figure 31: Stimulation initiation and termination thresholds based on the WalkAide tilt 
(bottom gray waveform) and heel sensor (top gray waveform) data [4]. 
2) Wait time: The wait time is defined as the minimum time interval between stimulation 
termination and a new stimulation.  
3) Minimum stimulation duration: The minimum stimulation duration is defined as the 
minimum stimulation time.  
4) Maximum stimulation duration: The maximum stimulation duration is the maximum 
duration of a sustained stimulation.  If stimulation termination threshold has not been 
achieved by this time, the stimulation will be terminated based on this setting.  
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After all the parameters have been set, WalkAide stimulation (tilt sensor control) occurs 
as follows: stimulation begins when the tilt angle exceeds the stimulation initiation threshold. 
Stimulation continues until the minimum stimulation duration is reached. Stimulation continues 
further until the tilt angle falls below the stimulation termination threshold or the maximum 
stimulation duration has been reached. A new stimulation may not be initiated until the minimum 
wait time has passed and the stimulation initiation threshold has again been exceeded. 
During clinical programming, the WalkAide is initially programmed with default 
parameter values (e.g., stimulation initiation/termination for heel and tilt sensors: 255/1; 
minimum/maximum stimulation duration: 0.5/1.0 seconds; wait time: 0.4 seconds).  The clinician 
monitors the subject’s ambulation, focusing on the subject's walking speed, ankle dorsiflexion 
and knee extension during loading response, knee flexion during swing and potential hip hiking 
or circumduction during swing. Based on these observations, the clinician adjusts the default 
parameters as needed for the specific subject.  For example, the minimum stimulation duration is 
increased if the subject is a slow walker; the stimulation termination angle is reduced if the 
subject has prolonged loading response, requiring ankle dorsiflexion for a longer period of time 
following swing termination).  
3.6.3 Theoretical Heel Sensor-Based Stimulation 
The WalkAide is typically programmed and controlled using the tilt sensor.  However, 
the clinician also has the option to program and control WalkAide stimulation using heel sensor 
data. This method requires that the clinician set the heel loading thresholds for stimulation based 
on heel loading (stance) and heel unloading (terminal stance and swing), see Figure 32 (top).  
Note that the heel sensor data are in arbitrary units; high values represent no load and low values 
correspond to sensor loading.  
In addition to tilt sensor and stimulation data, WalkAide heel sensor data were acquired 
during gait analysis sessions. Theoretical heel sensor-based stimulation was estimated using the 
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parameters designated during clinical tilt sensor programming (e.g. wait times, minimum and 
maximum stimulation durations) and setting the respective stimulation initiation and termination 
based on sample (3-4  ten second level walking trials) heel sensor data.  
The stimulation thresholds were now based, not on tilt data, but on heel sensor data.  Due 
to the inverse nature of the heel sensor output, unloading corresponded to periods in which the 
heel data were high; loading corresponded to period in which the heel data were low - see Figures 
32 and 33.  A single threshold was used to differentiate heel loading and unloading periods for a 
given subject.  This threshold was set in terms of the heel sensor loading range such that 
extraneous stimulations due to foot movement were minimized; threshold values ranged from 1-
15% for the respective subjects, see Figure 33 (bottom).  
This threshold define the preliminary stimulation initiation (heel unloaded) and 
termination (heel loaded) times. The first frame immediately prior to the heel sensor exceeding 
the threshold, signifying an unloaded heel sensor, was the stimulation initiation time. The first 
frame after the heel sensor value fell below the threshold, signifying a loaded heel sensor, was the 
stimulation termination time. 
The preliminary stimulation initiation and termination times were adjusted based on the wait 
time and minimum/maximum stimulation duration.  Each 10 second data trial was reviewed to 
ensure that relative timing of subsequent initial theoretical heel sensor-based stimulations did not 
occur during the wait time previously defined during clinical tilt sensor based programming.  Any 
theoretical stimulations occurring during this wait time were delayed such that the wait time was 
satisfied, defining a new stimulation initiation frame. 
Each 10 second data trial was reviewed a second time to ensure that each theoretical heel 
sensor-based stimulation duration met or exceeded the minimum stimulation duration previously 
defined during clinical tilt sensor based programming.   If the stimulation duration was less than 
the minimum duration, the stimulation termination frame was delayed such that the minimum 
stimulation duration was satisfied. 
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Finally, each 10 second data trial was reviewed a third time to ensure that each 
theoretical heel sensor-based stimulation duration did not exceed the maximum 
stimulation duration previously defined during clinical tilt sensor based programming.  If 
the stimulation duration was greater than the maximum, the stimulation termination 
frame was adjusted such that the stimulation duration satisfied the maximum stimulation 
duration setting. 
 
 
Figure 32: WalkAide heel sensor data illustrating loading and unloading periods (top) and 
corresponding stimulation periods (bottom) using threshold detection techniques to 
minimize extraneous stimulation due to small variations in heel sensor data (bottom). 
Note, the WalkAide heel sensor data are reported in arbitrary units. 
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Figure 33: Ankle angle as a function of “kinematic” frame number (A, 120 Hz), EMG data 
as function of “EMG” frame number (B, 1800 Hz), WalkAide heel sensor data as a function 
of “WalkAide” frame number (C, 25 Hz), and WalkAide heel sensor data as function of 
“kinematic” frame number (D, 120 Hz). 
3.6.4 Stimulation Reliability 
One of the hypotheses motivating this research was that as WalkAide stimulation 
initiation and termination is based on tibial angle data during level walking, missed or extraneous 
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stimulations may occur during inclined and declined ambulation. Missed and extraneous 
stimulations may decrease with heel sensor-based stimulation if heel sensor data (and 
loading/unloading thresholds) are less sensitive to treadmill.  The stimulation reliability (StR) for 
both tilt and heel sensor-based stimulation was characterized.   
Prior to determining the StR (and timing), the timing of WalkAide heel sensor data was 
adjusted to facilitate synchronization with the kinematic data. The WalkAide heel sensor data 
were sampled at 25 Hz, much slower than that for kinematic (120 Hz) and EMG (1800 Hz) data 
used to determine the gait cycle and stimulation initiation/termination, respectively.  To convert 
and synchronize the theoretical heel sensor-based stimulation initiation and termination frames 
(25 Hz) to the respective gait cycle frames (120 Hz), the following equation was used:  
𝑆𝑡𝑖𝑚𝑘_𝑓𝑟𝑎𝑚𝑒 = ��𝑊𝐴𝑓𝑟𝑎𝑚𝑒 −𝑊𝐴𝑠𝑡𝑖𝑚1�𝑋 12025 � + 𝐾𝑠𝑡𝑖𝑚1        (Eq 8) 
where Stimk_frame  is the heel sensor-based stimulation “kinematic” frame, WA frame is the 
WalkAide heel sensor stimulation frame, WA stim1 is the WalkAide frame of the first stimulation 
onset, and K stim1 is the “kinematic” frame of the first stimulation onset. 
StR of the WalkAide tilt and heel sensors was determined using the gait cycle period 
(defined in terms of heel strike events) and stimulation initiation frame data of each respective 
sensor. Specifically, StR was defined as:  
   𝑆𝑡𝑅 = 𝑆𝑡𝑖𝑚
𝐺𝐶
      (Eq 4)  
   
where GC is the number of gait cycles per trial and Stim refers to the number of stimulation 
periods per trial. The number of gait cycles per trial was one less than the number of affected 
limb HS’s. The number of stimulation periods per trial was the number of stimulation initiations 
that occurred between the first and last HS events of that respective trial. A StR value of one, 
therefore, indicated that the WalkAide stimulated during each gait cycle; StR values less than one 
indicated missed stimulations and values greater than one reflected extraneous stimulations.  StR 
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values for both tilt and heel sensor stimulations were evaluated to investigate the effect of 
treadmill orientation on StR, and whether StR was improved using heel sensor-based stimulation. 
3.6.5 Stimulation Timing 
In addition to potential effect of orientation on the StR of tibial angle-based 
programming, the timing of the stimulation initiation and termination may also be affected by 
treadmill orientation. As discussed in Chapter 2, ankle and knee kinematic data during non-level 
walking differ from that during level walking.  As such, the tibial angle is also expected to change 
during non-level walking. Since the WalkAide stimulation programming is based on tibial angle 
thresholds during level walking only, inaccurate or inconsistent stimulation timing may occur 
during non-level walking. Heel sensor-based stimulation may decrease the potential stimulation 
inaccuracy and inconsistency on non-level surfaces. To investigate the accuracy and consistency 
of the WalkAide tilt and heel sensor-based stimulation timing, the stimulation initiation and 
termination times for each sensor were investigated.  
The gait events (HS and TO) and stimulation initiation and termination frames were used 
to determine the timing of the respective WalkAide stimulation initiation and termination in terms 
of percent gait cycle. For each stimulation, the stimulation initiation frame was compared to the 
HS event frames. If the stimulation initiation frame fell between the two consecutive HS’s, the StI 
timing can be expressed as a function of gait cycle:  
𝑆𝑡𝐼 = 𝑆𝑡𝐼𝑓𝑟𝑎𝑚𝑒−𝐻𝑆(𝑛)
𝐻𝑆(𝑛+1)−𝐻𝑆(𝑛)  (Eq 5) 
 
where StIframe is the stimulation initiation frame, HS(n) is the frame corresponding to the first HS,  
HS(n+1) is the frame of the subsequent HS, and n  is the respective gait cycle. In Figure 33 for 
example, StI1 falls between hs1 and hs2; it is therefore part of gait cycle 1 and occurs at 45% of the 
gait cycle (mid-stance for this subject).  The relative stimulation termination timing (StT) was 
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similarly calculated, substituting the stimulation termination frame, StTframe, for StIframe in Eq 5.  
For the example shown in Figure 33, StT1 occurs at ~95% of gait cycle 1, during terminal swing.  
 
Figure 34: Stimulation periods (top) illustrating the stimulation initiation (StI) and 
termination (StT) timing during tilt sensor based stimulation; the corresponding sagittal 
plane ankle motion data are also shown (bottom), illustrating the respective HS and TO 
events for each gait cycle. 
Since peroneal nerve stimulation provides ankle dorsiflexion and therefore facilitates toe 
clearance during swing for individuals with foot drop, the StI timing was also expressed relative 
to the start of swing, as shown below: 
𝑆𝑡𝐼𝑠𝑤𝑖𝑛𝑔 = 𝑃𝑠𝑤𝑖𝑛𝑔 − 𝑆𝑡𝐼                    (Eq 6) 
where Pswing is the onset of swing (% gait cycle), and StI is the stimulation initiation (% gait 
cycle).  Positive StI swing values reflect stimulation initiation prior to swing, perhaps during the 
pre-swing functional stance phase. Negative StI swing values indicate that the stimulation initiation 
occurred during swing; these negative StI swing values reflect delayed stimulation that will likely 
result in insufficient toe clearance during swing. 
During able-bodied walking, the ankle dorsiflexors are also active during early to mid-
stance to prevent foot slap.  As such, WalkAide stimulation of the tibialis anterior may continue 
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through early stance.  StT timing was therefore expressed relative to the end of swing to 
determination whether stimulation terminated after swing (>100% gait cycle), extending into 
early stance of the subsequent gait cycle. 
𝑆𝑡𝑇𝑠𝑤𝑖𝑛𝑔 = 𝑆𝑡𝑇 + 100                    (Eq 7) 
The mean StI and StT timing during each trial, as well as the variability (standard 
deviation) in these parameters, was calculated for each subject and treadmill orientation for both 
tilt and heel sensor-based stimulations. StI and StT timing were compared amongst treadmill 
orientations to determine if the orientation influences the sensor stimulation timing. 
3.7 F-SCAN DATA PROCESSING 
Since kinetic data could not be acquired due to the treadmill, F-scan insoles were used to 
acquire plantar pressure data for each limb during ambulation in both treatments. However, initial 
attempts to contrast heel loading between the AFO and WalkAide treatments were unsuccessful 
as the rigid plantar surface of the AFO created wrinkles in the F-scan sensor, introducing elevated 
pressure artifacts (Figure 34).  Therefore, F-scan insoles were used during WalkAide trials only, 
facilitating comparison of WalkAide heel sensor data with F-scan heel loading data. 
 
Figure 35: Plantar pressure errors or artifacts introduced by rigid AFO plantar surface [no 
AFO (left), AFO (right)]. 
62 
 
 Due to complications with the WalkAide heel sensor, heel sensor data were not acquired 
for two subjects (S7 and S8). As such, the magnitude and duration of theoretical heel sensor-
based stimulation was based on the F-scan sensor.  
This section summarizes the plantar pressure data processing to assess heel loading, the 
comparison of F-scan heel loading versus WalkAide heel sensor loading, and the estimated heel 
loading-based stimulation, stimulation reliability and stimulation timing using the F-scan for the 
aforementioned two subjects (S7 and S8). 
3.7.1 Heel Plantar Pressure 
The F-scan plantar pressure data (sampled at 50 Hz) were reviewed using Tekscan 
software.  A box approximating the WalkAide heel sensor dimensions (2 cm by 2 cm) and 
location was defined to assess F-scan heel loading (Figure 35).  For each 8 second data trial, 
mean heel pressure data for the respective heel box region were evaluated. 
 
Figure 36: Heel loading via the F-scan insole [plantar pressure and heel box (left) and 
corresponding mean heel box loading time series (right)]. 
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3.7.2 Comparison of F-Scan versus WalkAide Heel Loading 
 For the six subjects for whom WalkAide heel sensor data were available, the F-scan heel 
loading data were compared to that obtained with the WalkAide, to validate the WalkAide heel 
sensor for possible stimulation control.  
The heel loading and unloading periods based on the F-scan heel box were determined 
using threshold detection, see Figure 36. Near-zero (psi) loading was considered unloading 
periods, while times in which the pressure increased above zero were considered loading periods. 
Similar to the analysis of the WalkAide heel sensor, a threshold was used to define specific 
loading/unloading periods. This threshold was based on a specific percent of the loading (2-13%).  
 
Figure 37: F-scan heel loading and unloading based on threshold detection techniques. 
The mean and maximum pressure during loading, and the duration of loading and 
unloading periods of the F-scan box were compared to the WalkAide heel sensor data collected 
from six of the study’s subjects. The mean and maximum heel box values and WalkAide heel 
sensor values for each loading period were determined for all trials and each treadmill orientation. 
The duration of each loading and unloading period based on both the heel box and the WalkAide 
heel sensor were also determined for all trials and each treadmill orientation. The F-scan heel box 
values were plotted against the corresponding WalkAide heel sensor value in a scatter plot. 
Separate plots were created for each of the four variables: maximum pressure during loading, 
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mean pressure during loading, heel loading duration, and heel unloading duration. Linear 
regression was performed for the four graphs to determine the potential correlation between F-
scan insole heel box data and WalkAide heel sensor data.   
3.7.3 Estimation of F-Scan Heel Box Based Stimulation 
Due to complications with the WalkAide heel sensor, heel sensor data were not acquired 
for two subjects (S7 and S8). For these subjects, the F-scan heel box (Section 3.7.1) was used to 
estimate theoretical heel loading and unloading, with thresholds set at 0.1 psi, see Figure 36. The 
frame immediately before the box value exceeded the threshold was considered stimulation 
initiation, while the first frame after the box value dropped below the threshold was considered 
stimulation termination. Stimulation initiation and termination frames were determined for all 
trials of subjects S7 and S8. 
Since F-scan data were sampled at 50 Hz, contrary to the kinematic (120 Hz), EMG 
(1800 Hz), and WalkAide (25 Hz) data, and the data could not be synchronized through 
hardware, the F-scan pressure under the entire foot was used to determine HS and TO.  To 
estimate HS and TO events, a “box” corresponding to the entire plantar surface was created. The 
mean plantar pressure for this box was evaluated; periods of zero pressure were considered swing 
(i.e. the foot was off the ground) and the periods of loading were considered stance (i.e. the foot 
was on the ground). The frames corresponding to the beginning and end of stance were stored as 
HS and TO frames, respectively. With frames for the HS, TO, stimulation initiation, and 
stimulation termination, the StR and relative StI and StT (percent gait cycle) could be calculated 
using Equation 4 and Equation 5, respectively.   
3.8 STATISTICAL ANALYSIS AND HYPOTHESIS TESTING 
Statistical analyses were conducted to test the research hypotheses, contrasting treatments 
in terms of temporal and kinematic symmetry (Hypothesis 1a) and efficacy or toe clearance 
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(Hypothesis 1b), treadmill orientation effect on the WalkAide tilt sensor-based stimulation in 
terms of stimulation reliability (Hypothesis 2a) and timing (Hypothesis 2b), and WalkAide tilt 
versus heel sensors in terms of stimulation reliability (Hypothesis 3a) and timing (Hypothesis 3b). 
To determine whether parametric or nonparametric analyses should be conducted, the 
normality of the data distribution was assessed. Power tests were also performed to verify sample 
size necessary to determine significant differences in each of the respective study parameters. 
3.8.1 Hypothesis 1 testing 
The first research hypothesis was that the use of a neuroprosthesis for post-stroke 
individuals with drop foot will improve gait symmetry [temporal symmetry (SR and gait 
asymmetry index) and sagittal plane kinematic GA] and efficacy (toe clearance) for all treadmill 
orientations when compared to ambulation with an AFO.  The normality of respective parameters 
was assessed using the Kolmogorov-Smirnov test (K-S test) [52]. This test indicated that both the 
temporal parameters and toe clearance were non-normally distributed.  Therefore, this hypothesis 
was tested using nonparametric statistical analyses. 
Initial analysis included Wilcoxon signed rank tests (paired, two-sided) across subjects to 
identify parameters that differ significantly:  
1) between limbs (e.g. affected vs. unaffected) of the same treatment and  
2) between treatment (e.g. AFO versus WalkAide) of the same limb for given treadmill 
orientation.  
This test assumes that the two data sets or pairs (affected vs. unaffected limbs and AFO vs. 
WalkAide treatments for the same subject) are independent random samples from continuous, 
symmetric distributions [52].  The null hypothesis for these Wilcoxon signed rank tests was that 
no difference exists between median measures of the respective pair.  Significance levels of 5% 
(p=0.05) and 1% (p=0.01) were documented. 
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Since measures of kinematic gait asymmetry were based on differences between limbs, 
only a single measure of asymmetry was calculated for each parameter (e.g. mean ankle or knee 
angle during IS). The standard errors of the respective parameter for both the affected and 
unaffected limb were individually determined and combined, using equation 9, to determine the 
standard error for the treatment (SE treatment): 
              𝑆𝐸𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 = �𝑆𝐸𝑎𝑓𝑓𝑒𝑐𝑡𝑒𝑑2 + 𝑆𝐸𝑢𝑛𝑎𝑓𝑓𝑒𝑐𝑡𝑒𝑑2        (Eq 9, adapted from [52]) 
where SE affected is the standard error of the respective parameter for the affected limb and  
SE unaffected is the standard error of the respective parameter for the unaffected limb.  
Using these standard errors for both the WalkAide and the AFO treatments, a Z-test was 
performed (Eq 10) for each subject, contrasting the two treatments:                          𝑍 − 𝑠𝑐𝑜𝑟𝑒 = 𝐺𝐴𝐴𝐹𝑂−𝐺𝐴𝑊𝑎𝑙𝑘𝐴𝑖𝑑𝑒
�𝑆𝐸𝐴𝐹𝑂
2+𝑆𝐸𝑊𝑎𝑙𝑘𝐴𝑖𝑑𝑒
2
            (Eq 10, adapted from [52]) 
where SEAFO is the standard error of the AFO treatment, SEunaffected is the standard error of 
WalkAide treatment, GAAFO is the gait asymmetry for the AFO, and GAWalkAide is the gait 
asymmetry for the WalkAide – all for the respective parameter of interest. The null hypothesis for 
these Z-tests was that the asymmetry measures for the WalkAide and AFO do not differ.  This 
test assumes that the asymmetry measures are random samples from populations with known 
means and variances, and are independent of one another [52]. Significance levels of 5% (p=0.05) 
and 1% (p=0.01) were again documented. To compare the GA of all subjects, the absolute value 
of each GA was determined for both treatments.  A Wilcoxon rank sum test was then performed 
to determine if the GA differed significantly between treatments across all study subjects. 
   Since all parameters were determined to be non-normally distributed based on the K-S 
test, nonparametric Freidman testing of the temporal parameters, toe clearance and gait 
asymmetry measures was conducted to identify parameters that differ significantly with treadmill 
orientation for a given treatment (AFO/WalkAide) and limb (affected/unaffected). The Friedman 
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test assumes that all observations are mutually independent and that all data have the same 
continuous distribution.  The Friedman tests were set up in a two-way layout (e.g. rows= 
blocks=subjects, columns=factors= treadmill orientations) to test the effects of the treadmill 
orientations on the given parameter for specific limb while using one treatment [52]. The null 
hypothesis for the Friedman test was that the treadmill orientation did not affect the given 
parameter; significance levels of 5% (p=0.05) and 1% (p=0.01) were documented. If significant 
differences were found, post-hoc testing (Wilcoxon sign rank tests with the Bonferroni correction 
for multiple comparisons [53]) was conducted to assess whether these differences occurred 
between level-inclined, level-declined, or inclined-declined treadmill orientations.  
3.8.2 Hypothesis 2 testing 
The second research hypothesis stated that WalkAide tilt sensor-based stimulation 
reliability (Hypothesis 2a) and timing (Hypothesis 2b) will differ for ambulation on level versus 
on non-level (e.g., level versus incline and level versus decline) surfaces. The WalkAide StR and 
stimulation timing were found to be non-normally distributed based on the K-S test. Therefore 
non-parametric Friedman testing was again conducted to determine whether StR or stimulation 
timing (StI and StT) differed significantly non-level walking (e.g., level versus incline and level 
versus decline) for tilt sensor-based stimulations. Post-hoc Wilcoxon signed rank tests with 
Bonferroni correction for multiple comparisons were completed to assess whether these 
differences occurred between level-inclined or level-declined walking. Significance levels of 5% 
(p=0.05) and 1% (p=0.01) were documented for all Friedman tests. 
3.8.3 Hypothesis 3 testing 
The third research hypothesis contrasts WalkAide tilt versus heel sensor-based 
stimulation in terms of stimulation reliability (Hypothesis 3a) and timing (Hypothesis 3b).  
During non-level walking, the heel sensor is hypothesized to result in improved StR and less 
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variable stimulation timing.  Wilcoxon signed rank testing was conducted to determine whether 
StR and variability in stimulation timing (StI and StT) differed significantly between sensors (tilt 
and heel) during the non-level (inclined and declined) walking trials. Significance levels of 5% 
(p=0.05) and 1% (p=0.01) were documented. 
3.8.4 Power tests  
 Large sample sizes are often required when analyzing data with non-parametric statistical 
tests. To determine whether additional subjects are needed to detect statistically significant 
differences, power analyses were conducted. These power analyses were used to determine both 
the power associated with the current sample size (n=8 corresponding to the full population 
subset) and the sample size necessary to achieve the desired power of 0.80 at the 0.05 level of 
significance. These tests were repeated for each of the temporal parameters, temporal symmetry 
measures, gait asymmetry measures, and toe clearance values. 
Three separate a priori power analyses were conducted using G-Power (v3.1.2, [54] to 
determine the number of subjects necessary to detect statistically significant differences at the 
0.05 level of significance, assuming small (0.2), medium (0.5) and large (0.8) effect sizes [55] 
and non-normal data distributions. 
A priori and post hoc power analyses based on the observed effect sizes in the respective 
parameters (temporal parameters, temporal symmetry, GA, and toe clearance) were also 
conducted,  both to determine the number of subjects necessary to detect statistical significance 
and the statistical power associated with the current sample size. A priori power analysis for each 
Wilcoxon rank sum analysis was computed using G-Power to determine the sample size needed 
to achieve the desired power (P=0.80). Priori power test input included the distribution (non-
normal), mean and standard deviation of the respective groups for the given parameter, and 
significance level (α=0.05) [55].  Post hoc test inputs included the sample size (n=8), distribution 
(non-normal), and the mean and standard deviation of the respective groups for a given parameter 
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(e.g. affected limb AFO/WalkAide data for temporal parameters, AFO/WalkAide GA measure 
for kinematic asymmetry, and affected limb AFO/WA values for toe clearance). 
3.9 SUMMARY 
 Post-stroke individuals with foot drop who met research selection criteria were recruited 
from the Milwaukee area and tested in two foot drop treatments, an AFO and WalkAide 
neuroprosthesis. After acclimating to each device for four weeks, gait analysis (two minute 
walking trials on a level, inclined and declined treadmill) was conducted. Acquired data included 
lower extremity joint kinematics and subject heart rate; for the WalkAide sessions data included 
plantar pressure and tibialis anterior EMG, as well as WalkAide tilt sensor, heel sensor and 
stimulation data.  
Using heel strike and toe off event markers, the temporal parameters were calculated. 
These gait events were also used to review kinematic data during the functional phases of swing 
and stance.  Gait asymmetry between the affected and unaffected limbs at the knee and  ankle was 
assessed for both treatments (AFO/WalkAide). Temporal parameters, asymmetry measures and 
were used to contrast the temporal and kinematic gait symmetry (Hypothesis 1a) and efficacy in 
terms of toe clearance (Hypothesis 1b) for the two treatments. The WalkAide tilt sensor 
stimulation reliability and initiation/termination timing were used to investigate the reliability 
(Hypothesis 2a) and stimulation timing consistency (Hypothesis 2b) of the WalkAide stimulation 
on level and non-level surfaces for the tilt sensor-based programming. Stimulation reliability 
(Hypothesis 3a) and variability in initiation/termination timing (Hypothesis 3b) were contrasted 
for tilt sensor and theoretical heel sensor-based programming to determine if the heel sensor 
produced more reliable and consistent stimulation during non-level walking. 
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CHAPTER 4: RESULTS 
Two gait analysis sessions were conducted on each of the eight subjects who completed 
this study, once while ambulating in the study-provided AFO and the other while ambulating in 
the WalkAide. Kinematic and heart rate data were collected for all sessions while plantar 
pressure, EMG, and WalkAide tilt, heel sensor, and stimulation timing data were collected during 
WalkAide gait sessions. 
Gait events, HS and TO, were determined using the velocity of the heel and toe markers, 
respectively. These events were used to determine temporal parameters such as cadence and 
stance duration. Each trial was divided into the respective gait cycles of the affected and 
unaffected limbs, as well as the functional phases of stance and swing. Gait asymmetry, which 
compared the dissimilarity of the mean, maximum and minimum sagittal plane motion of the 
ankle and knee, was calculated for each functional phase. The ankle ROM and toe clearance 
during swing phase were also determined. Temporal parameters, gait asymmetry, ankle ROM, 
and toe clearance were used to compare the effects of treatments.  
WalkAide tilt sensor-based stimulation reliability and stimulation initiation and 
termination timing were determined using the gait events and anterior tibialis EMG data. 
Theoretical heel sensor-based stimulation reliability and timing were determined using the gait 
events and WalkAide heel sensor data. The WalkAide heel sensor and F-scan data were reviewed 
to determine whether these data were correlated so that F-scan plantar pressure data might be use 
to estimate stimulation initiation/termination for subjects for whom WalkAide heel sensor data 
were not available.  
This chapter summarizes the results from the respective gait analysis sessions. 
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4.1 SUBJECT CHARACTERISTICS 
4.1.1 Subject Information 
 Eight post-stroke individuals were selected from the greater Milwaukee area for 
participation in this study. Subjects were between the ages of 48 – 76 years, had  experienced a 
stroke at least six months prior to testing (mean of 3.8 years), and had an average lower extremity 
Fugl-Meyer score of 24.4. Three subjects had right hemiparesis and five subjects had left 
hemiparesis. All subject characteristics are summarized in Table 9. 
Subjects S2 and S7 exhibited large variability in WalkAide stimulation reliability and 
initiation/termination timing data (see Section 4.5.3). Analyses were conducted both with (All) 
and without (Group A) these subjects.  
Table 9: Subject Characteristics 
*study outliers: data excluded from Group A analyses 
+ original stroke 9.5 years (mini stroke 4.5 years) prior to research participation 
++ original stroke 1 month before stroke which caused foot drop 
WA=WalkAide 
  Sex 
Age 
(years) 
Affected 
Side 
Lower 
extremity 
Fugl-Meyer 
Time since 
stroke  
(years) 
Weight 
(kg) 
Height 
(cm) 
AFO use 
prior to 
study 
First 
study 
treatment  
S2* M 51 L 27 4.5+ 123.15 185.42 articulated  WA 
S4 M 48 R 23 7.5 75.07 185.42 solid  WA 
S5 M 76 L 24 0.5 82.33 163.83 solid  AFO 
S6 F 65 R 23 2.5 60.21 154.94 solid  WA 
S7* M 53 L 24 8 85.73 177.8 solid  AFO 
S8 M 51 R 21 2 126.32 180.34 solid  AFO 
S10 F 56 L 28 2 105.91 167.64 none WA 
S12 M 58 L 25 3.5++ 119.29 177.8 solid  AFO 
Mean 
(std) 
 
57.3 
(9.2) 
 
24.4       
(2.3) 
3.8       
(2.7) 
97.3 
(24.8) 
174.1 
(10.9) 
 
 
 
 
4.1.2 Functional Assessment  
 To assess differences in subject impairment, Modified Ashworth Scale (Table 10), 
passive ankle ROM (Table 11) and muscle strength (Table 12) measures were acquired during the 
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initial fitting for the first study device and at the beginning of each gait session. For all subjects, 
passive ankle dorsiflexion was greater after WalkAide acclimation (e.g. beginning of the 
WalkAide gait session) than after AFO acclimation. Treatment did not consistently affect 
Modified Ashworth Scale scores, plantar flexion ROM or ankle dorsiflexion strength.   
 Heart rate was monitored during all walking trials to identify any potential subject fatigue 
during testing. As shown in Table 13, the mean heart rate did not vary by more than 15 beats per 
minute within a given gait session and never exceeded 110 beats/minute.  Subject fatigue was not 
observed during testing. 
Table 10: Modified Ashworth Scale scores 
  
Ashworth 
Initial 
Fitting WalkAide AFO  
S2 3 2 3 
S4 3 1 2 
S5 0 3 3 
S6 1 1 0 
S7 3 2 2 
S8 4 4 3 
S10 1 0 2 
S12 4 3 4 
 
Table 11: Passive ankle ROM 
  
Dorsiflexion ROM (deg) Plantar flexion ROM (deg) 
Initial 
Fitting WalkAide  AFO  
Initial 
Fitting WalkAide  AFO  
S2 5 7 2 35 35 30 
S4 10 20 15 30 35 35 
S5 10 8 5 30 35 30 
S6 10 8 5 24 28 30 
S7 5 5 5 25 30 25 
S8 5 5 3 25 25 35 
S10 5 10 5 30 25 30 
S12 5 5 5 30 30 25 
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Table 12: Ankle dorsiflexion strength based on MMT 
  
Dorsiflexion strength 
Initial 
Fitting WalkAide  AFO  
S2 2- 3 3 
S4 1 1 1 
S5 2 2+ 2+ 
S6 3 3 3 
S7 2 3- 3- 
S8 2 3+ 2+ 
S10 2+ 3- 2 
S12 3- 3- 3- 
 
Table 13: Mean heart rate (beats/min) for subjects, treatments and treadmill orientations 
  
S2 S4 S5 S6 S7 S8 S10 S12 
WA 
Decline 100 84 78 95 92 108 77 100 
Level 94 80 84 97 90 105 86 102 
Incline 89 81 78 100 92 94 81 102 
Mean 94 82 80 97 91 102 81 101 
AFO 
Decline 77 77 90 80 81 101 85 98 
Level 72 76 91 78 80 101 88 100 
Incline 81 78 100 82 79 110 91 102 
Mean 77 77 94 80 80 104 88 100 
 
 
4.2 TEMPORAL PARAMETERS 
 Cadence, gait cycle duration, stance and swing phase durations, and double limb support 
(DLS - initial, second and total) durations were computed using the gait events. Cadence was 
determined for each ten second walking trial; phase and support durations were evaluated for 
each full gait cycle within a trial for both the affected and unaffected limbs.  Mean temporal data 
were evaluated for the respective affected and unaffected limbs for each subject and treadmill 
orientation. The Wilcoxon rank sum test was used to compare affected versus unaffected limb 
values and WalkAide versus AFO treatments for each treadmill orientation.   
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4.2.1 Temporal Parameters for All Subjects 
 The mean cadence and gait cycle duration of all subjects are summarized in Figures 38 
both as a function of treatment (AFO versus WalkAide) and limb (affected versus unaffected) for 
each treadmill orientation.  As the research hypotheses address treatment efficacy, only the 
treatment differences will be presented.   The mean cadence ranged from 61.2 to 65.7 steps/min 
and the mean gait cycle duration ranged from 1.81 to 1.94 seconds.  Although the cadence was 
generally faster with the AFO versus WalkAide, these differences between treatments were not 
statistically significant.  The gait cycle duration was typically prolonged for AFO ambulation 
during inclined walking; during declined and level walking, the gait cycle duration was prolonged 
for WalkAide ambulation.  However, these treatment differences in gait cycle duration were not 
statistically significant. 
Although no statistically significant differences in gait cycle duration were found 
between treatments, the respective stance and swing durations were also examined.  The mean 
stance and swing durations of all subjects with respect to both limb (affected vs. unaffected) and 
treatment (WalkAide vs. AFO) are summarized in Figure 39. The mean stance duration ranged 
from 1.31 to 1.46 seconds, regardless of treatment or treadmill orientation, with greater inter-
subject variability noted during WalkAide ambulation The stance duration was prolonged (for 
both the affected and unaffected limbs) with the WalkAide vs. AFO for all treadmill orientations; 
these differences, however, were only statistically significant for level walking (both limbs) and 
declined walking (unaffected limb only).   
The mean swing [or single limb support (SLS) of the contralateral limb] duration ranged 
from 0.50 to 0.56 seconds, regardless of treatment or treadmill orientation. Greater inter-subject 
variability in swing duration was again noted during WalkAide ambulation. For the unaffected 
limb, longer swing (or longer affected limb SLS) durations were observed during AFO versus 
WalkAide ambulation for all treadmill orientations; these differences were statistically significant 
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for level and inclined orientations.  In contrast, for the affected limb, longer swing (or longer 
unaffected SLS) durations were observed with the WalkAide versus AFO during declined 
walking (not significant); longer affected limb swing durations were observed with the AFO 
during level (not significant) and inclined (significant) walking.   
The gait cycle was further subdivided into periods of DLS; the initial, second and total 
periods of DLS were examined. While the WalkAide’s primary objective is affected limb 
dorsiflexion during swing, the WalkAide may also stimulate the tibialis anterior during the 
transition from swing to stance (initial DLS) and stance to swing (second DLS). Continued 
anterior tibialis stimulation during initial DLS may enhance ankle stability during loading 
response, while WalkAide stimulation during the second DLS period may limit plantar flexion 
needed for push off.   Examining the durations of the initial and second DLS periods may provide 
insight into weight acceptance (e.g. loading response) and weight transfer, respectively, as well as 
insight into ankle function when examining subjects with unilateral deficits such as stroke [19].  
Examination of the total DLS period facilitates identification of balance problems [19].  
The mean periods of initial, second and total DLS are presented as a function of limb  
(affected vs. unaffected)  and treatment (WalkAide vs. AFO) in Figure 40.  Since weight 
acceptance occurs during initial DLS, prolonged initial DLS duration may indicate that the 
treatment does not fully address weight acceptance issues such as ankle and knee stability during 
loading response. Prolonged second DLS periods may indicate that the treatment restricts plantar 
flexion, potentially decreasing the efficiency of gait. The initial period of DLS was often 
prolonged during WalkAide (range: 0.42 to 0.49 sec) versus AFO (range: 0.37 to 0.47 sec) 
ambulation, with the exception of the unaffected limb during declined ambulation; all of these 
results were statistically significant.  The latter DLS period was also prolonged during WalkAide 
(range: 0.43 to 0.47 sec) versus AFO (range: 0.37 to 0.41 sec) ambulation for the unaffected limb 
on all treadmill orientations and the affected limb on the level treadmill orientation; all of these 
differences were statistically significant. The affected limb exhibited prolonged second DLS for 
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the AFO versus the WalkAide during declined and inclined ambulation; these differences were 
statistically significant.  Finally, although the total DLS period was generally longer with the 
WalkAide (0.87 to 0.92 sec) than for AFO (0.80 to 0.89 sec) ambulation, these differences were 
only statistically significant during level ambulation.   
 
 
Figure 38: Mean cadence (top) and gait cycle duration(bottom) for all  subjects during two 
minute walking trial, contrasting treatments (WA vs. AFO: +, ++ denotes a statistically significant 
differences at 0.05 and 0.01 levels, respectively) and limbs (unaffected vs. affected: W, A denotes a statistically 
significant differences at 0.05 level for WA and AFO ambulation, respectively). 
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Figure 39: Mean stance (top) and swing (bottom) duration of all subjects, contrasting 
treatments (WA vs. AFO: +, ++ denotes a statistically significant differences at 0.05 and 0.01 levels, 
respectively) and limbs (unaffected vs. affected: W, A denotes a statistically significant differences at 0.05 level 
for WA and AFO ambulation, respectively). 
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Figure 40: Initial (top), second (middle) and total (bottom) DLS duration, contrasting 
treatments (WA vs. AFO: +, ++ denotes a statistically significant differences at 0.05 and 0.01 levels, 
respectively) and limbs (unaffected vs. affected: W, A denotes a statistically significant differences at 0.05 level 
for WA and AFO ambulation, respectively), for all subjects. 
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4.2.2 Temporal Parameters for Group A 
As subjects S2 and S7 exhibited large variability in WalkAide stimulation reliability and 
initiation/termination timing data (see Section 4.5.3), the temporal parameters were also reviewed 
for Group A, a subject subset that excluded data from these two subjects. Cadence values were 
largely unchanged for this subject subset (Figure 41 versus Figure 38).  As for all subjects, 
although the cadence was generally faster with the AFO than with the WalkAide, these 
differences were not statistically significant.  Gait cycle durations were also unchanged for this 
population subset (Figure 41 versus Figure 38).  While differences in gait cycle duration were 
observed between treatments, these differences were not statistically significant. 
The stance duration for the Group A subset differed little from that of all subjects (Figure 
42 versus Figure 39). The mean stance duration ranged from 1.37 to 1.50 seconds, regardless of 
treatment or treadmill orientation; greater inter-subject variability was again noted during 
WalkAide ambulation. Similar to that for the full population, the stance duration was generally 
prolonged with the WalkAide versus AFO; however, statistically significant differences were 
only observed during level ambulation.   
Excluding subjects S2 and S7 from the analysis demonstrated fewer significant 
differences in swing duration between treatments (Figure 42 versus Figure 39).  For the Group A 
subset, both the affected and unaffected limbs exhibited longer swing durations during WalkAide 
versus AFO ambulation on all orientation; these differences were statistically significant for the 
affected limb during declined ambulation and for the unaffected limb during inclined walking.   
The duration of the initial, second and total periods of DLS were also evaluated for the 
Group A subject. Differences between WalkAide and AFO treatment (and affected and 
unaffected limbs) for Group A are shown in Figure 43 (versus Figure 40 for all subjects). While 
the inter-subject variability in DLS duration was reduced with the Group A subset, greater 
variability remained with the WalkAide versus AFO trials.  The results demonstrated fewer 
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statistically significant differences between treatments when compared to the analysis of all study 
subjects (Figure 43 versus Figure 40).  The initial period of DLS of the affected limb for the 
Group A subset was shorter during AFO (range: 0.37 to 0.43 sec) versus WalkAide (range: 0.42 
to 0.43sec) ambulation on all treadmill orientations. Contrary to all subjects, the initial period of 
DLS of the unaffected limb was prolonged during AFO (range: 0.47 to 0.50 sec) versus 
WalkAide (range: 0.45 to 0.49 sec) ambulation on all treadmill orientations; this difference was 
statistically significant for declined ambulation only. Additionally, prolonged latter DLS periods 
for the affected limb were observed during AFO (range: 0.47 to 0.50 sec) versus WalkAide 
(range: 0.45 to 0.49 sec) ambulation for all orientations, but were only statistically significant 
during declined ambulation. For the unaffected limb, prolonged latter DLS was observed with the 
WalkAide compared with the AFO for all treadmill orientation; statistically significant 
differences were observed during declined and level walking only. Finally, the total DLS period 
was prolonged during WalkAide (range: 0.87 to 0.93 sec) compared to AFO (range: 0.84 to 0.93 
sec) use for all treadmill orientations; these treatment differences were only statistically 
significant during level walking. 
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Figure 41: Mean cadence (top) and gait cycle (bottom) duration of Group A subset during 
two minute walking trial, contrasting treatments (WA vs. AFO: +, ++ denotes a statistically significant 
differences at 0.05 and 0.01 levels, respectively) and limbs (unaffected vs. affected: W, A denotes a statistically 
significant differences at 0.05 level for WA and AFO ambulation, respectively). 
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Figure 42: Mean stance (top) and swing (bottom) durations for Group A subset, contrasting 
treatments (WA vs. AFO: +, ++ denotes a statistically significant differences at 0.05 and 0.01 levels, 
respectively) and limbs (unaffected vs. affected: W, A denotes a statistically significant differences at 0.05 level 
for WA and AFO ambulation, respectively). 
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Figure 43: Initial (top), second (middle) and total (bottom) DLS duration, contrasting 
treatments (WA vs. AFO: +, ++ denotes a statistically significant differences at 0.05 and 0.01 levels, 
respectively) and limbs (unaffected vs. affected: W, A denotes a statistically significant differences at 0.05 level 
for WA and AFO ambulation, respectively), for Group A subset. 
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4.2.3 Swing Time Variability 
 Prior research of post-stroke individuals ambulating in both an AFO and a 
neuroprosthesis has been limited (see Section 2.5). In addition to walking speed and PCI, another 
parameter of interest is swing time variability of the unaffected limb. Since swing duration of the 
unaffected limb is also the SLS of the affected limb, the unaffected limb swing time variability 
can provide insight into gait stability, balance and fall risk [39]. This measure is independent of 
walking speed and therefore may indicate changes in a subject’s balance and fall risk that may not 
be identified by walking speed alone. 
 Swing time variability was quantified in terms of the coefficient of variation (CV) of the 
unaffected limb’s swing duration. The swing time variability was determined for all subjects and 
again for the Group A subset, as shown in Figure 44. While the swing time variability was less 
during AFO (range: 3.07 to 3.87%) versus WalkAide (range: 3.96 to 4.53%) ambulation, these 
differences were not statistically significant. 
 
Figure 44: Swing time variability of the unaffected limb of all subjects and the Group A 
subset during WalkAide and AFO ambulation for all treadmill orientations. 
+, ++denotes a statistically significant difference (0.05 and 0.01 levels, respectively) 
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simply a ratio of the respective temporal parameter for the affected versus unaffected limb.  As 
such, SR’s of 1.0 reflect greater symmetry.  A SR less than one indicates that the respective 
parameter is shorter for the affected limb; a SR greater than one indicates that the respective 
parameter is longer for the affected limb.  
The SR for the stance and swing durations was determined for all subjects and again for 
Group A, as shown in Figure 45. The SR for both stance and swing ranged from 0.97 to 1.01.  No 
significant differences in stance and swing SRs between treatments (WalkAide versus AFO) were 
observed for any treadmill orientation for either all subjects or for the Group A subset. 
 
 
Figure 45: Mean symmetry ratio (SR) during two minute walking trial for stance (top) and 
swing (bottom) phase durations of all subjects and the Group A subset. 
+, ++ denotes a statistically significant difference (0.05 and 0.01 levels, respectively) 
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4.2.5 Gait Asymmetry Index 
 In addition to the SR, the gait asymmetry index has also been used to quantify symmetry 
of temporal parameters [39]. Contrary to the SR which was normalized by the unaffected limb 
value, the gait asymmetry index is normalized with respect to the average value of the affected 
and unaffected limbs.  The gait asymmetry index is similar to the SI (Section 2.6.2.2), differing 
only with respect to the denominator; the gait asymmetry index is double that of the SI.  The gait 
asymmetry index has been used to compare the swing times of the affected and unaffected limbs.   
The gait asymmetry index for swing duration was determined for all subjects and again 
for the Group A subset, as shown in Figure 46. The mean gait asymmetry index for swing 
duration was greater during WalkAide versus AFO ambulation for all treadmill orientations, 
reflecting greater temporal swing asymmetry with the WalkAide.  However, these differences 
were not statistically significant for either all subjects or the Group A subset. 
 
Figure 46: Mean gait asymmetry index for swing of all subjects and the Group A subset, 
contrasting WalkAide and AFO treatments for all treadmill orientations. 
+, ++ denotes a statistically significant difference (0.05 and 0.01 levels, respectively) 
4.2.6 Key Temporal Parameter Findings 
 There were no trends or statistically significant differences in cadence or gait cycle 
duration between treatments for the full subject population or for the Group A subset.  
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For both all subjects and the Group A subset, the stance duration was a longer during 
WalkAide versus AFO use, with statistically significant differences observed for level and 
decline (all subjects only) walking. For all subjects, both limbs exhibited statistically greater 
swing durations with the AFO than the WalkAide during inclined walking. For the Group A 
population subset, the unaffected swing duration was greater with the AFO than the WalkAide 
during inclined walking.  The swing duration of the affect limb was greater during WalkAide 
ambulation on all treadmill orientations, although these differences were statistically significant 
for declined walking only.  
The initial period of DLS of the affected limb was significantly longer during WalkAide 
versus AFO ambulation for all treadmill orientations, for both all subjects and the Group A 
subset. The second period of DLS for the affected limb was significantly longer for AFO versus 
WalkAide ambulation on non-level surfaces for all subjects; these differences were statistically 
significant during declined walking only for the Group A subset. Finally, for all subjects and the 
Group A subset, both limbs exhibited prolonged total DLS during WalkAide versus AFO 
ambulation, although these differences were statistically significant during level walking only. 
4.3 GAIT KINEMATICS 
4.3.1 Gait Asymmetry 
 In contrast to the aforementioned SR and gait asymmetry index used to investigate 
temporal symmetry between the affected and unaffected limb, kinematic asymmetry between the 
affected and unaffected limb can be investigated using the GA measure proposed and defined in 
Section 3.5.2. This new measure facilitates comparison between subjects and joints as values are 
normalized with respect to the joint ROM of the unaffected limb; this measure also accounts for 
changes in kinematic sign that may occur during gait.  
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GA was evaluated for the mean, minimum, and/or maximum sagittal plane motion of 
each lower extremity joint for each functional phase of stance and swing, see Appendix B for 
mean GA for both the knee and ankle for the full gait cycle and Appendix C for individual knee 
and ankle GA . As this research investigates treatment for drop foot, ankle and knee joint motion 
were of primary interest.  In addition, as drop foot causes problems with foot clearance during 
swing, the primary functional phases of interest were: initial swing (IS), midswing (MS) and 
terminal swing (TS), as well as the respective transition regions [stance to swing: pre-swing (PS), 
swing to stance: loading response (LR)].  The potential GA measures were further narrowed so 
only clinically relevant measures (mean, minimum or maximum values) were reported.  For 
example, the maximum ankle GA during MS was reported to help assess whether difference in 
maximum dorsiflexion during swing might providing insight into foot clearance mechanisms.  
GA of the knee for both all subjects and the Group A population subset are summarized 
in Figures 47 and 48, respectively (subject specific data are presented in Appendix C). For all 
subjects, sagittal plane knee GA was greater during the swing (AFO: 20.5-34.2, WalkAide: 15.1-
35.6) than the stance (AFO: 11.0-19.0, WalkAide: 12.6-21.4) functional phases.  Knee GA for the 
Group A subset increased with respect to all subjects during the stance functional phases (AFO: 
12.1-22.8, WalkAide: 13.2-24.8), but were similar to that for all subjects for the swing functional 
phases (AFO: 15.6-33.4, WalkAide: 16.6-43.4).  Greater knee GA was observed during 
WalkAide versus AFO ambulation during initial and mid-swing during both level and inclined 
walking. However, no statistically significant differences between treatments were found for any 
treadmill orientation during any of the functional gait phases of interest for either all subjects or 
the Group A subset. 
Similarly, sagittal plane ankle GA for both all subjects and the Group A subset are 
summarized in Figures 49 and 50, respectively (subject specific data are presented in Appendix 
C). As for knee GA, ankle GA was greater during the swing (range: 16.4-50.6) than the stance 
(range: 16.4-36.5) functional phases of interest for AFO ambulation; during WalkAide 
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ambulation, ankle GA was similar during swing (range: 13.2-26.4) and stance (range: 16.2-37.1).  
Removal of subjects S2 and S7 from Group A analysis resulted in greater ankle GA during stance 
(AFO: 18.4-40.7, WalkAide 17.9-44.5), but decreased ankle GA during swing (AFO: 23.3-58.0, 
WalkAide: 10.4-27.2). Although no trends were noted during the various functional phases of 
stance, greater ankle GA was observed during AFO (range: 16.4-50.6) versus WalkAide (range: 
13.2-26.4) ambulation for all functional swing phases during both level and inclined walking for 
both the full population and the Group A subset. Statistically significant differences in minimum 
(AFO: 50.6-58.0, WalkAide: 19.7-26.4) and mean (AFO: 44.5-51.6, WalkAide: 14.6-22.8) ankle 
GA during IS were observed for both level and inclined walking for both all subjects and Group 
A.  The increased ankle GA during AFO ambulation during mid and terminal swing was not 
statistically significant. 
The effects of treadmill orientation on ankle GA can be seen by contrasting the top 
(declined), middle (level) and bottom (inclined) graphs in Figures 49 and 50. For all subjects and 
the Group A subset, the ankle GA during AFO use increased as the treadmill progressed from 
declined to inclined, especially during the swing functional phases; ankle GA during WalkAide 
ambulation was not affected by treadmill orientation. Specifically, the mean and minimum ankle 
GA during IS significantly increased, as confirmed by Friedman tests, during AFO ambulation as 
the treadmill orientation progressed from declined to inclined for all subjects and for the Group A 
subset.  Subsequent post-hoc testing of IS demonstrated significant differences in mean ankle GA 
between level and inclined treadmill orientations. 
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Figure 47: GA of knee motion for functional gait phases for all subjects during declined 
(top), level (middle), and inclined (bottom) treadmill walking. 
+, ++ denotes a statistically significant difference (0.05 and 0.01 levels, respectively) 
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Figure 48: GA of knee motion for functional gait phases for the Group A subset during 
declined (top), level (middle), and inclined (bottom) treadmill walking. 
+, ++ denotes a statistically significant difference (0.05 and 0.01 levels, respectively) 
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Figure 49: GA of ankle motion for functional gait phases for all subjects during declined 
(top), level (middle), and inclined (bottom) treadmill walking. 
+, ++ denotes a statistically significant difference (0.05 and 0.01 levels, respectively) 
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Figure 50: GA of ankle motion for functional gait phases for the Group A subset during 
declined (top), level (middle), and inclined (bottom) treadmill walking. 
+, ++ denotes a statistically significant difference (0.05 and 0.01 levels, respectively) 
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4.3.2 Ankle Range of Motion 
4.3.2.1 Unaffected Ankle Range of Motion 
The treatment differences in ankle GA during swing may be attributed, at least in part, to 
differences in unaffected ankle ROM, as ankle GA is normalized with respect to the unaffected 
ankle ROM over the full gait cycle, see Equation 3 in Section 3.5.3.  To further investigate the 
statistically significant differences in sagittal plane ankle GA between treatments, unaffected 
ankle ROM during gait was investigated for both AFO and WalkAide ambulation. 
Unaffected ankle ROM differed between the WalkAide (range: 22.1-24.3°) and AFO 
(range: 22.8-24.4°) treatments, as shown in Figure 51.  These differences, however, were not 
significant.  Additionally, while statistically significant differences in ankle GA were observed 
with treadmill orientation, such differences were not observed in unaffected ankle ROM.   
 
Figure 51: Mean sagittal plane unaffected limb ankle ROM for all subjects and the Group 
A subset contrasting treatments and treadmill orientation. 
+, ++ denotes a statistically significant difference (0.05 and 0.01 levels, respectively) 
4.3.2.2 Affected Ankle Range of Motion 
Restricted active and passive ankle ROM has been correlated with impaired balance 
(goniometric measure of passive and active ROM, [56]) and energy efficiency (active ROM 
during gait, [57]).  As such, the passive ankle ROM was measured (without AFO) before each 
gait session and the active ROM during gait (AFO on) of the affected versus unaffected limbs 
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were contrasted.  Table 14 shows the subject specific passive ROM and Figure 52 displays the 
mean passive ROM before each treatment gait session. The passive ankle ROM was significant 
greater for the unaffected limb compared to the affected limb before the WalkAide gait session 
when examining all subjects; although the same trend was observed for Group A, it was not 
statistically significant. No difference in passive ROM was observed before the AFO gait session. 
 The ankle ROM of the affected and unaffected limbs differed on an individual subject 
basis (Figure 53, subject S12) and across subjects (Figure 54).  The mean ankle ROM of the 
affected (All: 17.0- 21.0°, Group A: 15.3-20.9°) limb was less than that for the unaffected (All: 
22.0-24.4°, Group A: 21.6-23.7°) limb. These differences were statistically significant for all 
treadmill orientations during AFO ambulation, and during inclined walking with the WalkAide 
(Group A subset).   
Table 14: Passive ankle ROM before WalkAide and AFO gait sessions 
  WalkAide AFO 
  Affected Unaffected Affected Unaffected 
S2 37 40 22 30 
S4 55 55 50 53 
S5 43 45 42 35 
S6 36 42 35 35 
S7 35 40 30 30 
S8 30 45 38 40 
S10 35 40 37 35 
S12 35 45 30 40 
Mean (std) 38⁰ (8) 44⁰ (5) 36⁰(8) 37⁰(7) 
 
 
Figure 52: Mean passive ankle ROM of the affected and unaffected ankles measured before 
each gait session, for all subjects and Group A. 
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Figure 53: Representative sagittal plane ankle motion (+: dorsi, -: plantar) during 
WalkAide (left) and AFO (right) ambulation during declined (top), level (middle) and 
inclined (bottom) treadmill walking for subject S12. 
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Figure 54: Mean sagittal plane ankle ROM during gait for all subjects (top) and the Group 
A subset (bottom), contrasting the affected versus unaffected limbs. 
+, ++ denotes a statistically significant difference (0.05 and 0.01 levels, respectively) 
4.3.3 Ankle Plantar Flexion and Dorsiflexion 
 As noted in section 4.3.1, differences in ankle GA between treatments were observed 
during IS (but not during MS or TS).  These differences might be due to differences in the GA 
denominator (unaffected ankle ROM, section 4.3.2) and/or the numerator (mean and minimum 
ankle position).  These potential differences in the GA numerator (i.e. affected-unaffected), 
namely the minimum (peak plantar flexion, or minimum dorsiflexion if plantar flexion not 
achieved) ankle motion, were investigated. Also, since a new measure for GA was used, the 
difference in maximum (peak dorsiflexion) ankle motion was also investigated to verify that the 
measure could accuracy detect both differences and the lack of difference in GA. 
0
5
10
15
20
25
30
35
40
Decline Level Incline Decline Level Incline
WalkAide AFO
A
nk
le
 R
O
M
 (d
eg
 ) 
Affected Unaffected
0
5
10
15
20
25
30
35
40
Decline Level Incline Decline Level Incline
WalkAide AFO
A
nk
le
 R
O
M
 (d
eg
 ) 
Affected Unaffected
98 
 
The difference in minimum ankle motion between the affected and unaffected limbs 
during IS is shown in Figure 55 for all subjects and the Group A subset. As the unaffected limb of 
the full subject population was plantar flexed for all treadmill orientations, the difference in 
minimum ankle position between the affected and unaffected limbs was positive. Positive 
differences were also seen during AFO use and during level and inclined walking with the 
WalkAide for the Group A subset. During declined WalkAide ambulation for the Group A subset, 
many subjects (S4, S5, S6, S7, and S8) did not achieve plantar flexion with either the unaffected 
or affected limbs. In fact, the minimum ankle position was more dorsiflexed for the unaffected 
limb during IS, resulting in negative differences in minimum ankle position.  While the difference 
in minimum ankle motion between limbs was larger for all subjects and Group A during AFO 
ambulation compared with WalkAide ambulation on all treadmill orientations, no statistically 
significant differences between treatments were found.  
 
Figure 55: Difference in minimum ankle motion between the affected and unaffected limbs 
during IS for all subjects and Group A. 
+, ++ denotes a statistically significant difference (0.05 and 0.01 levels, respectively) 
The difference in affected versus unaffected parameters used to calculate GA 
(maximum/dorsiflexion motion during MS and TS and minimum/plantar flexion during IS) were 
also examined to verify the accuracy of the GA measure. Although the tibialis anterior of the 
affected limb was stimulated with the WalkAide to produce dorsiflexion similar to the unaffected 
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limb, while the AFO only provides structural support with a fixed angle, no significance 
difference in GA were observed. Since there was no difference in the denominator of the GA 
measure, there should not be a difference in the numerator of the measure. Figure 56 shows the 
difference in maximum ankle motion (i.e. dorsiflexion) between the affected and unaffected limbs 
during MS and TS for all subjects and Group A. As expected, there was no statistically significant 
difference in the relationship between the affected and unaffected limbs during WalkAide 
ambulation when compared to AFO ambulation.  
 
 
Figure 56: Difference in peak ankle dorsiflexion between the affected and unaffected limbs 
during midswing (top) and terminal swing (bottom) for all subjects and the Group A subset. 
+, ++ denotes a statistically significant difference (0.05 and 0.01 levels, respectively) 
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4.3.4 Ankle Angular Velocity 
 The ankle dorsiflexion rate or angular velocity during IS influences toe clearance and the 
efficiency of swing. To investigate the treatment efficacy with respect to toe/foot clearance during 
swing, the peak ankle angular velocity of the affected limb during IS was determined.  
The maximum angular velocity of the affected limb during IS for all subjects and the 
Group A subset for all treadmill orientations is shown in Figure 57. The peak ankle angular 
velocity was consistently higher during the WalkAide versus AFO trials; these differences with 
treatment were statistically significant for all treadmill orientations. No differences in angular 
velocity with treadmill orientation were noted for either treatment during subsequent post-hoc 
testing. 
 
Figure 57: Peak ankle angular velocity (+: dorsi) during IS for all subjects and the Group A 
subset. 
+, ++ denotes a statistically significant difference (0.05 and 0.01 levels, respectively) 
4.4 TOE CLEARANCE 
 Individuals with drop foot have difficulty with foot clearance during swing, a problem 
that is addressed by both AFO and WalkAide treatments.  To investigate the treatment efficacy of 
these devices (Hypothesis 1b), toe clearance of both the affected and unaffected limbs was 
determined for each full gait cycle for all treadmill orientations.   
0
20
40
60
80
100
120
140
Decline Level Incline Decline Level Incline
All Group A
A
ng
ul
ar
 V
el
oc
ity
 (d
eg
/s
ec
) WalkAide AFO
101 
 
 
 
 
 
Figure 58: Toe clearance for all subjects (top) and Group A (bottom), contrasting 
treatments (WA vs. AFO: +, ++ denotes a statistically significant differences at 0.05 and 0.01 levels, 
respectively) and limbs (unaffected vs. affected: W, A denotes a statistically significant differences at 0.05 level 
for WA and AFO ambulation, respectively). 
Affected limb toe clearance was contrasted between treatments (Hypothesis 1b) to assess 
treatment efficacy. Greater toe clearance of the affected limb was observed during AFO versus 
WalkAide ambulation; these treatment differences were statistically significant for level and 
inclined walking. No statistically significant treatment differences were observed for the 
unaffected limb. For the Group A subset, the affected limb demonstrated greater toe clearance 
using the AFO during decline and level walking, although these differences were statistically 
significant during declined walking only.  Significantly greater affected limb toe clearance was 
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seen with the WalkAide versus AFO during inclined walking. Again, no statistically significant 
differences between treatments were observed for the unaffected limb for the Group A subset. 
 Although increased toe clearance may indicate greater treatment efficacy or a reduced 
risk of falling for individuals with drop foot, greater toe clearance with the affected versus 
unaffected limb may require more energy during ambulation and may reflect a fear of falling. 
Since an optimal value for toe clearance is not known, the absolute value of the difference 
between the affected and unaffected limb toe clearance was also investigated.  
The mean difference in toe clearance magnitude between the affected and unaffected 
limbs was calculated for each treadmill orientation and contrasted between treatments (see Figure 
59). While the AFO treatment appeared to result in higher (although not statistically significant) 
mean toe clearance differences or more asymmetric toe clearance for all subjects, this trend was 
not apparent for the Group A population subset that excluded subjects S2 and S7.  [As noted 
previously, the toe clearance of the affected limb was typically greater than that of the unaffected 
limb (e.g. negative difference in toe clearance)]. 
 
Figure 59: Mean difference in toe clearance magnitude during swing between the affected 
and unaffected limbs for all subjects and the Group A subset. 
+, ++ denotes a statistically significant difference (0.05 and 0.01 levels, respectively) 
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4.5 WALKAIDE STIMULATION 
 The WalkAide is a neuroprosthesis designed to stimulate the ankle dorsiflexors during 
swing to assist with foot clearance for individuals with drop foot.  In this study, these 
neuromuscular stimulation periods were identified using the anterior tibialis electromyogram and 
threshold detection techniques.  The stimulation reliability (Hypothesis 2a) and 
initiation/termination timing (Hypothesis 2b) of the WalkAide, clinically programmed using the 
tilt sensor, were assessed using these data for level versus non-level walking.  Estimated or 
theoretical heel sensor-based stimulation was determined using the WalkAide heel sensor (or F-
scan sensors when WalkAide heel sensor data were not available) and heel sensor-based 
stimulation reliability (Hypothesis 3a) and initiation/termination timing (Hypothesis 3b) were 
compared with tilt sensor-based stimulation. 
4.5.1 Stimulation Reliability 
WalkAide stimulation reliability (StR) was determined for each subject. Ideally, each gait 
cycle would have one WalkAide stimulation, occurring during swing to provide the ankle 
dorsiflexion needed for toe clearance. Trials in which the number of gait cycles and WalkAide 
stimulations were equivalent correspond to a StR of one; StR values less than one reflect missed 
stimulations, while StR values greater than one are indicative of extraneous WalkAide 
stimulations. 
4.5.1.1 Tilt Sensor-Based Stimulation Reliability 
 WalkAide tilt sensor-based StR was calculated for each subject for all treadmill 
orientations (see Figure 60). Four (S5, S8, S10, S12) of the eight subjects demonstrated consistent 
StR values of unity for all treadmill orientations.  Three subjects (S2, S4, S6) exhibited missed 
stimulations for declined walking and extraneous stimulations for level and inclined walking.  
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Subject S7 demonstrated extraneous stimulations for all treadmill orientations. None of these 
differences in StR between treadmill orientations, however, were statistically significant. 
  
Figure 60: WalkAide tilt sensor-based StR for all subjects for all treadmill orientations. 
+, ++ denotes a statistically significant difference (0.05 and 0.01 levels, respectively) 
4.5.1.2 Heel-Sensor Based Stimulation Reliability 
The WalkAide is typically programmed using the tilt-sensor to control stimulation, 
although the clinician also has the option to control stimulation using heel sensor data. 
Programming for heel sensor-based stimulation requires setting the stimulation heel loading 
thresholds for stance (loaded heel sensor) and swing (unloaded heel sensor). 
WalkAide heel sensor data were acquired and threshold detection (in conjunction with tilt 
sensor stimulation programming parameters) was used to identify the respective stance and swing 
periods, defining the theoretical on (swing) and off (stance) stimulation times for each WalkAide 
walking trial. These WalkAide data were synchronized to the kinematic data as described in 
Section 3.6.2 such that the theoretical StR of heel sensor-based stimulation might also be 
estimated, as shown in Figure 61.  [WalkAide heel sensor data were not available for subjects S7 
and S8; heel sensor-based StR for these subjects were based on the F-scan insoles].  
The theoretical heel sensor-based StR (Figure 61) can be contrasted with the clinically 
programmed tilt sensor-based stimulation (Figure 60) so as to test Hypothesis 3a.  Two subjects 
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(S4, S5) exhibited extraneous (StR > 1) and/or missed (StR < 1) theoretical stimulations for non-
level walking (both declined and inclined). Subject S4 had a combination of extraneous and 
missed stimulations for both declined and inclined ambulation, while S5 exhibited missed 
stimulations during inclined ambulation. These results differed from that observed using the 
clinically programmed tilt-sensor for which missed stimulations were observed for subject S4 
during declined walking and extraneous stimulations were observed during inclined walking.  
Similarly, the extraneous theoretical stimulations with the heel sensor for subject S5 were not 
observed during tilt sensor-based stimulation (StR = 1). The remaining subjects showed a 
theoretical heel sensor-based StR of one for all treadmill orientations.   The results were 
consistent with the tilt sensor-based stimulations for subjects S8, S10 and S12. However, 
improved StR was observed for subjects S2, S6 and S7 with the theoretical heel sensor-based 
versus clinical tilt sensor-based stimulation, although these sensor differences were not 
statistically significant. Combined theoretical heel sensor-based StR were approximately unity for 
all treadmill orientations; no statistically significant differences between sensors (tilt vs. heel) for 
any treadmill orientation were observed (Hypothesis 3a).   
 
Figure 61: WalkAide heel sensor-based StR for all subjects for all treadmill orientations. 
+, ++ denotes a statistically significant difference (0.05 and 0.01 levels, respectively) 
# F-scan insole used to estimate heel loading 
  
0
0.4
0.8
1.2
1.6
2
S2 S4 S5 S6 S7# S8# S10 S12 All
St
im
ul
at
io
n 
Re
lia
bi
lit
y 
Decline Level Incline
106 
 
4.5.2 Stimulation Initiation and Termination Timing 
4.5.2.1 Tilt Sensor-Based Stimulation Timing 
 The neuromuscular stimulation periods based on EMG data were used to identify the 
stimulation initiation (StI) and stimulation termination (StT) times in percent gait cycle. Each StI 
value was then compared to the initiation of swing phase for that respective gait cycle such that 
the StI timing could also be expressed relative to swing (e.g. Did stimulation occur early, prior to 
swing, or late, after initial swing?).  Similarly each StT value was expressed relative to the 
beginning of stance (e.g. Did stimulation cease after swing, during the subsequent stance phase?). 
Sample StI and StT times in both percent gait cycle and relative swing and stance periods are 
illustrated in Figure 62.  
 
Figure 62: Sample StI and StT as defined in terms of both gait cycle (gc) and swing and 
stance, respectively. 
 While StI and StT can be easily calculated, outliers often existed due to extraneous 
stimulations related to anomalies in the tilt sensor data (e.g. movement artifact due to tremors or 
limb circumduction and/or tilt sensor alignment errors).   As shown in Figure 63, omitting those 
gait cycles which included extraneous stimulations reduced much of the variability in the tilt 
sensor-based stimulation timing data.  These outliers and excessive variability were particularly 
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prominent for subjects S2 and S7 for whom standard deviations greater than 15% gait cycle were 
noted for all treadmill orientations prior to outlier elimination. Even after eliminating these 
outliers, however, subject S2 exhibited standard deviations in stimulation timing greater than 10% 
gait cycle.  For subject S7, omission of gait cycles with extraneous stimulations resulted in the 
elimination of nearly half of all gait cycles.  [These extraneous stimulations and excessive 
variability warranted re-analysis of several parameters for the Group A subset that excluded these 
two subjects from the sample population.] 
For most subjects (S2, S4, S7, S8, S10, and S12), StI occurred at approximately -20% 
swing, indicating that SI occurred during PS.  In contrast, for subject S5, StI occurred during 
early swing (~5-10% swing, during IS); for subject S6, StI was seemingly early, occurring at 
approximately -30 to -40% swing (during mid or terminal stance). In general, StI was delayed as 
the treadmill orientation progressed from declined to inclined, occurring later in stance, closer to 
swing phase itself. Post-hoc testing revealed statistically significant differences in StI between 
declined/inclined treadmill orientations, both before and after eliminating outliers.  StI occurred 
earlier in the gait cycle during declined walking (-15% swing) when compared with level (-10% 
swing); StI occurred later in the gait cycle during level (-10% swing) when compared to inclined 
(-7% swing) walking. Although differences were observed between level and inclined walking 
(Hypothesis 2b), these differences between level and non-level walking trials were not 
statistically significant. 
For most subjects (S2, S4, S6, S7, S8, and S10), StT occurred during the first 20% of the 
subsequent gait cycle (i.e. 120% gait cycle), indicating that StT typically occurred during loading 
response of the following cycle. For subjects S6 and S7, StT occurred as late as 130% gait cycle 
for inclined walking. StT was also quite late for subjects S5 and S12 (130 to 150% gait cycle). 
For these subjects and the inclined walking trials of subjects S6 and S7, StT most likely occurred 
during the subsequent mid or terminal stance. Although differences in StT were observed 
between level and non-level walking (Hypothesis 2b) for some subjects (S4, S5, S6, and S7), no 
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statistically significant differences in StT timing were observed between level and non-level 
ambulation.  
 
Figure 63: WalkAide tilt sensor-based stimulation timing before (top) and after (bottom) 
elimination of extraneous stimulations or outlier gait cycles. 
Note that StI occurs prior to swing, during the previous stance phase (negative %cycle); StT occurs after swing, 
during the subsequent gait cycle (> 100% cycle). 
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4.5.2.2 Heel Sensor-Based Stimulation Timing  
StI and StT  were also estimated for theoretical heel sensor-based stimulation for all 
subjects.  StI and StT were estimated based on WalkAide heel sensor data for the six subjects for 
whom WalkAide heel sensor data were available; StI and StT were estimated using F-scan data 
for subjects S7 and S8.  As for the tilt sensor-based stimulation, these StI and StT data were 
calculated both before and after eliminating outliers (e.g. gait cycles with extraneous 
stimulations). 
The results of the stimulation timing based on the WalkAide heel sensor (and F-scan 
insoles for subjects S7 and S8) before and after eliminating outliers can be seen in Figure 64. 
Outliers due to extraneous theoretical stimulations in this case may be attributed to heel pressure 
anomalies due to potential movement of the heel sensor or foot within the shoe, resulting in extra 
peaks in heel sensor loading. Although elimination of outliers did not reduce the intra-subject 
variability as dramatically as for tilt sensor-based stimulation, such elimination influenced the 
timing results for subjects S4 and S10. StI again occurred prior to swing (-20 to -25% swing 
before and after omitting outliers). Although StI occurred at approximately -20% swing for both 
tilt and heel sensor-based stimulations theoretical heel sensor-based StI demonstrated more 
consistent timing among subjects during non-level ambulation (Hypothesis 3b), with StI 
occurring outside this range for only one subject (S5).  As for tilt sensor programming, no 
statistically significant differences in heel sensor-based StI were observed with treadmill 
orientation; additionally, no statistically significant differences in StI between sensors (tilt vs. 
heel) for any non-level treadmill orientations were observed. 
 As with tilt sensor-based stimulation, StT occurred during the subsequent stance period.  
These StT times, however, were slightly earlier (approximately 0-10% stance or 100-110% gait 
cycle) than that observed during tilt sensor-based (approximately +20% stance or 120% gait 
cycle) stimulation.  Only one subject (S8) demonstrated theoretical heel sensor-based StT during 
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swing (95% gait cycle, -5% stance), prior to the subsequent gait cycle.  Again, no statistically 
significant differences in heel sensor-based StT were observed between treadmill orientations and 
no significant differences StI were observed between sensors for non-level surfaces. 
 
Figure 64: WalkAide heel sensor-based theoretical stimulation timing before (top) and after 
(bottom) elimination of extraneous stimulations or outlier gait cycles. 
Note that StI occurs prior to swing, during the previous stance phase (negative %cycle); StT occurs after swing, 
during the subsequent gait cycle (> 100% cycle). 
#: F-scan insole used to estimate heel loading. 
While extra stimulations occurred with both tilt sensor and (theoretical) heel sensor-based 
stimulations, fewer extra stimulations were observed for the theoretical heel sensor-based 
stimulation (Hypothesis 3a), particularly for subjects S2 and S7 for whom nearly 50% of the gait 
cycles resulted in extra stimulation with the tilt sensor and less than 10% of the gait cycles 
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resulted in extra stimulations for theoretical heel sensor-based stimulation. Eliminating all gait 
cycles with extraneous stimulations resulted in less variability (smaller standard deviations) in StI 
and StT for both tilt and heel sensor-based stimulation. As shown in Figure 65, the StI and StT 
timing variability was consistently less for the theoretical heel sensor-based stimulation than for 
the clinical tilt sensor-based stimulation.  However, these differences were statistically significant 
for StT during level walking only; no statistically significant differences in stimulation timing 
variability were observed during ambulation on non-level surfaces (Hypothesis 3b).  
 
Figure 65: Tilt sensor- and theoretical heel sensor-based WalkAide stimulation timing [StI 
(left) and StT (right)] variability. 
+, ++ denotes a statistically significant difference (0.05 and 0.01 levels, respectively) 
4.5.3 Study Groups 
Inconsistent WalkAide stimulation and high variability in StI and StT timing affects gait 
kinematics, influencing measures such as gait symmetry and toe clearance. StR values less than 
one, which indicate missed stimulations, result in minimal or no ankle dorsiflexion affecting toe 
clearance and gait symmetry measures. StR values greater than one (extraneous stimulations) 
result in anterior tibialis activation at various times during the gait cycle, providing potential 
ankle dorsiflexion that does not address foot clearance during swing.  Due to the poor StR and 
high variability in StI and StT timing observed for subjects S2 and S7, the temporal and 
kinematic data for these two subjects were omitted in the aforementioned Group A subset 
analyses.    
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4.6 F-SCAN PLANTAR PRESSURE DATA 
F-scan plantar pressure data were collected during WalkAide gait sessions and compared 
to the WalkAide heel sensor data for all subjects except S7 and S8 for whom WalkAide heel 
sensor data were not available.  This comparison was used to assess the validity of using F-scan 
heel box loading data as a substitute for the WalkAide heel sensor in the determination of 
theoretical heel sensor-based stimulation timing.   
Both the mean and maximum heel loading magnitudes were contrasted, as shown in 
Appendix D (Figure D1). As WalkAide heel sensor magnitude varied inversely with load (Figure 
32), the WalkAide loading data were converted by subtracting the maximum unloaded value or 
bias.  While the maximum heel loading magnitudes of the F-scan and heel sensor data were not 
correlated (R2 = 0.0004), the mean heel loading magnitudes of these two sensors were positively, 
although modestly, correlated (R2 = 0.19). 
 The mean heel loading (~stance) and unloading (~swing) duration for both the WalkAide 
and F-scan sensors was also contrasted. As shown in Figure D2, the heel load duration data for 
the F-scan versus WalkAide heel sensors were positively correlated, as illustrated by the 
relatively high correlation coefficient (0.91).  While the heel unloading duration data for these 
two sensors were also positively correlated (Figure D3), the correlation coefficient for the 
unloading duration (0.76) was less than that for the loading duration (0.91).  Based on these 
comparisons and positive correlations, the use of the F-scan sensor data as a substitute for the 
missing WalkAide heel sensor data (subjects S2 and S7) can be justified, particularly with respect 
to timing.  
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4.7 POWER ANALYSIS 
As the post-stroke population in this study was relatively non-homogenous, the various 
measured parameters were not normally distributed and non-parametric tests (Wilcoxon rank 
sum, Friedman) were necessary for statistical analysis. Non-parametric tests do not assume 
normal distribution, are more robust, and can accommodate the variability in the post-stroke 
population; however, these non-parametric tests are less powerful than parametric tests. As such, 
larger sample sizes are often required [55]. To determine the number of subjects necessary to 
achieve statistical differences (p>0.05) with sufficient power (P>0.80), as well as to determine the 
power of the various parameters of the current study, a priori and post hoc power analyses were 
conducted.  
 Three a priori power analyses were conducted to determine the number of subjects 
necessary to detect statistically significant differences, assuming small (0.2), medium (0.5) and 
large (0.8) effect sizes [55].  Sample sizes were determined for both individual, non-paired 
parameter analysis (e.g. GA and toe clearance of the affected limb for the WalkAide versus AFO 
treatments) and paired, repeated measures analysis (e.g. 30 gait cycles per subject for various 
temporal parameters), as shown in Table 15.  For individual, non-paired measures, 15- 208 
subjects are necessary to detect large and small effect sizes, respectively.  For paired, repeated 
measures analysis, 1-7 subjects are needed to detect large and small effect sizes, respectively.  
Table 15: A priori power analysis to determine sample size 
*assumes 30 steps per subject  
Effect  
Effect size, d 
[55] # subjects 
# of subjects for repeated 
measures analysis* 
Small 0.2 208 7 
Medium 0.5 35 2 
Large 0.8 15 1 
 
A priori and post hoc power analyses based on the actual effect sizes of current study 
were also conducted both to determine the number of subjects necessary to detect statistical 
significance and the actual statistical power.  The results of these power analyses are summarized 
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in Table 16 for the various temporal parameters. For the stance and total DLS durations on 
decline and level orientations, and the initial DLS on decline and incline orientations, a prior 
analysis revealed that eight subjects are sufficient to observe statistically significant differences 
(p>0.05) between treatments of the affected limb temporal parameters with sufficient power 
(P>0.80). Inclined swing duration and level initial DLS indicate that nine subjects are needed to 
detect statistically significant differences with sufficient power. Although statistically significant 
differences were observed for the affected limb second DLS period between treatments for 
declined and inclined walking, the statistical power for these parameters was low (P<0.50). 
Power analysis of the swing and second DLS duration during level walking indicate that more 
than 1000 subjects may be needed to detect statistically significant differences.  
Table 16: A priori and post hoc power analyses to investigate treatment effects of the 
affected limb temporal parameters 
Treatment effects: WalkAide versus AFO 
  Effect Size, d  
Power, P                                       
(post hoc) 
# of subjects                            
(a priori) 
  Decline Level Incline Decline Level Incline Decline Level Incline 
Stance Duration 0.22 0.19 0.03 0.84 0.71 0.07 6 8 260 
Swing Duration 0.16 0.00 0.18 0.61 0.05 0.67 10 >1000 9 
Initial DLS 0.40 0.18 0.36 0.99 0.67 0.99 2 9 2 
Second DLS 0.07 0.00 0.15 0.16 0.05 0.49 58 >1000 13 
Total DLS 0.26 0.27 0.12 0.94 0.95 0.37 4 4 18 
 
The a priori and post hoc power analyses were also conducted for the non-repeated 
temporal gait symmetry measures, as shown in Table 17. Based on the SR data collected in this 
study, more than 100 subjects are required to observe a significant difference in stance and/or 
swing phase SR on non-level surfaces; more than 1,000 subjects are required to detect statistically 
significant differences in these parameters for level walking. Similarly, more than 100 subjects 
are required to detect statistically significant differences in the temporal gait asymmetry index 
between treatments for both level and non-level walking. These large populations are necessary to 
observe statistically significant differences in temporal symmetry measures due to the small to 
moderate effect sizes (0.02≤d≤0.33) and low power (0.06-0.21).   
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Table 17: A priori and post hoc power analyses to investigate treatment effects of the 
temporal symmetry parameters 
 
Treatment effects: WalkAide versus AFO 
  Effect size, d 
Power, P                                                   
(post hoc) 
# of subjects                                                
(a priori) 
  Decline Level  Incline Decline Level  Incline Decline Level  Incline 
SR stance 0.16 0.02 0.13 0.11 0.06 0.09 446 >1000 682 
SR swing 0.32 0.10 0.13 0.20 0.08 0.09 113 >1000 658 
Gait Asymmetry Index 0.33 0.17 0.24 0.21 0.11 0.15 105 391 199 
  
The a priori and post hoc power analyses were also conducted for the non-repeated GA 
measures of the knee and ankle, as shown in Table 18. For all the functional phases of swing, 
more than 100 subjects are required to determine statistically significant differences in knee GA 
between treatments. Fewer subjects (N≥10) are needed to detect treatment differences in ankle 
GA.   
Table 18: A priori and post hoc power analyses to investigate treatment effects in GA during 
IS, MS and TS 
Treatment effects: WalkAide versus AFO 
Knee GA Effect Size, d 
Power, P                                       
(post hoc) 
# of subjects                  
(a priori) 
  Decline Level Incline Decline Level Incline Decline Level Incline 
IS max 0.22 0.26 0.25 0.07 0.08 0.07 331 237 269 
MS avg 0.03 0.13 0.14 0.05 0.06 0.06 16742 995 899 
TS avg 0.36 0.20 0.23 0.10 0.07 0.07 129 410 312 
Ankle GA Effect Size, d 
Power, P                                       
(post hoc) 
# of subjects                  
(a priori) 
  Decline Level Incline Decline Level Incline Decline Level Incline 
IS avg 0.16 1.32 1.26 0.06 0.67 0.63 665 11 12 
IS min 0.16 1.39 1.25 0.06 0.71 0.62 665 10 12 
MS avg 0.17 0.57 0.40 0.06 0.18 0.11 571 51 105 
TS avg 0.19 0.41 0.49 0.06 0.11 0.15 481 101 69 
 
Finally, the results for the a priori and post hoc power analyses for toe clearance 
treatment differences are summarized in Table 19. A priori tests reveal that only 2-4 subjects are 
necessary to observe statistically significant differences in the affected limb toe clearance for 
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level and inclined walking. Due to the small to moderate effect size (0.02≤d≤0.11) and low power 
(0.05-0.29), substantially larger subject populations (N≥24) are required to observe statistically 
significant treatment differences in the remaining (affected, level, or unaffected limb, all) toe 
clearance results.  
Table 19: A priori and post hoc power analyses to investigate treatment differences in 
affected and unaffected toe clearance, and limb differences in toe clearance 
Treatment effects: WalkAide versus AFO 
  Effect size, d 
Power, P                                       
(post hoc) 
# of subjects                  
(a priori) 
Toe Clearance Decline Level Incline Decline Level Incline Decline Level Incline 
Affected Limb 0.11 0.28 0.46 0.29 0.96 0.99 24 4 2 
Unaffected Limb 0.02 0.10 0.06 0.06 0.25 0.12 511 30 74 
Difference in Toe 
Clearance Effect size, d 
Power, P                                       
(post hoc) 
# of subjects                  
(a priori) 
Between Limbs 0.47 0.68 0.44 0.14 0.23 0.13 75 38 85 
 
4.8 SUMMARY 
 Temporal parameters, gait asymmetry, joint kinematics and WalkAide stimulation 
reliability and timing were examined to test the respective research hypotheses. Statistically 
significant differences between treatments in the stance and swing durations, as well as initial and 
second DLS periods were observed, demonstrating potentially improved balance with the AFO, 
and improved ankle function with the WalkAide. However, contrary to Hypothesis 1a, no 
statistically significant differences in temporal symmetry (i.e. SR and SI) were observed between 
treatments. Statistically significant differences between the mean and minimum ankle GA during 
IS between treatments were observed, with AFO ambulation demonstrating greater ankle GA 
during IS (supporting Hypothesis 1a), indicating greater kinematic symmetry of the ankle with 
the WalkAide.  No statistically significant differences in unaffected ankle ROM (GA 
denominator) between treatments were observed; the differences in ankle GA may therefore be 
attributed to differences in minimum ankle motion between the limbs during swing (GA 
numerator). 
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Significantly greater affected limb toe clearance was found during AFO versus WalkAide 
ambulation (Hypothesis 1b).  However, greater affected vs. unaffected limb toe clearance was 
observed with the AFO compared to the WalkAide, possibly indicating that the increased affected 
limb toe clearance may contribute to increased energy expenditure during AFO ambulation rather 
than increased treatment efficacy (Hypothesis 1b).  
WalkAide stimulation reliability and timing were investigated for the clinically 
programmed tilt sensor. Tilt sensor-based stimulation reliability (Hypothesis 2a) was not affected 
by non-level walking.  Stimulation initiation timing changed during level versus non-level 
walking (Hypothesis 2b); StI occurred earlier (closer to IS) as the treadmill progressed from 
declined to inclined orientation. In contrast, stimulation termination timing did not vary between 
level and non-level walking trials (Hypothesis 2b). 
Finally, theoretical WalkAide heel sensor stimulation reliability and timing were 
compared with the clinically programmed tilt sensor stimulation. Theoretical heel sensor 
stimulation resulted in more consistent, optimal (unity) StR values (six of eight subjects for all 
treadmill orientations) than for tilt sensor-based stimulation (four of eight study subjects for all 
treadmill orientations), Hypothesis 3a.  Stimulation timing, both StI and StT, during non-level 
walking was unaffected by the WalkAide sensors (tilt vs. heel, Hypothesis 3b). 
These results and their clinical relevance will be discussed further in the Discussion 
chapter. 
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CHAPTER 5: DISCUSSION 
In 1961 Liberson and colleagues first proposed a neuroprosthesis to treat foot drop [33]. 
Currently, there are three FDA approved neuroprostheses on the market [34]. Despite numerous 
studies demonstrating that the use of a neuroprosthesis increases walking speed and decreases 
energy cost, insurance reimbursement for neuroprostheses is often denied. Reimbursement denial 
is usually attributed to the lack of studies documenting conclusive evidence of the benefits of a 
neuroprosthesis over conventional therapies such as the AFO; only two studies have directly 
compared neuroprosthesis function to that of an AFO [39,40]  (Section 2.5). In addition, while 
walking speed and energy cost are clinically relevant, these parameters provide limited insight 
into the control of walking and the impact of neuroprostheses on functional rehabilitation goals 
such as weight bearing symmetry, improved balance and decreased risk of falling. Therefore, 
research comparing neuroprosthesis and AFO function using more specific gait parameters may 
make neuroprostheses more readily available to stroke patients. 
In addition to these limitations in functional measures used to date, previous studies 
investigated level walking only, ignoring non-level walking surfaces routinely encountered 
during household and community ambulation. Significant changes in joint kinematics occur 
during declined and inclined ambulation ([41], Section 2.6.1). Since WalkAide stimulation is 
based on the angle of the tibia, the reliability and timing of WalkAide tilt sensor-based 
stimulation may change during non-level walking, affecting toe clearance and causing an 
increased risk of falling. 
Due to limitations in prior research involving neuroprostheses to treat foot drop in post 
stroke individuals, the goal of this research study was to conduct more thorough analyses of post-
stroke ambulation, contrasting AFO and neuroprosthesis treatments during both level and non-
level walking. The specific research hypotheses were:  
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1) Use of a neuroprosthesis for post-stroke individuals with drop foot will improve a) temporal 
and kinematic gait symmetry and b) toe clearance on both level and non-level surfaces when 
compared to an AFO,  
2) Non-level walking will affect the WalkAide tilt sensor-based stimulation reliability and 
timing, resulting in a) missed or extraneous stimulations during non-level ambulation and b) 
changes in stimulation initiation/termination timing during ambulation on non-level surfaces, 
and  
3) The use of the WalkAide heel sensor for stimulation control will result in a) improved 
stimulation reliability and b) more consistent stimulation timing with respect to tilt sensor 
based control during non-level ambulation.  
The results of this study and the testing of the aforementioned hypotheses will be discussed in this 
chapter. Temporal parameters, gait symmetry, joint kinematics, toe clearance, WalkAide 
stimulation reliability and timing during ambulation on level and non-level surfaces, power 
analyses results, study limitations, and clinical implications will be discussed. 
5.1 TEMPORAL PARAMETERS 
 Temporal parameters are the most common clinical measures used to assess the function 
of post-stroke individuals. Although these measures are limited in their ability to describe gait 
pathologies and compensatory mechanisms [39, 42], temporal and spatial parameters are useful in 
rehabilitation planning due their ease of measure, reproducibility, and correlation to overall 
functional status [22]. Walking speed is the most common temporospatial parameter measured 
when assessing stroke subjects’ function; it has been used extensively to evaluate neuroprosthesis 
function.  However, studies have shown that comprehensive gait evaluation should include 
descriptions of stance and swing phase duration and proportion, as well as measures of gait 
asymmetry [17, 19, and 22].  
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5.1.1 Cadence and Gait Cycle Duration   
The mean cadence, a measure indirectly related to walking speed, was approximately the 
same for the affected and unaffected limbs during both WalkAide and AFO ambulation, as seen in 
Figure 38. Although no statistically significant differences in cadence were observed, subject 
cadence was generally faster with the AFO versus WalkAide for both limbs. Increased cadence 
with AFO use could indicate that the subjects either increased their walking speed or took shorter 
steps. The specific mechanism for the increased cadence could not be determined, however, as 
stride parameters are not acquired during treadmill ambulation.   
The observed cadences (61 to 63 steps/min) for these post-stroke subjects were 
substantially lower than that of healthy, age-matched individuals (101.0 steps/min) during level 
over ground self-selected walking [58]. The cadence of these post-stroke subjects was more 
comparable to that of other post-stroke subjects, as summarized in Table 20. The cadence values 
reported in this study during treadmill ambulation without an assistive device (but with handrail 
support) were nearly 20% less than that reported in other post-stroke studies of over ground 
walking with an assistive device.  The slower cadences of the current study (~63 steps/min) may 
be largely attributed to the elevated treadmill and moving belt, as well as increased subject 
impairment in comparison to post-stroke subjects who did not require assistive devices for 
ambulation (~89 steps/min, [45]). However, the post-stroke subjects in the current study also 
exhibited slower cadences than reported in previous studies examining neuroprostheses (86.1 
steps/min, [60]) suggesting that the current study’s subjects may be moderate, not high 
functioning, individuals – as confirmed by their lower extremity Fugl-Meyer scores (range: 21-28 
and mean: 24.4; severe 0-19, moderate 20-28, mild >29 [61]). 
 The mean gait cycle duration, a parameter which varies inversely with cadence, was also 
compared between treatments, as shown in Figure 38. During inclined walking, the gait cycle 
duration was typically prolonged for AFO ambulation.  In contrast, a prolonged gait cycle 
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duration was observed with WalkAide use during declined and level walking.  However, these 
treatment differences in gait cycle duration were not statistically significant. Similar to cadence, 
gait cycle duration is dependent on walking speed. Increases in both cadence and gait cycle 
duration reflect increased walking speed (more, longer steps). Increased walking speed with AFO 
use contradicts previous studies comparing a neuroprosthesis to an AFO. However, the increased 
walking speed in concert with greater GA with the AFO versus WalkAide suggests that increased 
walking speed was not linked to increased kinematic gait symmetry and therefore do not reflect 
improved gait function.  
The gait cycle durations for these post-stroke subjects (1.81 to 1.94 sec) were much less 
than that reported for healthy, age-matched individuals (1.10 sec) during self-selected, level, over 
ground walking [58]. As seen by Table 20 in which the gait cycle durations measured during level 
treadmill ambulation were contrasted with previous investigations involving post-stroke subjects, 
the gait cycle durations measured in the current study (~1.9 sec) were comparable to that reported 
by Roth et al. (2.2 sec) [22], and nearly 25-30% greater than that reported by others [39, 42, 45]. 
This again suggests that the current study’s subjects may be moderate, not high functioning, post-
stroke individuals. 
As alluded to above, the slower cadence and prolonged gait cycle duration in the current 
study may also be attributed, at least in part, to treadmill versus over ground walking. Level 
treadmill ambulation of post-stroke individuals with training and/or prior treadmill experience 
typically results in faster cadences than during over ground walking [45]. While three of the 
current study’s subjects had treadmill experience, five subjects had no prior treadmill walking 
experience since their stroke.  The slower cadence demonstrated by the subjects in the current 
study may have been due to tentativeness and lack of confidence due to the moving belt, or 
heightened insecurity as the treadmill was elevated on a ramp – despite the fact that subjects were 
encouraged to grasp the treadmill handrails. Additionally, subjects were not blinded to treadmill 
speed and nearly all subjects selected the same speed for all treadmill orientations (S2, S4, S5, 
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S7, S8, S10) and/or for both treatments (S4). Qualitative observation of the current subjects’ gait 
indicated that all but one subject (S7) walked faster over ground than on the treadmill.  
 As expected for this non-homogeneous post-stroke population, substantial variability in 
cadence and gait cycle duration (nearly 20% for the WalkAide, 10% for AFO use) was observed.  
Large variability in cadence (approximately 14% [45], 28% [42], and 26% [18]) and gait cycle 
duration (approximately 11-14% [39], 41% [22] and 10% [60]) has been reported in previous 
studies investigating temporal parameters of post-stroke individuals.  This variability affects the 
statistical power, making it more difficult to detect significant differences between treatments (or 
between limbs or treadmill orientations).  No statistically significant differences in cadence or 
gait cycle duration were found between treatments (or between limbs or treadmill orientations) 
across all subjects and for the Group A subset.  Differences in these parameters may still, 
however, exist although more subjects are needed to effectively contrast the AFO/WalkAide 
treatments, affected/unaffected limbs, and treadmill orientations (see Section 4.7).   
Table 20: Comparison of cadence and gait cycle duration [mean and (s.d.)] during level 
walking for various post-stroke investigations; DNS= does not specify 
Reference N Treatment Assistive 
Device 
Surface Cadence 
(steps/min) 
Gait cycle 
duration (sec) 
Current 
Study 8 
WalkAide           
(4 wks)  none Treadmill 62.6 (12.6) 1.91 (.38) 
AFO none Treadmill 63.5 (7.7) 1.88 (.24) 
Brouwer, 
2009 [45] 10 none none 
Over ground 87.0 (11.4) - 
Treadmill 90.8 (13.4) - 
Gok, 2003 
[59] 12 AFO,  100% 
cane, 
100% Over ground 65 - 
Kim, 2003 
[42] 20 none 
cane, 
~25% Over ground 73.9 (20.7) - 
Ring, 
2009 [39] 15 
AFO 
DNS 
Over ground - 1.48 (0.21) 
Bioness (4 wks) Over ground - 1.47 (0.18) 
Bioness (8 wks) Over ground - 1.41 (0.16) 
Roth, 
1997 [22] 25 DNS 
cane or 
walker  Over ground 54.4 (2.4) 2.22 (.92) 
von 
Schroeder, 
1995 [18] 49 AFO, ~15% 
cane or 
walker, 
25% Over ground 84.8 (22.4) 1.5 (.06) 
Voigt, 
2000 [60] 8 
KDC 2000A, 
(similar to ODFS) DNS Over ground 86.1 (8.6) 1.39 (0.14) 
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5.1.2 Stance and Swing Phase Durations 
Although no statistically significant differences in gait cycle duration were observed 
between treatments (or limbs or treadmill orientations), resolving the gait cycle further into stance 
and swing phase duration may better reflect functional changes in the gait of post-stroke subjects. 
Differences in stance and swing phase durations between treatments and/or limbs may indicate 
motor impairment [62], difficulty with limb advancement [19], weakness of the affected limb [18, 
63], and instability [18] or poor balance [63]. Specifically, stance duration was found to be an 
indicator of the severity of motor impairment, with prolonged stance duration of the unaffected 
limb linked to increased impairment and weakness of the affected limb [62]. Prolonged affected 
limb swing duration may reflect difficulty in advancing the affected limb [19], possibly due to 
decreased affected ankle power during push-off in late stance and early swing [17]. Swing phase 
duration is also related to single limb support (SLS) duration of the contralateral limb; therefore 
prolonged affected limb swing corresponds to prolonged SLS of the unaffected limb. Shorter SLS 
duration of the affected limb (i.e. decreased swing duration of unaffected limb) may indicate 
difficulty in balancing or full weight bearing on the affected leg [18-19, 62]. As such, increasing 
affected limb SLS duration is a common rehabilitative goal [19].    
As shown in Figure 39, the mean stance duration of the unaffected limb (AFO: 1.31-
1.435 seconds, WA: 1.4036-1.464 seconds) was prolonged compared to the affected limb (AFO: 
1.31-1.4139 seconds, WA: 1.385-1.421 seconds) for both treatments and all treadmill 
orientations; these differences were statistically significant for level and inclined 
WalkAide ambulation and decline AFO ambulation. Group A showed these significant 
results for AFO decline and WalkAide incline, but not WalkAide level ambulation.  As 
only some of these differences in stance duration between limbs were statistically significant, 
further analysis of additional subjects is needed to confirm these results as population variability 
and limited sample size may mask significant differences (see Section 5.5). This similarity in 
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stance duration between limbs may reflect increased gait symmetry, although kinematic 
symmetry (see Section 5.2.1) during stance was not observed.  Prolonged stance duration with the 
unaffected limb is commonly observed with impaired ambulators, such as post-stroke amputees, 
and is often caused from trouble with balance and weakness of the affected limb when compared 
to the unaffected limb [15, 22].   
 Statistically significant differences in stance duration were also observed between 
treatments for both limbs. As shown in Figure 39, prolonged stance duration was observed during 
WalkAide (unaffected: 1.40-1.46, affected: 1.38-1.42 seconds) versus AFO (unaffected: 1.31-
1.45, affected: 1.31-1.41 seconds) ambulation. For all subjects, these differences were statistically 
significant for the affected limb during level walking and the unaffected limb during decline and 
level walking.  For the Group A subset, these differences were only statistically significant during 
level walking for both limbs.  The prolonged stance durations during level WalkAide ambulation 
suggest that the AFO may address motor impairment and weakness of the affected limb more 
effectively on level surfaces, although the WalkAide and AFO treatments are comparable in 
addressing these problems during non-level ambulation.  Further analysis of additional subjects, 
however, may reveal additional differences with treatment (see Section 4.7 regarding limitations 
due to the small sample size and population nonhomogeneity).    
Although stance phase is important for gait analysis, the treatments investigated in this 
study primarily influence the swing phase of gait; therefore differences in swing duration were 
expected between limbs, and between treatments.  For all subjects, the affected limb swing 
duration (WalkAide: 0.52-0.54, AFO: 0.50-0.55 seconds, Figure 39) was significantly prolonged 
with respect to that of the unaffected limb (WalkAide: 0.50-0.51, AFO: 0.50-0.52 seconds) during 
inclined walking, suggesting potential difficulties with limb advancement during inclined 
ambulation. . Significantly longer swing phase durations for the unaffected versus affected limb 
were also observed during declined AFO ambulation for both the full population and the Group A 
subset.  
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Similar affected and unaffected limb swing duration during level and declined walking 
may indicate that limb advancement was easier during declined and level walking with respect to 
inclined walking. Swing duration during inclined walking requires additional knee and hip 
flexion [41]. As these post-stroke subjects lacked sufficient affected limb muscle strength for 
increased knee and hip flexion (e.g. lower MMT scores for the hip and knee on the affected 
versus unaffected side), the prolonged affected limb swing phase duration during inclined 
walking was to be expected. 
For both the full subject population and Group A subset, the unaffected limb swing 
duration was significantly longer with the AFO versus WalkAide treatment during level (full 
population) and inclined (full population and Group A subset) walking. The prolonged unaffected 
limb swing duration with AFO treatment implies longer affected limb SLS duration with AFO 
ambulation, suggesting increased affected limb stability and balance with the AFO during 
inclined ambulation. Greater stability during stance during AFO ambulation is expected since the 
AFO provides structural support during mid to late stance.  In contrast, such stance stability is not 
provided by the WalkAide, although stimulation often occurs during late stance prior to swing.   
The stance and swing phase duration measured during level treadmill ambulation in this 
study are contrasted with that of previous investigations of post-stroke subjects in Table 21. The 
stance durations reported in the current study (WalkAide: 1.38, AFO: 1.36 seconds), while nearly 
double that reported for healthy, age-matched subjects (0.67 seconds, [58]), were comparable to 
that measured by Kim for the unaffected limb (~1.34 seconds, [42]) during over ground walking 
with no assistive device (75% subjects) or a cane (25% subjects). The stance duration of the 
affected and unaffected limbs measured in the current study, however, were greater than that 
reported in other studies [18, 42, 45; affected limb [42]].  Although many of the post-stroke 
individuals did not require assistive devices during over ground and treadmill ambulation, their 
stance durations were almost half (0.65-0.87 seconds) that measured in the current study. Only 
Roth’s subjects [22], all of whom required an assistive device for ambulation, exhibited longer 
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stance durations (affected: 1.67, unaffected: 1.86 seconds) than those reported in the current 
study.  Contrary to the current study for which the stance duration of the affected and unaffected 
limbs were similar, these prior investigations all reported shorter stance durations for the affected 
versus unaffected limb. Shorter stance durations for the affected limb would reflect temporal 
based asymmetry, associated with gait inefficiency, difficulty with balance control, and risk of 
musculoskeletal injury and bone loss [43]. Although the current study’s subjects had longer stance 
durations, they demonstrated greater temporal symmetry, which may reflect increased gait 
efficiency and balance when compared to those in previous studies, but is more likely an artifact 
of treadmill ambulation [48] and/or use of the handrail support, see Section 5.6.1.4. 
The mean swing duration of both the affected and unaffected limbs was longer than the 
swing duration reported for healthy, age-matched individuals over the age of 51 years (0.43 
seconds [58]). However, the mean swing duration of both limbs was similar to that reported in 
previous studies involving post-stroke subjects. While the stance duration measured in the current 
study differed from that reported in the literature for post-stroke individuals, the swing durations 
were more comparable (current study: 0.51-0.53, literature: 0.44-0.65, mean: 0.51 seconds).  
The prolonged stance duration and comparable swing durations reported in the current 
versus literature studies suggest that the prolonged gait cycle duration in the current study was 
primarily due to increases in stance duration. Although the subjects in the current study exhibited 
greater motor impairment than many of the post-stroke subjects that required assistive devices in 
prior investigations, the current subjects’ ability to advance their limbs during swing while 
ambulating with the WalkAide and AFO was comparable.  
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Table 21: Comparison of stance and swing duration [mean and (s.d.)] during level walking 
with previous studies of post-stroke ambulation 
Reference N Treatment Assistive 
Device 
Surface Limb Stance Duration Swing 
sec % cycle sec % cycle 
Current 
Study 
8 WalkAide    
(4 wks) 
none Treadmill Aff 1.38 
(.31) 
72.2  
(3.4) 
0.52  
(.09) 
27.8  
(3.4) 
Unaff 1.39 
(.32) 
72.8  
(4.2) 
0.51  
(.09) 
27.2  
(4.2) 
AFO  none Treadmill Aff 1.36 
(.19) 
72.0  
(4.2) 
0.53  
(.08) 
28.0  
(2.7) 
Unaff 1.37 
(.20) 
73.0  
(2.8) 
0.52  
(.12) 
27.0  
(2.8) 
Brouwer, 
2009 [45] 
10 none none Over 
ground 
Aff 0.82  
(.13) 
63.3  
(3.2) 
0.48  
(.09) 
36.7  
(3.2) 
Unaff 0.87  
(.16) 
66.3  
(3.1) 
0.44  
(.05) 
33.7  
(3.1) 
Treadmill Aff 0.65  
(.09) 
50.8  
(8.0) 
0.65 
(.18) 
49.2  
(8.0) 
Unaff 0.71  
(.14) 
54.7  
(7.0) 
0.59  
(.13) 
45.3  
(7.0) 
Kim, 2003 
[42] 
20 none cane, 
~25% 
Over 
ground 
Aff 1.14  
(.45) - - - 
Unaff 1.34  
(.51) - - - 
Roth, 
1997 [22] 
25 DNS Cane or 
walker  
Over 
ground 
Aff 1.67  
(0.8) 
74        
(8) 
0.59  
(.27) 
26     
(9) 
Unaff 1.86  
(.94) 
82       
(8) 
0.41  
(.10) 
18        
(9) 
von 
Schroeder, 
1995 [18] 
49 AFO, ~15% cane or 
walker, 
25% 
Over 
ground 
Aff 1.06  
(0.5) 
67.6  
(6.6) 
0.51  
(.23) 
33.0 
(6.6) 
Unaff 1.14  
(0.6) 
70.8  
(8.6) 
0.43 
(0.19) 
29.2  
(8.6) 
  
5.1.3 Double Limb Support Duration 
 Another temporal parameter commonly examined is double limb support (DLS). 
Prolonged affected limb DLS with either treatment may be required to control the continuously 
changing base of support during ambulation and may reveal balance differences between 
treatments. Goldie et al. [19] suggest that each DLS support phase (initial and second) be 
investigated individually due to the unilateral deficits that occur with stroke. Examination of both 
DLS periods can give insight into not only balance, but also weight acceptance and ankle 
function.  During the initial period of DLS (e.g. loading response), the limb contacts the ground 
initiating stance, accepting body weight, absorbing shock, and facilitating forward progression 
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(see Section 2.2.1). As such, prolonged initial DLS may indicate difficulty with weight 
acceptance or weight transfer to that limb. The second period of DLS (e.g. pre-swing) 
corresponds to weight transfer from the ipsilateral to the contralateral limb in preparation for 
ipsilateral swing. The decreased load on the ipsilateral limb and activation of the ipsilateral 
gastrocnemius typically results in rapid plantar flexion. A prolonged latter DLS period for the 
affected limb may indicate difficulty with affected limb push off or loading response of the 
unaffected limb. 
The initial DLS durations were contrasted between treatments (Figures 40 and 43). 
Prolonged (statistically significant) initial DLS durations for the affected limb were observed on 
all treadmill orientations while using the WalkAide versus AFO for all subjects and the Group A 
subset. This prolonged initial DLS may reflect greater difficulty with affected limb weight 
acceptance using the WalkAide compared to the AFO which may be attributed to the enhanced 
structural stability of the AFO.  
When comparing the second period of DLS between treatments for all subjects, the 
affected limb exhibited significantly prolonged second DLS periods for AFO versus WalkAide 
use during declined and inclined ambulation. (For the Group A subject, treatment differences in 
the latter period of DLS were statistically significant during declined walking only.) The 
prolonged periods of latter DLS during non-level walking with the AFO suggests that the 
WalkAide, not the AFO, allows the affected limb to plantar flex more effectively during pre-
swing and ease weight transfer during unaffected limb loading response. 
Finally, the total DLS was significantly longer with WalkAide (0.87-0.92 seconds) versus 
AFO (0.80-0.89 seconds) during level ambulation for both the affected and unaffected limbs, 
suggesting generally improved weight acceptance and transfer with AFO versus WalkAide use. 
This result must be interpreted with caution, however, as the WalkAide typically resulted in 
prolonged stance duration than that observed during AFO ambulation.  As such, the total DLS 
duration was also contrasted between treatments when expressed as a function of gait cycle 
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percentage.  Using this normalized total DLS duration, WalkAide ambulation actually resulted in 
similar total DLS duration as during AFO ambulation (45 %, see Table 22). The prolonged 
periods of total DLS during level WalkAide walking may therefore be attributed to the prolonged 
stance duration rather than functional differences between treatments.   
These DLS durations were compared to existing literature involving level ambulation of 
post-stroke subjects, as seen in Table 22. The normalized total DLS durations for both limbs and 
treatments in the current study were approximately 40-45% gait cycle, within the range of that 
reported in the literature (37.4 % [18], 52 % [22]). The initial DLS duration time (0.41-0.46 
seconds) reported for the current study was longer for both the affected and unaffected limbs than 
that reported previously by Goldie et al. (0.23-0.25 seconds, [19]). However, the normalized 
initial DLS period for these two studies is similar (20-24% vs. 18%).  The differences in initial 
DLS duration time between these studies may be attributed to faster cadence of Goldie’s subjects 
(85.2 steps/min) versus that of the current study (~63 steps/min), as cadence is inversely related 
to gait cycle duration. 
Table 22: Comparison of initial and total DLS durations [mean and (s.d.)] during level 
walking with previous studies of post-stroke ambulation 
Reference
  
N Treatment Assistive 
Device  
Surface DLS 
Duration Initial DLS Duration 
 sec 
% 
cycle  sec % cycle 
Aff Aff Unaff Aff Unaff 
Current 
Study 
8 WalkAide 
(4 wks) 
none Treadmill 0.92 
(.27) 
45  
(6) 
0.45 
(.21) 
0.46 
(.13) 
21 
(5) 
23  
(3) 
AFO  none Treadmill 0.87 
(.16) 
45  
(4) 
0.41 
(.11) 
0.46 
(.12) 
20 
(3) 
24  
(3) 
Roth, 
1997 [22] 
25 DNS Cane or 
walker  
Over 
ground - 
52 
(17) - - - - 
von 
Schroeder, 
1995 [18] 
49 AFO, 
~15% 
cane or 
walker, 
25% 
Over 
ground - 37 (11) - - - - 
Goldie, 
2001 [19] 
42 none none Over 
ground - - 
0.25 
(.15) 
.23 
(.20) 
18 
(6) 
18  
(3) 
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5.1.4 Stride Time Variability  
 Prior investigation of post-stroke individuals ambulating in both an AFO and a 
neuroprosthesis has been limited (see Section 2.5). One parameter previously reported is swing 
time variability of the unaffected limb. Since swing duration of the unaffected limb is also the 
SLS duration of the affected limb, the unaffected limb swing time variability can provide insight 
into gait stability, balance, and fall risk [39, 64 and 65]. Swing time variability is independent of 
walking speed and thus may indicate changes in a subject’s balance and fall risk that may not be 
identified by walking speed.  
To quantify swing time variability, the coefficient of variation (CV) of the unaffected 
limb swing time was determined. As shown in Figure 44, greater swing time variability was 
observed during WalkAide [All: 4.45 ± 1.97, Group A: 3.97 ± 1.82] versus AFO [All: 3.43 ± 
0.81, Group A: 3.47 ± 0.82] ambulation for all treadmill orientations; however, this trend was not 
statistically significant. Large variability of the unaffected limb swing time or affected limb SLS 
duration may indicate affected limb weight bearing difficulty, instability, and balance problems. 
As such, the trend of increased unaffected limb swing time variability during WalkAide 
ambulation may reflect greater affected limb stance instability or balance problems, indicative of 
increased risk of tripping and falling while using the WalkAide compared to the AFO.  
The CV has been used previously to quantify swing time variability. Ring et al. [39] 
contrasted unaffected limb swing time variability for 15 post-stroke individuals using both a 
neuroprosthesis (NESS L300, Bioness) and an AFO during level, over ground walking. While no 
statistically significant differences between treatments after 4 weeks of neuroprosthetic adaptation 
were reported, a significant decrease in swing time variability with the neuroprosthesis versus 
AFO was observed after 8 weeks of neuroprosthetic acclimation.  
While the current study also incorporated a 4 week neuroprosthesis acclimation period, 
the acclimation protocol varied between these two studies, as did the timing of the AFO gait 
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analysis.  The initial adaptation period in the Ring’s study involved only partial use of the 
neuroprosthesis in conjunction with the AFO, while subjects in the current study achieved full-
time use of the WalkAide after 2 weeks. Ring et al. only tested the AFO at the gait session 
following the initial neuroprosthesis adaptation period. However, overall function of the subject 
could have increased during this time, decreasing the swing time variability in both the AFO and 
WalkAide. In the current study, half of the subjects were tested in the AFO following testing in 
the WalkAide. Therefore, a possible carry-over effect due to WalkAide treatment may have 
contributed to the decreased AFO variability that was not observed in Ring’s study.  
Overall, both studies indicate that a four week adaptation period with a neuroprosthesis 
may not be sufficient to significantly improve swing time variability when compared to an AFO. 
However, Ring et al. found a significant decrease in swing time variability with the 
neuroprosthesis versus AFO after 8 weeks of neuroprosthetic acclimation. As such, future studies 
should include at least 8 weeks of neuroprosthesis acclimation to assess differences in swing time 
variability between treatments; additional acclimation to the AFO is not necessary. 
5.1.5 Summary of Temporal Parameter Findings 
 Temporal parameters are the most common parameters used to assess the lower extremity 
motor function of post-stroke individuals due to their ease of measure, reproducibility, and 
correlation to overall function. Temporal parameters, such as cadence and swing duration, were 
compared between treatments to determine if the use of a neuroprosthesis influences temporal 
parameters and/or temporal symmetry on both level and non-level surfaces when compared to an 
AFO. 
 Although trends of greater cadence during AFO versus WalkAide  use (all treadmill 
orientations) and prolonged gait cycle duration during AFO versus WalkAide use (inclined 
walking) were observed, no statistically significant differences in either parameter were detected.  
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The unaffected limb exhibited significantly longer stance duration than the affected limb 
(both treatments), consistent with previous research. Longer unaffected limb stance durations 
suggest temporal asymmetry with both treatments.  The stance duration was significantly 
prolonged during WalkAide versus AFO ambulation (level walking, both affected and unaffected 
limbs, declined walking for the unaffected limb only). These results suggest that the AFO may 
address motor impairment and weakness of the affected limb more effectively than the WalkAide 
during level ambulation.  
As the treatment objective of both AFO and WalkAide treatment is to assist with foot 
clearance during swing, differences in swing duration between treatments were expected.  
Significantly prolonged swing duration was observed for the affected versus unaffected limb 
(inclined walking) for both treatments. This temporal swing asymmetry suggests that inclined 
walking adversely affects limb advancement for both treatments; results investigating temporal 
symmetry based on swing duration (SR) can be found in Section 5.2.1.1. Significantly prolonged 
unaffected limb swing duration (e.g. prolonged affected limb SLS) was observed during AFO 
versus WalkAide ambulation (level and inclined orientations). Prolonged affected limb SLS 
reflects increased balance and limb stability, suggesting that the AFO improves balance and limb 
stability when compared with the WalkAide during level and inclined ambulation.  This  result  is 
most likely due to the extra structural support provided by the AFO during mid to late stance 
which is not present with the WalkAide. 
The initial DLS duration of the affected limb was significantly longer during WalkAide 
versus AFO ambulation (all treadmill orientations). The shorter initial DLS duration of the 
affected limb during AFO use suggests improved affected limb weight acceptance, which may be 
attributed to the enhanced structural support of the AFO. Significantly prolonged second DLS 
durations were observed during AFO versus WalkAide ambulation (non-level: inclined and 
declined), reflecting potential difficulty with affected limb plantar flexion during pre-swing. As 
such, the WalkAide may better facilitate affected limb plantar flexion during pre-swing.  
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Greater swing time variability was observed with the WalkAide versus AFO (all treadmill 
orientations), although these treatment differences were not statistically significant.  
5.2 GAIT SYMMETRY AND KINEMATIC PARAMETERS 
 Full gait analysis and investigation of lower extremity joint kinematics have been used to 
assess functional rehabilitative gains for individuals post-stroke; specifically, symmetry in weight 
bearing and weight transfer between the affected and unaffected limbs [45- 47], as well as 
temporal symmetry of stance and swing duration, have been investigated [30, 43, 45].  However, 
while temporal asymmetry may reflect differences in motor function, muscle strength, balance, 
and ankle function of the affected versus unaffected limbs, investigation of kinematic symmetry 
(or asymmetry) is necessary to fully quantify gait changes post-stroke.   
5.2.1 Temporal Based Gait Symmetry 
The investigation of temporal gait symmetry has most commonly been conducted using 
the symmetry ratio (SR).  This measure, suggested by Patterson et al., may indicate gait 
inefficiency, difficulty with balance control, risk of musculoskeletal injury, and bone loss [43]. 
5.2.1.1 Symmetry Ratio 
SR’s for stance and swing durations for the current study were calculated using Equation 
1 (Section 2.6.2.2).  Across all subjects, the SR for stance duration during level ambulation was 
0.99 with both the WalkAide and the AFO (Figure 45), while SR for stance duration during non-
level walking ranged from 0.97 to 1.00. Analysis of the SR for stance duration of the Group A 
subset revealed similar results. The SR for swing duration for all subjects was also similar 
between treatments [AFO: 1.03 ± 0.15, WA: 1.05 ± 0.15] during level treadmill walking and non-
level (0.97-1.10) walking for both treatments. Similar ranges (0.97-1.06) for swing SR’s were 
observed for the Group A subset. No statistically significant differences in stance or swing 
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duration SR’s were observed between treatments (AFO versus WalkAide) on any treadmill 
orientation, suggesting similarities in gait efficiency, balance control and injury risk between 
treatments (Hypothesis 1a). The lack of statistically significant differences in SR between 
treatments may also be attributed to the small sample size (n=8) and large inter-subject variability 
(0.15), as well as temporal symmetry artifact due to treadmill ambulation [48]. 
Patterson et al. compared the SR’s for stance and swing duration for 161 post-stroke 
subjects and 81 age- matched controls. The SR for stance duration was 1.09 ± 0.10 for the post-
stroke subjects and 1.02 ± 0.02 for healthy control subjects.  For swing, the SR was 1.24 ± 0.34 
for the post-stroke subjects and 1.02 ± 0.02 for healthy control subjects. The SR’s for both stance 
and swing phase duration differed significantly between the post-stroke and age-matched healthy 
subjects. Note that the “affected” limb for the healthy control subjects was randomly assigned; 
therefore, an SR range from 1.02 ± 0.02 could also be reported as 0.98 ± 0.02. 
The SR for stance duration was comparable for the post-stroke subjects in the current 
study was most similar to Patterson’s healthy control (not post-stroke) subjects. This suggests that 
both the WalkAide and AFO allowed for “normal” symmetry of the stance phase duration during 
both level and non-level ambulation. Since the SR for stance duration of the current study’s 
subjects was more similar to Patterson’s normal versus post-stroke subjects, the current study’s 
subjects may be considered higher functioning (i.e. greater gait efficiency and balance) than the 
post-stroke subjects in Patterson’s study. However, Patterson’s subjects were assessed during 
over ground walking; the moving belt of the treadmill in the current study may have forced 
symmetry that might not otherwise be observed during over ground walking. As such, 
comparisons between the study subjects are not conclusive. 
The swing SR for the post-stroke subjects in the current study was also most similar o 
that for Patterson’s healthy subjects, again suggesting near normal swing duration SRs for the 
current study’s subjects. Near normal swing duration SR’s suggest greater gait efficiency and 
balance, although this is inconclusive do to the potential influence of the treadmill on temporal 
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symmetry. The large variability in SR swing duration in the current study is similar to that 
measured for Patterson’s post- stroke subjects, suggesting that some asymmetric swing durations 
may exist with WalkAide and/or AFO treatments. Due to the lack of trends or statistically 
significant differences in swing duration SR between treatments, neither treatment increased 
swing duration symmetry more effectively than the other.  Further study of additional subjects is 
needed to confirm this. 
5.2.1.2 Gait Asymmetry Index 
In contrast to the aforementioned temporal symmetry measure, Ring et al. [39] defined a 
temporal asymmetry measure, the gait asymmetry index, to contrast swing phase duration for 
AFO versus neuroprosthesis treatments. 
Previous research has shown that large swing time asymmetry indices reflect uneven 
weight distribution and potential increased risk of falling. Swing asymmetry may be attributed to 
insufficient power generated for swing by affected limb push-off and/or increased time required 
for affected foot placement and weight acceptance [64].  
Gait asymmetry indices for swing are summarized in Figure 46. The swing gait 
asymmetry indices for all subjects were greater during WalkAide (0.053-0.065) ambulation on all 
treadmill orientations when compared to the AFO gait asymmetry indices (0.044-0.052); these 
differences, however, were not statistically significant (Hypothesis 1a). Similar results were 
observed for the Group A subset, again with no statistically significant differences in gait 
asymmetry index between treatments. The trend in increased swing asymmetry during WalkAide 
ambulation suggests increased asymmetry of weight distribution and increased risk of falling 
while using the WalkAide compared to the AFO on all treadmill orientations. However, these 
differences in the swing gait asymmetry index between treatments (~0.01) are too small to be 
statistically significant, and in fact, are less that the gait asymmetry indices reported in previously 
in the literature for post-stroke individuals (AFO: 0.20, neuroprosthesis: 0.17-0.20, [39]). 
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Ring et al. contrasted the gait asymmetry index for swing duration for 15 post-stroke 
individuals during AFO and neuroprosthesis (NESS L300) over ground ambulation after 4 and 8 
weeks of neuroprosthesis adaptation. Gait asymmetry indices of 0.20 ± 0.09 and 0.19 ± 0.09 were 
reported during AFO and neuroprosthesis ambulation, respectively (4 week neuroprosthesis 
acclimation).  Longer neuroprosthesis acclimation resulted in swing asymmetry indices of 0.17 ± 
0.08. While no statistically significant differences in swing asymmetry indices were observed 
between treatments after 4 weeks of neuroprosthesis acclimation, significant differences between 
treatments, favoring the neuroprosthesis, were observed after 8 weeks of neuroprosthesis use. 
The gait asymmetry indices for swing measured for the current study were substantially 
less than those reported by Ring et al., as expected due to the greater swing symmetry (less 
asymmetry) demonstrated by the subjects in the current study.  The greater symmetry or 
decreased asymmetry suggest better balance and equal weight bearing (i.e. similar SLS durations) 
between limbs demonstrated by the current subjects, regardless of treatment. The enhanced 
temporal symmetry may also be attributed to the treadmill itself; previous studies have suggested 
that the consistent speed of the treadmill belt experienced by both limbs encourages temporal and 
spatial symmetry [48]. 
5.2.2 Kinematic Asymmetry 
 As indicated above, temporal symmetry (or asymmetry) measures are more appropriate 
for over ground walking as the moving belt of a treadmill forces the affected limb to keep pace 
with the unaffected limb during treadmill ambulation, enhancing temporal symmetry [48].  In 
addition, temporal symmetry measures assess overall motion and fail to capture the complex 
movement of the various limb segments, providing limited information regarding the behavior of 
each joint [48]. These shortcomings can be addressed by kinematic measures of symmetry.  
As stated previously (Section 3.5.2), while the SR and SI can be used to investigate 
kinematic symmetry or asymmetry, both measures are insensitive to sign changes in joint motion, 
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differences in ROM that may occur between subjects or joints, and lack the resolution to observe 
small inter-limb differences.  As such, a new measure of gait asymmetry, GA, was defined. 
 GA was assessed for each functional phase of stance and swing.  As this research 
investigates treatment for drop foot, ankle and knee joint motion were of primary interest, 
particularly during swing as drop foot causes problems with foot clearance during swing. In 
addition, as the WalkAide may stimulate the anterior tibialis prior to swing and continue 
stimulation after heel strike, the PS and LR transition periods were also investigated. 
As shown in Figures 47 and 48, increases in sagittal plane knee GA during WalkAide 
versus AFO ambulation were observed during IS, while increases in knee GA during AFO versus 
WalkAide ambulation were observed during MS and TS for all treadmill orientations. Increased 
knee GA indicate either increased or decreased affected versus unaffected limb knee flexion. 
Throughout swing, decreased knee flexion may limit foot clearance and lead to trips/falls; 
increased knee flexion may increase energy consumption. While Figures 47 and 48 summarize 
the knee GA magnitude or absolute value, all subjects (individual data reported in Appendix B) 
exhibited negative knee GA throughout swing for both treatments.  This negative knee GA 
reflects decreased affected versus unaffected limb knee flexion during swing. Decreased affected 
limb knee flexion during IS with WalkAide use may lead to less affected versus unaffected limb 
toe clearance if not compensated by ankle dorsiflexion; missed WalkAide stimulations may result 
in both decreased affected versus unaffected limb knee flexion and ankle dorsiflexion, potentially 
increasing the risk of stumbles or falls. Decreased knee GA (i.e. increased affected limb knee 
flexion for this population) with the WalkAide during MS and TS might also indicate that knee 
flexion occurred later in swing when compared to the unaffected limb and AFO treatment.  
Delayed affected limb knee flexion, combined with missed stimulations, may again contribute to 
increased potential risk of stumbles or falls. Although these trends in knee GA during swing were 
noted, no statistically significant differences in knee GA with treatment were found. As the 
WalkAide and AFO primarily influence the ankle, this lack of statistically significant differences 
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in knee GA between treatments was not unexpected, although treatment differences in both knee 
and ankle GA are tested via Hypothesis 1a. 
As expected, the sagittal plane ankle GA (Figures 49-50, 20-60%) typically exceeded that 
reported for the knee (20-40%).  In addition, greater ankle GA was observed during swing for 
level and inclined ambulation with the AFO (mean: 25-58%) versus WalkAide (mean: 10-27%), 
particularly during mid and terminal swing, although these differences were not statistically 
significant. As such specific conclusions regarding differences in ankle GA during MS and TS 
between treatments (Hypothesis 1a) are not possible. When examined on an individual basis 
(Appendix C), the sign of ankle GA during MS and TS was consistently positive, reflecting 
increased affected versus unaffected limb dorsiflexion.  While greater affected versus unaffected 
limb dorsiflexion may increase energy consumption, such potential increases were likely modest 
as affected limb knee flexion (see Figure C1 and C2) did not also increase.  The greater ankle GA 
observed during mid and terminal swing with AFO use suggests that the AFO may have been less 
effective than the WalkAide in addressing foot drop, despite increased affected versus unaffected 
ankle dorsiflexion and greater affected versus unaffected limb toe clearance. This increased 
affected limb dorsiflexion and toe clearance may increase energy consumption and  risk of 
muscle fatigue during AFO ambulation. 
In addition to trends in increases in both minimum and mean sagittal plane ankle GA 
during AFO versus WalkAide ambulation in MS and TS, the minimum and mean ankle GA was 
significantly higher during IS for AFO ambulation (level and inclined walking).  This increased 
kinematic asymmetry with AFO versus WalkAide use supports Hypothesis 1a. Increased ankle 
GA during IS may signify either decreased (positive GA) or increased (negative GA) ankle 
plantar flexion motion of the affected limb relative to the unaffected limb.  Examination of 
individual ankle GA data during IS (Appendix C) demonstrated positive ankle GA values for 
nearly all subjects for both treatments, indicating decreased affected versus unaffected limb 
plantar flexion during IS. The greater ankle GA during IS with AFO use therefore suggests that 
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the AFO resulted in a greater reduction in affected limb plantar flexion during level and incline 
walking when compared to the WalkAide. Decreased affected limb plantar flexion after push off 
may reflect decreased ankle power, as needed for forward progression of the limb during swing 
phase. This potential decreased affected limb ankle push-off with AFO use is further supported 
by the shorter latter DLS or PS periods for the affected versus unaffected limb.  
 Although not related to the specific research hypotheses, the effect of treadmill 
orientation on ankle GA for both treatments was also assessed. No statistically significant 
differences in mean and minimum sagittal plane ankle GA during swing were found between 
treadmill orientations during WalkAide ambulation. However, statistically significant differences 
in mean and minimum ankle GA during IS were observed between treadmill orientations during 
AFO ambulation, both between level/inclined and declined/inclined treadmill orientations for 
minimum ankle GA, as well as between declined/inclined treadmill orientations for mean ankle 
GA. Since 7 of 8 ankle GA values were positive when assessed on an individual basis, greater 
ankle GA as the treadmill orientation progressed from declined to inclined indicates increasingly 
reduced levels of affected versus unaffected limb ankle plantar flexion during AFO ambulation 
from declined to inclined ambulation. 
Further investigation of sagittal plane ankle GA indicated that these differences in 
minimum and mean GA during swing were not due to changes in unaffected ankle ROM between 
treatments or amongst treadmill orientation (e.g. GA denominator, Figure 51), but were due to 
differences in ankle motion between limbs with treatment (e.g. GA numerator, Figure 55 and 56). 
Mean passive ankle ROM, measured at the beginning of the gait session without the AFO, was 
similar during the AFO (affected: 36°,unaffected: 37°) and WalkAide (affected: 38°, unaffected: 
44°) gait sessions, as was mean dorsiflexion strength (AFO: 2.25, WalkAide: 2.33) and ankle 
spasticity (AFO: 2.4, WalkAide: 2). Therefore the restricted active ankle ROM of the affected 
versus unaffected limb observed during AFO ambulation (Figure 54) may be attributed to the 
rigidity of the AFO, specifically the plantar flexion stops and AFO stiffness, not the functionality 
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of the affected ankle. As with temporal asymmetry, differences in affected versus unaffected 
ankle motion have been correlated with balance [56] and energy efficiency [57]. The lack of 
statistically significant differences in ankle GA during WalkAide ambulation may result in 
greater balance and energy efficiency when compared with the AFO for all treadmill orientations.  
  These measures of sagittal plane knee and ankle GA were contrasted with that calculated 
from data reported in a pilot study of a single post-stroke subject ambulating over ground with 
both a neuroprosthesis (NESS L300) and an AFO [66], see Table 23. Note that van Swigchem’s 
subject was tested after 2 weeks and 1.5 years of neuroprosthesis use. Table 23 demonstrates that, 
if kinematic data are available, GA can be calculated for prior studies.  The GA values for van 
Swigchem’s subject were comparable to that of the current study. This single subject data also 
indicate that GA may change with time. 
Table 23: Sagittal plane knee and ankle GA 
      
GA @ 2 
wks 
[66] 
GA @ 
1.5y 
[66] 
GA @ 4 wks 
(current study) 
Knee 
AFO 
IS max 11 75 30 
PS min 22 0 16 
neuroprosthesis 
IS max 4 2.5 36 
PS min 22 0 16 
Ankle 
AFO 
IS min 40 17 50 
MS avg 20 0 29 
neuroprosthesis 
IS min 20 3 26 
MS avg 0 33 13 
 
5.2.3. Maximum Ankle Angular Velocity During IS 
WalkAide stimulation of the anterior tibialis facilitates ankle dorsiflexion.  The 
effectiveness of this stimulation in addressing drop foot and toe clearance during swing can be 
assessed by contrasting the ankle dorsiflexion rate or angular velocity during IS. Greater peak 
ankle angular velocity corresponding to rapid ankle dorsiflexion is desired to achieve toe 
clearance quickly and prevent stumbles or falls. As shown in Figure 57 the peak dorsiflexion 
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velocity during IS was significantly greater during WalkAide (62.4-68.3 ⁰/sec) than during AFO 
(30.2-34.3 ⁰/sec) ambulation, both for all subjects and the Group A subset. The greater 
dorsiflexion velocity with the WalkAide indicates that WalkAide stimulation results in more 
rapid dorsiflexion than that provided with the passive AFO.   
5.2.4 Summary of Gait Symmetry Findings 
 Temporal and kinematic symmetry can provide insight into motor function, muscle 
strength, balance and ankle function. Hypothesis 1a predicted that both temporal and kinematic 
symmetry will improve during ambulation with a neuroprosthesis when compared with 
ambulation with an AFO on both level and non-level surfaces.  Investigation of temporal gait 
symmetry revealed no statistically significant differences in stance SR, swing SR or gait 
asymmetry index with treatment, contrary to Hypothesis 1a. However, this temporal symmetry 
might be attributed to treadmill ambulation. 
Kinematic asymmetry at the knee and ankle were compared between treatments to further 
test Hypothesis 1a and assess whether the WalkAide improved kinematic symmetry during both 
level and non-level walking. Although greater sagittal plane knee GA during swing was observed 
during WalkAide ambulation on all treadmill orientations when compared with the AFO, no 
statistically significant differences in knee GA were observed between treatments. Sagittal plane 
ankle GA was increased with the AFO versus the WalkAide during all the phases of swing, 
although these treatment differences were statistically significant during IS only.   These 
increased in kinematic asymmetry with AFO use (or increased kinematic symmetry with 
WalkAide use) support Hypothesis 1a. The increased ankle GA reflects decreased affected limb 
plantar flexion with the AFO during IS, suggesting potentially decreased ankle power during PS. 
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5.3 TOE CLEARANCE 
Toe clearance is important for evaluating the treatment efficacy of the neuroprosthesis 
and AFO in addressing foot drop (Hypothesis 1b). Increased toe clearance is indicative of greater 
efficacy and decreased risk of falling [67]. However, greater affected versus unaffected limb toe 
clearance may lead to increased energy costs and may reflect a fear of falling.  The optimal toe 
clearance is not known, although values of 12.6 mm [67] and 10.3 mm [69] have been reported 
for young, healthy subjects. 
The mean toe clearance was greater for the affected versus unaffected limb [WalkAide: 
affected: 29.7-32.0, unaffected: 25.9-29.6 mm; AFO: affected: 33.0-36.1, unaffected: 27.3-30.6 
mm, Figure 58]. These differences in toe clearance between limbs were statistically significant 
for either treatment regardless of treadmill orientation. While sufficient toe clearance is necessary 
to prevent falls, increased affected versus unaffected limb toe clearance may reflect over 
compensation and potentially wasted energy and inefficient gait. 
Toe clearance was contrasted between treatments to test Hypothesis 1b which stated that 
increased affected limb toe clearance would result with WalkAide versus AFO ambulation for 
both level and non-level surfaces. As shown in Figure 58 the toe clearance of the affected limb 
was significantly greater with AFO than during WalkAide ambulation for all subjects on level 
and inclined treadmill orientations, refuting this research hypothesis. The increased affected limb 
toe clearance during AFO ambulation reflects decreased fall risk due to toe/foot drag, although 
the increased affected versus unaffected limb toe clearance may also indicate some 
overcompensation for drop foot.  
The difference between the affected and unaffected limb toe clearance was evaluated to 
investigate this potential overcompensation and elevated energy cost. Smaller differences reflect 
less wasted energy expenditure.  For all subjects, the difference in toe clearance between limbs 
was less during WalkAide versus AFO ambulation (Figure 59), although these differences were 
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not statistically significant; for the Group A subset, this trend was only observed during declined 
and inclined walking.    These results suggest that the WalkAide provides adequate toe clearance 
compared to the AFO – supporting, but not confirming the first research hypothesis which 
predicted greater efficacy with neuroprosthesis use.  Further investigation with more subjects is 
needed to fully test this hypothesis.   
In addition to examining differences in toe clearance between treatments, the potential 
effects of treadmill orientation on toe clearance were investigated. However, no statistically 
significant differences in toe clearance magnitude or relative change were observed between 
treadmill orientations. Similarities in toe clearance between treadmill orientations suggest that 
each treatment provides sufficient affected limb foot clearance when compared to the unaffected 
limb foot clearance, despite changes in treadmill orientation. 
No prior studies investigating neuroprostheses to treat foot drop in post-stroke subjects 
have reported toe clearance. However, toe clearance during level, over ground walking has been 
investigated for young, healthy and elderly adults. Winter et al. examined toe clearance in 11 
healthy young adults and found an average toe clearance of 12.6 ± 4.5 mm during level over 
ground walking [68], about half that measured for the post-stroke subjects in the current study. In 
a second study, Winter et al. reported mean toe clearance in healthy elderly subjects as 15.0 mm 
[68], similar to that found for young adults in his previous study. Khandoker et al. also 
investigated toe clearance of both young and elderly adults, reporting median toe clearances of 
10.3 and 10.1 mm, respectively during over ground walking [69]. These toe clearance for healthy 
young and elderly subjects were 30-50% that observed for the post-stroke subjects in the current 
study. The greater toe clearances in the current study may be attributed to the stroke, with 
subjects over compensating due to foot drop and a fear of falling. Ambulation on a treadmill, as 
opposed to over ground walking, may have also encouraged subjects to increase their toe 
clearance to minimize stumbles. Methodological artifact may also have elevated these toe 
clearance measure.  Toe clearance was based on a marker placed on the shoe; this marker 
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placement, however, likely affected toe clearance only by several millimeters. Small errors due to 
treadmill plane definition may also have affected these toe clearance measures.  The treadmill 
plane was estimated by three treadmill markers; errors in the distance between the center of these 
markers and the moving belt of the treadmill may have resulted in slight (< 1 mm) over-
estimation of toe clearance.  
Comparison of toe clearance between treatments was used to test Hypothesis 1b, which 
stated that use of the neuroprosthesis would improve treatment efficacy (i.e. increase toe 
clearance) on level and non-level surfaces when compared to the AFO. Significantly greater 
affected versus unaffected limb toe clearance was observed (all treadmill orientations) for both 
treatments. Affected limb toe clearance was significantly increased during AFO versus WalkAide 
ambulation (level and inclined walking), reflecting a decreased risk of falling due to toe drag 
during AFO use.  As such, these results do not support Hypothesis 1b.  However, the increased 
affected limb toe clearance may also reflect potential overcompensation to foot drop and 
potentially increased energy expenditure. Smaller differences (not statistically significant) in 
affected versus unaffected toe clearance were observed during WalkAide ambulation when 
compared with the AFO (all treadmill orientations) suggesting that adequate toe clearance is still 
provided by the WalkAide. 
5.4 WALKAIDE STIMULATION RELIABILITY AND TIMING 
 Currently there are three commercially available neuroprostheses: the Odstock Dropped 
Foot Stimulator, the NESS L300 and the WalkAide. Both the Odstock Dropped Foot Stimulator 
and the NESS L300 utilize a heel switch placed in the shoe of the affected limb to define the 
stimulation periods during gait.  The WalkAide uses an accelerometer on the affected limb to 
measure the 2D tibial angle or tilt. The clinician programs the WalkAide using this tilt data, 
setting the stimulation initiation and termination thresholds. Additional programming parameters 
include the minimum “wait” time between stimulations, as well as the minimum and maximum 
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stimulation duration, so as to prevent anterior tibialis fatigue. Anterior tibialis stimulation is 
initiated when the tilt angle exceeds the stimulation initiation threshold; stimulation is terminated 
when the tilt angle falls below the stimulation termination threshold.  If the tilt angle exceeds the 
stimulation initiation threshold during the wait time, stimulation will not occur.   
As clinicians typically program the WalkAide using these tibial tilt angles during level 
walking, stimulation errors may occur during non-level walking as lower extremity limb 
kinematics have been shown to vary on inclined and declined surfaces [41]. Stimulation errors 
may result in missed or extraneous stimulations, adversely affecting the stimulation reliability, 
and/or changes in the stimulation timing (i.e. stimulation initiation and termination) – thereby 
increasing the risk of falls during non-level walking.  
5.4.1 WalkAide Stimulation Reliability for Tilt Sensor-based Programming 
The stimulation reliability (StR) of the WalkAide is important in assuring the safety of 
the individuals using the neuroprosthesis. Missed stimulations, indicated by StR values less than 
one, may result in little to no ankle dorsiflexion during swing, leading to insufficient toe 
clearance and increased risk of falling. Extraneous stimulations, indicated by StR values greater 
than one, may result in stimulations occurring at random times throughout the gait cycle.  
As shown in Figure 60, four (S5, S8, S10, S12) of the eight subjects demonstrated near 
optimal StR values of one for all treadmill orientations. Only one subject (S7) demonstrated StR 
values of 1.5 or greater, reflecting extraneous stimulations, for all treadmill orientations. This 
subject walked significantly slower on the treadmill than over ground. Since the subject’s 
WalkAide programming was set during faster over ground walking, stimulation programming 
included a shorter wait time; during the slow treadmill ambulation, the WalkAide stimulated 
twice during some gait cycles. The remaining subjects (S2, S4, S6) demonstrated extra 
stimulations (StR>1) for level and inclined treadmill orientations, and missed stimulations 
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(StR<1) for the declined treadmill orientation. Missed stimulations during declined walking were 
also reported by several subjects (S4, S6, and S8) during the acclimation period.  
Hypothesis 2a of this study stated that the StR would be affected by treadmill orientation, 
namely that missed or extraneous stimulations would occur during non-level walking (e.g. StR < 
1 or StR > 1during non-level walking).  No statistically significant differences in tilt sensor-based 
StR were found between treadmill orientations, refuting Hypothesis 2a. However, several subjects 
(S2, S4, S6, S7) demonstrated extraneous and missed stimulations during non-level walking – 
providing partial support of this second research hypothesis. Extraneous and missed stimulations 
for subjects on declined/inclined walking surfaces suggest that, depending on the individual’s 
environment, the PT/clinicians should include non-level walking during the WalkAide 
programming sessions. It is worth noting that three subjects (S8, S10, S12) who visited the PT 
more frequently (at least 3 times) exhibited consistent optimal StR, suggesting that supplemental 
programming sessions with the clinician may improve WalkAide stimulation during both level 
and non-level ambulation.  
The extraneous (StR>1) and missed stimulations (StR<1) may be attributed to changes in 
baseline tilt due to treadmill orientation, accelerometer noise, alignment errors and/or movement 
artifact, as well as inappropriate wait times between stimulations. As seen in Figure 66, the extra 
peaks in tilt sensor data due to movement artifact and/or alignment errors (Figure 67) may cause 
extraneous stimulations if the wait time is too small (less than 0.20 sec). Extraneous tilt sensor 
peaks may be more common during inclined walking if the subject circumducts to assist toe 
clearance. Declined walking introduced a positive tilt bias (Figure 68), thereby requiring an 
increased tilt threshold for stimulation termination. 
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Figure 66: Sample WalkAide tilt sensor data (blue), stimulation on (green) and off (red) 
thresholds illustrating potential extraneous stimulations (circled) due to insufficient wait 
time between gait cycles. 
The heel strike of each respective gait cycle is indicated by a dashed vertical line, while stimulation periods are 
indicated by the gray box. 
 
Figure 67: Sample WalkAide stimulator and tilt sensor positioning.  
The red line represents alignment of the device with the tibial crest; Correct placement (left) and malalignment 
(right) 
 
Figure 68: Sample WalkAide tilt data (blue) during declined walking illustrating the 
positive tilt bias, causing potential missed stimulation (circled) due to too low a stimulation 
termination (“off”) threshold. 
The heel strike of each respective gait cycle is indicated by a dashed vertical line, while stimulation periods are 
indicated by the gray box. 
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Extraneous stimulations may lead to instability due to the lack of ankle control or 
confusion due to unexpected stimulations. Extra stimulations during late stance may also prevent 
or reduce affected limb plantar flexion or push-off during PS. Unnecessary stimulation during 
mid-stance may result in greater affected versus unaffected limb dorsiflexion and decreased knee 
stability during SLS [14, 70].  These extraneous stimulations during stance may also prevent the 
desired stimulation during swing due to the wait time between successive stimulations.  
Missed stimulations may lead to decreased affected limb toe clearance and potential 
increased risk of falls. No stumbles or falls resulted from missed stimulations during gait analysis 
since the subjects could either provide some active dorsiflexion or extra knee flexion to clear the 
floor, and they were using the treadmill handrails for support. Since walking trials were only 2 
minutes long, the additional muscle activity needed to accommodate the missed stimulations 
without toe drag likely did not induce muscle fatigue.  
During community ambulation, the cognitive attention needed for concomitant tasks and 
potential knee or hip muscle fatigue may contribute to stumbles or falls due to missed 
stimulations.  Future studies to investigate potential cognitive effects on gait may be warranted.  
Cognitive demands might be increased by having the subject perform simultaneous tasks such as 
counting backwards during ambulation. If subjects are unable to accommodate missed 
stimulations with the tilt sensor programming while dual tasking, a common experience during 
community ambulation, the heel sensor may be a safer option for community ambulators during 
level and non-level walking.  
5.4.2 WalkAide Stimulation Reliability for Heel Sensor-based Programming 
Heel sensor data were also reviewed to determine whether the heel sensor (as used for the 
Odstock and NESS neuroprostheses) was more robust than the tilt sensor for stimulation control 
during non-level walking (Hypotheses 3a and 3b).  Heel sensor-based stimulations were 
simulated by reviewing 3-4 WalkAide level walking trials and identifying the stimulation 
149 
 
initiation and termination thresholds that minimized potential extraneous stimulations due to heel 
sensor noise or movement artifacts (as done clinically during tilt sensor programming).  The wait 
time and the maximum/minimum stimulation durations were  the same as those set during clinical 
tilt-sensor based programming. As WalkAide heel sensor data were not available for subjects S7 
and S8, theoretical heel sensor-based StR was based on heel loading data from the F-scan.  This 
alternative sensor may also influence the StR values as the thickness, size, placement, range (F-
scan: 0-25 psi, WalkAide: 0-150 arbitrary units), sensitivity, resolution (F-scan: 1 psi, WalkAide: 
1 arbitrary unit), and sampling rate (F-scan: 50Hz, WalkAide: 25Hz) of the F-scan and WalkAide 
sensors differ.  
StR for theoretical heel sensor-based stimulation is shown in Figure 61. Two subjects 
(S4, S5) exhibited missed (StR < 1) and/or extraneous (StR > 1) theoretical stimulations for 
declined and inclined ambulation, while the remaining subjects exhibited optimal StR values (StR 
= 1) during theoretical heel sensor-based stimulation. The StR values of the theoretical heel 
sensor-based programming were unaffected by treadmill orientation; combined subject data 
resulted in StR values of approximately one for all treadmill orientations. These results suggest 
that the heel sensor programming is not influenced by treadmill orientation, and may result in 
more optimal StR for than for tilt sensor-based stimulation, supporting Hypothesis 3a.  
These theoretical heel sensor-based StR results, however, are dependent on the selected 
stimulation initiation and termination thresholds, as well as the assumed wait time and stimulation 
duration restrictions. The stimulation initiation and termination thresholds selected for the heel 
sensor-based stimulations were selected to minimize extra stimulations; as such, these StR values 
represent optimal programming.  During clinical WalkAide programming (using the tilt or heel 
sensor), stimulation thresholds are similarly optimized during level over ground walking, not post 
hoc review of level treadmill ambulation.   
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Figure 69: StR error for tilt and theoretical heel sensor-based stimulations for decline (top), 
level (middle), and incline (bottom) walking. 
5.4.3 WalkAide Stimulation Reliability for Tilt versus Heel Sensor-based Programming 
To test the research Hypothesis 3a, that StR would be improved using the heel versus tilt 
sensor during non-level walking, the StR results of Figures 60 and 61 were compared.  
Specifically, the StR error (e.g. |SR-1|*100%) was contrasted for each sensor, as shown in Figure 
69.  With the exception of subject S5 for inclined walking, theoretical heel sensor-based StR 
errors were less than that for the tilt sensor for all treadmill orientations. For subject S5, heel 
sensor-based StR errors was negative (e.g. StR < 1) during non-level walking, indicating missed 
stimulations; these missed stimulations were not observed during tilt sensor-based stimulation. 
These missed stimulations may be attributed to the combination of increased heel pressure due to 
foot and/or heel sensor movement and the wait time and minimum/maximum stimulation 
durations. If the stimulation begins and must be sustained for the minimum stimulation duration 
-0.60
-0.30
0.00
0.30
0.60
0.90
S2 S4 S5 S6 S7# S8# S10 S12 AllS
tR
 E
rr
or
 
Tilt Heel
-0.60
-0.30
0.00
0.30
0.60
0.90
S2 S4 S5 S6 S7# S8# S10 S12 AllS
tR
 E
rr
or
 
Tilt Heel
-0.60
-0.30
0.00
0.30
0.60
0.90
S2 S4 S5 S6 S7# S8# S10 S12 AllS
tR
 E
rr
or
 
Tilt Heel
Decline 
 
 
 
 
 
 
 
 
Level 
 
 
 
 
 
 
 
Incline 
151 
 
followed by no stimulation during the specified wait time, the subsequent stimulation as indicated 
by the stimulation initiation threshold might be missed. These heel sensor-based StR errors may 
be minimized by more effectively positioning (i.e. by clinician or PT instead of research staff) 
and securing the heel sensor (i.e. taped directly to the shoe insole rather than merely secured to 
the shoe’s heel counter).  
Although differences in StR errors between tilt versus theoretical heel-sensor based 
stimulation were observed in individual subjects, overall StR errors across all subjects did not 
differ significantly between sensors for any treadmill orientation.  This suggests that the 
theoretical heel sensor-based stimulation was not more reliable than tilt sensor-based stimulation 
during non-level walking, contrary to Hypothesis 3a. This lack of statistically significant 
differences in StR between sensors, however, may be due to the small sample size. Seventy-five 
per cent (6/8) subjects exhibited optimal (unity) theoretical heel sensor-based StR values and only 
50% (4/8) subjects demonstrated optimal tilt sensor-based StR values during non-level walking.  
As such, one might argue that the heel sensor may still be considered a better sensor for more 
reliable stimulation control during non-level walking, partially supporting Hypothesis 3a.  
There are advantages and disadvantages associated with the WalkAide heel and tilt 
sensors. In contrast to the WalkAide heel sensor, the tilt sensor (integrated within the WalkAide 
stimulation unit) is positioned with respect to the tibia as the WalkAide cuff and unit are secured 
on the affected limb.  As such, no sensor is placed inside the shoe and individuals are free to wear 
any shoe (even heels and sandals) and WalkAide donning is more facile – although consistent tilt 
sensor alignment along the tibial crest may be a concern.  Use of the heel sensor requires that the 
shoe has an adequate heel box, and placement of this sensor can be difficult for hemiparetic 
individuals with upper limb impairment.  Improved StR with the heel sensor may offset these 
shoe placement limitations.  Several subjects complained about missed stimulations during non-
level walking while using the tilt sensor-based programming.  
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5.4.4 WalkAide Tilt Sensor-based Stimulation Initiation and Termination Timing 
 Hypothesis 2b stated that, due to changes in tibial angle during non-level walking [40], 
tilt sensor-based StR and stimulation timing would vary during non-level versus level walking.    
The primary goal of WalkAide stimulation of the anterior tibialis is to provide ankle 
dorsiflexion during swing to assist with foot clearance for individuals with foot drop.  Stimulation 
may also extend into loading response to minimize foot slap (see Section 2.2.1).  As seen by 
Figure 63, tilt sensor-based stimulation initiation (StI) occurred at approximately -20% swing for 
most subjects (S2, S4, S7, S8, S10, and S12), indicating that StI occurred during late stance, more 
specifically during PS.  In contrast, for subject S5, StI occurred during early swing (~5-10% 
swing, during IS); for subject S6, StI was seemingly early, occurring at approximately -30 to  
-40% swing (during mid or terminal stance).  
In general, StI was delayed as the treadmill orientation progressed from declined to 
inclined, occurring later in stance, closer to swing phase itself. Post-hoc testing revealed 
statistically significant differences in StI between declined/inclined treadmill orientations; no 
statistically significant differences in StI were observed between level and non-level surfaces, as 
posed in Hypothesis 2b. StI occurred earlier in the gait cycle during declined walking (-15% 
swing) when compared to inclined (-5% swing) walking. The earlier stimulation initiation during 
declined walking may result in decreased plantar flexion during push-off, muscle activity that 
assists forward progression of the affected limb during swing. However, such plantar flexion may 
be less necessary for declined walking [41] since the limb does not need to be elevated as high for 
swing (i.e. less knee flexion during declined walking [41]). The earlier dorsiflexor stimulation 
and reduced push-off during PS during declined walking may, in fact, be advantageous.  Delayed 
dorsiflexion stimulation until IS during declined ambulation may result in decreased affected limb 
dorsiflexion and toe clearance during swing.   
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For most subjects (S2, S4, S6, S7, S8, and S10; Figure 63), tilt sensor-based StT occurred 
during the first 20% of the subsequent gait cycle (i.e. 120% gait cycle), indicating that StT 
typically occurred during LR of the following cycle. For subjects S6 and S7, ST occurred as late 
as 130% gait cycle for inclined walking. StT was also quite late for subjects S5 and S12 (130 to 
150% gait cycle). For these subjects and the inclined walking trials of subjects S6 and S7, StT 
most likely occurred during the subsequent mid or terminal stance period. Although differences in 
StT between treadmill orientations were observed for some subjects (S4, S5, S6, and S7), no 
statistically significant differences in StT timing were observed between level and non-level 
walking trials, contrary to Hypothesis 2b.   
Changes in StI (but not StT) timing during non-level walking reflect changes in the 
stimulation duration during non-level walking. StI occurred earlier in the gait cycle, prior to 
swing, during declined vs. level ambulation. Since the StT timing did not change, the earlier StI 
reflected prolonged stimulation duration during decline walking, potentially leading to muscle 
fatigue if declined walking trials are extended. Muscle fatigue, combined with the missed 
stimulations observed during declined walking, may lead to stumbles or falls if the subject can no 
longer accommodate the missed stimulation due to fatigue. For inclined walking, the StI occurred 
later in the gait cycle, closer to swing, thereby reflecting shorter stimulation periods. Potential 
muscle fatigue during inclined walking is therefore unlikely. 
During clinical WalkAide programming with the tilt sensor, the stimulation initiation and 
termination tilt thresholds are specified, as well as the minimum wait time between stimulation 
periods and the minimum and maximum stimulation durations.  The lack of changes in StT 
timing during non-level walking may be due, at least in part, to these wait times and 
minimum/stimulations durations.  Delayed StT may reduce dorsiflexion during terminal swing or 
loading response, contributing to potential toe drag and stumbles or foot slap and first ankle 
rocker inhibition, respectively; however this was not observed for this study. Limiting the first 
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ankle rocker may adversely affect affected limb forward progression and shock absorption during 
LR. 
 In addition to changes in the StI timing itself, the variability of the StI and StT timing was 
also examined for tilt sensor-based stimulation. Large variability (2-30% gait cycle, mean 9.62% 
gait cycle) in both stimulation timing parameters was observed, although this variability was 
substantially reduced (2-18% gait cycle, mean 6.7% gait cycle) after eliminating gait cycles with 
extraneous stimulations (Figure 65).  This remnant variability in StI and StT timing may be 
attributed to tilt sensor errors (e.g. movement artifact due to lower limb tremors or circumduction, 
sensor alignment errors) and/or programming parameters (wait time, stimulation minimum or 
maximum duration). Note that the StI and StT variability was reduced for three subjects (S8, S10, 
and S12) who met with the clinician one week prior to gait analysis for WalkAide programming 
adjustment.   It is recommended that future studies require that subjects meet more frequently (at 
least 3 times) with the clinician for WalkAide adjustment and meet with the clinician one week 
prior to gait analysis for final adjustments.  
5.4.5 WalkAide Heel Sensor-based Stimulation Initiation and Termination Timing 
The StI, StT and the variability in these parameters were also investigated for theoretical 
heel sensor-based stimulation, using both the WalkAide heel sensor and F-scan plantar pressure 
data (Figure 64).    
For the theoretical heel sensor-based stimulations, the StI occurred at approximately -
20% swing; statistically significant differences in heel sensor-based StI were not observed with 
treadmill orientation. Since heel sensor-based StI occurred around -20% swing for inclined 
walking, plantar flexion during late stance needed during inclined walking may be prevented by 
the early dorsiflexion activity during heel sensor-based stimulations, resulting in prolonged 
swing.  
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Heel sensor-based StT timing occurred slightly earlier in stance (approximately +10% 
stance or 110% gait cycle) than that observed during tilt sensor-based (approximately +20% 
stance or 120% gait cycle) stimulation. Only one subject (S8) demonstrated theoretical heel 
sensor-based StT during swing (95% gait cycle, -5% stance), prior to the subsequent gait cycle. 
StT typically extended into stance to provide ankle support during LR and prevent foot slap. 
Earlier StT during heel sensor-based stimulation may limit the stimulation’s effect on ankle 
stability during LR (specifically for subject S8). As with StI timing, no statistically significant 
differences in heel sensor-based StT were observed between treadmill orientations. 
5.4.6 WalkAide Tilt versus Heel Sensor-based Stimulation Initiation and Termination Timing 
As predicted by Hypothesis 3b, more consistent StI timing was observed among subjects 
with the heel versus tilt sensor, with only one subject (S5; versus two with the tilt sensor) 
demonstrating StI earlier than -20% swing. Unlike the tilt sensor-based stimulations, the StI 
timing for heel sensor-based programming was not influenced by treadmill orientation, 
potentially making the heel sensor a more predictable and reliable sensor for non-level 
ambulation (which is not observed during programming), supporting Hypothesis 3b. However, 
the consistent StI timing with the heel sensor may adversely affect inclined ambulation. StI earlier 
in stance would initiate dorsiflexion sooner, possibly preventing the extra plantar flexion needed 
during inclined ambulation. 
As for tilt sensor-based stimulation, theoretical heel sensor-based StT occurred during the 
subsequent stance period; however, StT occurred slightly earlier with the heel (+10% stance) 
versus the tilt (+20% stance) sensor. Stimulation typically continues into the following stance 
duration to provide ankle support during LR and prevent foot slap; therefore earlier StT during 
heel versus tilt sensor-based stimulation may limit the heel sensor-based stimulation’s effect on 
ankle stability during LR when compared with the tilt sensor-based stimulation. Additionally, the 
consistent StI and earlier StT timing with heel sensor-based programming corresponds to a 
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decreased stimulation duration, possibly minimizing the likelihood of tibialis muscle fatigue 
during walking. Therefore, these results suggest that the tilt sensor may support improved weight 
transfer and balance throughout LR when compared to the heel sensor, but may lead to muscle 
fatigue during prolonged walking.  
To test Hypothesis 3b, the variability in the StI and StT timing was compared between 
sensors. The variability in theoretical heel sensor-based stimulation timing was substantially less 
(1-10% gait cycle) than that observed with tilt sensor-based timing (2-18% gait cycle), Figure 65, 
supporting Hypothesis 3b. This reduced variability is most likely due to the greater consistency of 
the heel sensor data; the careful review of heel sensor data during multiple gait cycles for 
selection of the stimulation initiation and termination thresholds may also have reduced this 
theoretical timing variability.   
Based on the decreased variability in StI/StT timing (and increased StR) of heel sensor 
versus tilt sensor--based stimulation, the heel sensor may be considered more reliable for non-
level walking, supporting Hypotheses 3b (and Hypothesis 3a).  However, the differences in tilt 
sensor StI with treadmill orientation may actually improve the efficacy of tilt sensor-control, 
increasing the stimulation period during declined walking.  Further testing is recommended to 
determine if the changes in stimulation timing observed with the tilt sensor during non-level 
walking are more beneficial than the consistency of the heel sensor stimulation timing. Future 
gait analysis, inclusive of kinetic data, may help determine if the delayed StI observed during tilt 
sensor-based stimulation facilitates greater push-off (i.e. increased ankle moment and/or ankle 
power) during PS while ambulating on inclined versus level surfaces. 
5.4.6 Summary of WalkAide Stimulation Findings 
 Tilt sensor-based stimulation reliability and timing on level versus non-level surfaces 
were compared to test Hypotheses 2a and 2b.  No statistically significant differences in StR were 
observed between level and non-level walking trials for tilt-sensor based programming, refuting 
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Hypothesis 2a. Several subjects (4 out of 8), however, exhibited missed or extraneous 
stimulations during non-level walking with tilt sensor-based programming, providing partial 
support of Hypothesis 2a. Statistically significant differences in StI timing were observed 
between level and non-level walking trials for tilt sensor-based programming. The StI occurred 
earlier in the gait cycle during declined versus level walking; StI occurred later in the gait cycle 
during inclined versus level walking.  These results support Hypothesis 2b. No trends or 
statistically significant differences in StT timing were observed between level and non-level 
walking for tilt sensor-based programming.  
 Stimulation reliability and timing based on tilt sensor- versus heel sensor-based 
programming were contrasted to test Hypotheses 3a and 3b.  No statistically significant 
differences in SR were observed between tilt versus heel sensor-based programming during non-
level walking, contrary to Hypothesis 3a. Missed or extraneous stimulations were observed for 6 
of 8 subjects with tilt sensor-based stimulation; missed or extraneous stimulations were only 
observed for 4 of 8 subjects with heel sensor-based programming during non-level walking trials.  
These differences in stimulation reliability support, but do not confirm, Hypothesis 3a. StI or StT 
timing variability was decreased for heel sensor- versus tilt-sensor-based stimulation during non-
level walking; however these differences between sensors were not statistically significant and 
therefore no definitive conclusions about Hypothesis 3b can be made. Based on the StR and 
StI/StT variability results, the heel sensor may provide more consistent stimulation when 
compared with the tilt sensor during non-level walking, potentially supporting Hypotheses 3a and 
3b. 
5.5 POWER ANALYSIS 
As the post-stroke population in this study was relatively non-homogeneous, the various 
measured parameters were not normally distributed and non-parametric tests (Wilcoxon rank 
sum, Friedman) were necessary for statistical analysis. Non-parametric tests do not assume 
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normal distribution, are more robust, and can accommodate the variability in the post-stroke 
population; however, these non-parametric tests are less powerful than parametric tests. As such, 
larger sample sizes are often required [55]. To determine the number of subjects necessary to 
achieve statistical differences (p>0.05) with sufficient power (P>0.80), as well as to determine the 
power of the various parameters of the current study, a priori and post hoc power analyses were 
conducted.  
 A priori power analyses were conducted to determine the subject population needed to 
detect statistically significance differences, assuming small (0.20), medium (0.50) and large 
(0.80) effect sizes [55] – see Table 15. A priori power analyses for individual, non-paired 
measures (i.e. GA and toe clearance) indicate that 15, 35, and 208 subjects are necessary to detect 
statistically significant differences with small, medium, and large effects. Due to the robust nature 
of non-parametric tests, only large differences between means, accompanied by small standard 
deviations (i.e. large effect size, d>1.0) result in statistically significant differences for measures 
such as GA and toe clearance of only eight subjects. The use of repeated measures in non-
parametric statistical analyses facilitate identification of statistically significant difference with a 
small sample size, as supported by the a priori power analyses of paired, repeated measures 
analysis (1, 2, and 7 subjects needed for small, medium, and large effect sizes, respectively).  
 Multiple a priori and post hoc power analyses based on the actual effect sizes of the 
current study were conducted both  to determine the number of subjects necessary to detect 
statistical significance and the actual statistical power – see Table 16. A priori analyses of the 
affected limb temporal parameters indicate that eight subjects are sufficient to observe 
statistically significant differences (p>0.05) with sufficient power (P>0.80) in affected limb 
stance and total DLS durations for declined and level walking. Despite an adequate sample size 
and sufficient power, these temporal parameters did not demonstrate statistically significant 
differences between treatments during declined walking, due to both the large parameter 
variability and the temporal symmetry due to treadmill ambulation. For inclined swing duration 
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and level initial DLS, nine subjects are necessary to observe statistically significant differences in 
these parameters between treatments with sufficient power; statistically significant differences in 
these parameters between treatments, however, were observed for the 8 subjects in the current 
study. The low power in these parameters may be attributed to the relatively large variability in 
the temporal parameters and the associated small effect sizes (d=0.18).  Finally, power analysis of 
the swing and second DLS duration during level walking indicate that more than 1000 subjects 
may be needed to detect statistically significant differences between treatments for these 
parameters. The large number of subjects required for statistically significant treatment 
differences in these parameters may be attributed to the high variability, but is most likely due to 
the similarity in means (< 0.01 seconds difference in means for both parameters). Therefore, even 
with the addition of more subjects, statistically significant differences in level swing and second 
DLS between WalkAide and AFO treatments are unlikely. 
To determine the power and number of subjects necessary to observe statistically 
significant differences in temporal symmetry measures (Hypothesis 1a), a priori and post hoc 
power analyses were conducted, see Table 17. For stance and swing SR, as well as the gait 
asymmetry index, more than 100 subjects are required to observe statistically significant 
differences between treatments during both level and non-level walking. The lack of statistically 
significant differences in temporal symmetry measures between treatments may be attributed to 
the small to moderate effect sizes (0.02≤d≤0.33) and low power (0.06-0.21) due to the small 
sample size (n=8) and large inter-subject variability (SR: 0.15, gait asymmetry index: 0.60). 
Additionally, the similar temporal symmetry may have been an artifact of treadmill ambulation 
[48].  
A priori and post hoc power analyses were also conducted for the GA (non-repeated) 
measures of the knee and ankle to determine the number of subjects need to test Hypothesis 1a 
(kinematic symmetry) and to quantify the power of the current results, respectively. As seen in 
Table 18, more than 100 subjects are needed to detect statistically significant differences in knee 
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GA during between treatments (Hypothesis 1a). These requisite large sample sizes suggest that 
differences in knee GA between treatments may not be observed, even with an expanded subject 
population. The post hoc power analyses indicate that the power of the knee GA results is very 
low (P<0.10); as such, the probability for a false negative is high [55].  
As the WalkAide and AFO treatments for drop foot directly affect the ankle, it is not 
surprising that fewer subjects (N≥10) are needed to detect treatment differences in ankle GA. 
These smaller requisite sample populations may be attributed to the greater effect size in ankle 
(0.16-1.39) versus knee (0.03-0.36) GA and the moderate power (0.11-0.71 for level and inclined 
ambulation).   Statistically significant treatment differences in minimum and mean ankle GA 
during IS on level and inclined treadmill orientations were observed for the current study, 
although the associated power (mean GA: ~0.65, minimum GA: ~0.66) was moderate. Two to 
four additional subjects may be necessary to achieve power of 0.80. Statistically significant 
differences between treatments were not observed for ankle GA during MS and TS, consistent 
with the a priori power analyses which indicate that more than 51 subjects are required for 
medium effect sizes (d=0.40-0.57). With the high probability of false negative due to low power 
(0.11-0.18) and medium effect sizes (d=0.41-0.57), the small sample size (n=8) and the large 
inter-subject variability likely prevented detection of statistically significant differences in mean 
dorsiflexion during MS and TS. 
A priori and post hoc power analyses for toe clearance (Table 19) indicate that only 2-4 
subjects are required to observe statistically significant differences in affected limb toe clearance 
between treatments for level and non-level walking (Hypothesis 1b). These sample size 
projections and study power are consistent with the aforementioned hypotheses testing, which 
showed statistically significant differences in affected limb toe clearance between treatments 
during level and inclined walking. Larger subject populations (N≥24) are required to detect 
statistically significant treatment differences in the affected limb toe clearance during declined 
walking. The low power (0.05-0.29) and moderate effect size (0.02≤d≤0.11) suggest that there is 
161 
 
a high probability of a false negative for these measures and that more subjects may reveal 
differences that could not be detected with eight subjects.  
Power analyses were also conducted to investigate differences in toe clearance between 
the affected and unaffected limbs (i.e. toe clearance symmetry) with treatment. Fewer (38-85) 
subjects, although still more than that in the current study, are required to detect statistically 
significant differences in toe clearance symmetry between treatments. These requisite enlarged 
sample populations may be attributed to the large variability in measured toe clearance for the 8 
subjects in the current study.  The low power (P<0.23) and medium to large effect sizes (d=0.44-
0.68) again suggest that statistically significant differences might be observed if the subject 
population were increased (N>38). 
In summary, more than 100 subjects are required to observe statistically significant differences 
with small to medium effect sizes for temporal symmetry measures (SR and gait asymmetry 
index). Eight to more than 100 subjects are required to detect statistically significant treatment 
differences in ankle and knee GA, respectively. Finally, 38-85 subjects are required to detect 
significant differences in affected limb toe clearance between treatments.   
5.6 STUDY LIMITATIONS  
 There are a number of limitations that must be taken into consideration when interpreting 
the results of this study. These limitations result from assumptions and/or errors associated with 
study protocol procedures, sensors, data acquisition, and/or signal processing. 
5.6.1 Study Procedures 
5.6.1.1 Event Detection  
All kinematic data were processed and reviewed as a function of gait cycle.  The 
respective gait cycle events, heel strike and toe off, were identified based on the velocity of the 
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heel and toe markers since the attempted use of foot switches generated inconsistent and 
inaccurate event detection (see Section 3.3.2).   These heel and toe markers were placed on the 
shoes themselves, not directly on the calcaneus and metatarsal heads, as subjects were shod 
during all walking trials.  As such, although the subject wore the same shoes for both AFO and 
WalkAide ambulation, heel and toe marker position errors may have occurred.  Such position 
errors, in turn, affect heel and toe marker velocity calculations.  For example, positioning the toe 
marker on the shoe surface over the second metatarsal phalangeal joint, as done in the current 
study, likely resulted in earlier toe off estimation (earlier swing initiation, potentially prolonging 
swing duration) than would have been estimated by positioning the toe marker at the tip of the 
shoe. In addition to position/velocity errors due to marker placement on the shoe itself, heel 
position/velocity is also affected by the relative heel compliance (a compliant heel may delay heel 
strike); the effects of heel compliance are likely minimal, however, as the same shoes were worn 
for both gait analysis sessions.  
5.6.1.2 Shod Walking  
To facilitate comparison between AFO and WalkAide ambulation, the same shoes were 
worn for both gait analysis sessions. However, accommodation of an AFO often requires that 
shoes be 1-2 sizes larger than otherwise worn.  The larger shoes can be laced more tightly during 
WalkAide trials, but may result in kinematic errors with respect to the toe marker.  In addition, 
the extra shoe length may require increased toe clearance during WalkAide ambulation to 
minimize toe drag and potential stumbling.   
The placement of the heel and toe markers on the shoes may also influence the estimated 
lower extremity joint kinematics and the GA measures at the knee and ankle.  A study examining 
the difference in gait parameters of normal children ambulating in shoes compared to barefoot 
walking found that all differences in shod kinematic data for the lower extremity joints remained 
within 5° of that for barefoot ambulation [71].   
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5.6.1.3 KAD Alignment  
Another factor potentially influencing joint kinematics was the placement of the knee 
alignment devices (KAD’s) used to correct the knee axis of rotation.  If the KAD is placed 
slightly anterior to the femoral epicondyle, additional knee flexion is introduced; posteriorly 
placed KAD’s introduce a knee extension bias and may result in knee hyperextension artifacts. 
Rotation of the KAD’s about the femoral epicondyles in the transverse plane may also introduce 
both coronal and sagittal plane knee kinematic errors [72]. KAD positioning errors also affect the 
pelvis angle [72], and in turn, the hip, knee and ankle angles. Due to the sensitivity of joint 
kinematics to KAD placement, extra care was taken with KAD placement during static trials. 
5.6.1.4 Treadmill Walking  
An additional procedural limitation was the inclusion of treadmill versus over ground 
ambulation.  While over ground ambulation may better approximate household and community 
ambulation, inclusion of multiple trials of level and non-level walking over ground would  likely 
have introduced subject fatigue (and/or reduced study power if less than 30 gait cycles per 
orientation were included).  The moving belt of the treadmill encourages the affected limb to keep 
pace with the unaffected limb, minimizing potential temporal asymmetry. To facilitate level and 
non-level walking, the treadmill was positioned on a wooden ramp; the increased height may 
have heightened a potential fear of falling, resulting in decreased walking speed and potentially 
increased knee or hip flexion and toe clearance. 
While treadmill ambulation can be justified to minimize potential subject fatigue, these 
subjects were not blinded to treadmill speed.  Most subjects opted to keep the same belt speed for 
all treadmill orientations (S2, S4, S5, S7, S8, S10) for a given treatment – thereby minimizing 
temporal differences between treadmill orientations.  Only one subject (S4) opted to keep the 
same belt speed for both treatments. 
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5.6.1.5 WalkAide Programming  
The small number of visits with the study affiliated PT or clinician in charge of 
WalkAide programming (minimum of 3 visits, 2 for initial programming and a third 1 week 
following initial programming) required of all study subjects may have adversely affected StR 
and consistency of stimulation timing. At the beginning of this study, subjects were only required 
to see the PT one week after the initial fitting. Additional visits with the PT were only scheduled 
upon the subject’s request; only one of these early subjects (S5) revisited the PT. As the study 
progressed, it was highly recommended that the subjects revisit the PT the week prior to the gait 
session; the last four subjects were compliant with this recommendation and revisited the PT 
before the gait session. These additional PT visits the week prior to gait analysis likely resulted in 
improved WalkAide programming and the resultant StR and consistency of stimulation timing. 
Three of the last four subjects demonstrated optimal StR’s (i.e. StR=1) for all treadmill 
orientations, confirming that these additional PT visits were beneficial. Therefore the StR and 
variability in stimulation timing for the first four study subjects were likely worst case scenarios. 
5.6.2 Sensors 
5.6.2.1 Skin Movement 
Joint kinematic data are also influenced by marker placement and skin movement. For all 
subjects except S4 and S6, the ASIS markers were referenced to markers on the lateral pelvis for 
more consistent viewing. While the lateral pelvis markers were placed so as to minimize skin 
movement, these markers were not placed on bony prominences and may be subject to increased 
movement errors. These potential movement artifacts also affect the subsequent pelvic orientation 
calculations and hip, knee and ankle joint kinematics as per the PlugInGait model. Such skin 
movement errors, however, are likely less than 4.2⁰ in the sagittal plane [73].  
165 
 
5.6.2.2 WalkAide Heel Sensor 
Errors in theoretical heel sensor-based stimulation timing may have been introduced due 
the WalkAide heel sensor itself.  This heel sensor (20 mm diameter) was smaller than the heel, 
and its position was not prescribed by the study PT.  The relative thickness of the sensor (~0.5 
mm) likely introduced plantar stress concentrations, resulting in potentially higher heel loading 
that was more easily detected. Sensor placement (and movement) errors may have affected 
theoretical heel sensor-based stimulation reliability and timing (maximum timing error estimated 
at 0.20 seconds based on F-scan heel sensor box sensitivity analysis for a single subject).  Further 
stimulation reliability and timing errors may have been introduced via the selected heel initiation 
and termination stimulation thresholds, although these errors are likely minimal as the thresholds 
were based upon review of several (3-4) level walking trials so as to minimize potential 
extraneous and/or missed stimulations. Heel sensor-based stimulation reliability and timing data 
based on clinical programming (stimulation initiation/termination thresholds, heel not tilt sensor-
based wait time, minimum/maximum stimulation duration) is recommended to minimize 
potential theoretical heel sensor-based programming errors.   
5.6.2.3 F-scan Insoles 
In the current study, theoretical heel sensor-based stimulation was based on F-scan data 
for subjects S7 and S8. Since the F-scan insole covered the full plantar surface, a 20 mm by 20 
mm box was used to approximate the WalkAide heel sensor (same box location for all treadmill 
trials). This heel box was positioned to encompass the region of peak heel loading (due to 
potential stress concentration due to concurrent placement on mal-functioning WalkAide heel 
sensor, 0.15 mm thick). While potential movement of the F-scan insole was likely minimal, 
potential movement of the mal-functioning WalkAide heel sensor may have occurred; such 
movement errors, however, were likely minimal as the heel box loading remained inclusive of 
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peak forces.  Both the timing and magnitude of the heel sensor loading was also influenced by the 
location of the F-scan heel sensor box, with a maximum error estimate of 0.20 seconds and 0.268 
psi (only 1.4% of the maximum F-scan heel sensor amplitude) based on F-scan sensitivity 
analysis results for a single subject.  
5.6.3 Data Acquisition  
5.6.3.1 Synchronization 
The WalkAide tilt sensor-based stimulation timing parameters, StI and StT, were based 
on the anterior tibialis surface EMG signal (1800 Hz).  As the WalkAide does not provide analog 
output, direct data acquisition of WalkAide stimulation data was not possible. Due to nerve 
conduction (54 m/s [74-75] and muscle conduction velocity (5 m/s [76]), stimulation timing 
delays of 19.7-29.5 msec assuming 0.33-0.5 m travel) may have been introduced to EMG-based 
stimulation timing estimates. Additional stimulation timing errors may be introduced due to the 
low pass filtering (zero-phase digital filter) and threshold detection algorithm.  These potential 
stimulation timing errors, however, were likely less than that which would have occurred if 
WalkAide stimulation data (acquired at 25 Hz) had been used.  
5.6.3.2 Sampling Rate 
Theoretical heel sensor-based stimulation timing estimates were likely affected by the 
modest WalkAide sampling rate (25 Hz, 40 msec sampling interval).  This sampling rate may 
have introduced theoretical stimulation timing errors of ± 40 msec. For subjects S7 and S8 for 
whom the theoretical heel sensor-based stimulation was based on F-scan data, potential 
stimulation timing errors were likely somewhat less as F-scan data were acquired at 50 Hz 
(sampling interval of 20 msec). 
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5.6.4 Signal Processing  
In addition to potential errors in heel strike and toe off event detection due to marker 
placement, additional event detection timing and kinematic errors may have been introduced due 
to digital filtering (Woltring filter) prior to event detection.   Such filtering, although strongly 
recommended prior to numerical differentiation so as to calculate heel and toe velocity, may have 
affected the location of velocity minima and maxima used in the event detection algorithm. The 
motion data were sampled at 120 Hz, so potential errors of 1-2 frames correspond to timing errors 
less than 17 msec.  
5.6.5 Proposed Study Modifications  
5.6.5.1 Enhanced Clinician Involvement 
 In the current study, only a single follow-up clinician visit was required for WalkAide 
programming adjustment; additional visits were encouraged based on subject perceived need.  A 
minimum of 3 visits with the clinician to review WalkAide programming is recommended, with 
one of these sessions to occur one week prior to scheduled gait analysis to optimize programming 
and minimize stimulation variability. 
In addition, it is recommended that the clinician attend the WalkAide gait analysis 
session to confirm WalkAide electrode/tilt sensor placement and programming during over 
ground ambulation.  The clinician might also program the WalkAide for heel sensor-based 
stimulation (setting the heel sensor stimulation initiation/termination thresholds, wait time, and 
minimum/maximum stimulation duration).  This clinical programming would ensure that 
theoretical heel sensor-based stimulation was more clinically appropriate, facilitating clinical 
comparison of the two WalkAide sensor stimulation control options. Subsequent acclimation to 
clinical heel sensor-based stimulation and a second WalkAide gait analysis session might also be 
incorporated.   
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5.6.5.2 Over Ground Versus Treadmill Ambulation 
Over ground walking may reveal temporal differences masked by treadmill ambulation. 
Over ground walking trials would also facilitate comparison of self-selected walking speed with 
the two treatment options, as well as potential acquisition of force plate data for kinetic analysis. 
Such over ground walking trials might augment treadmill walking trials, as treadmill walking 
maximizes the number of gait cycles acquired without introducing fatigue.  The self-selected 
walking speed determined during over ground walking can be used to select a proper treadmill 
walking speed for each subject for each respective treatment. 
The use of an instrumented split-belt treadmill (e.g. Bertec) for gait analysis maximizes 
the number of gait cycles (and study power), minimizes potential fatigue, and enables kinetic data 
acquisition to assess joint moment and power.  For any treadmill gait analyses, subjects should be 
blinded to treadmill speed.     
5.6.5.3 Subject Recruitment and Sample Population Size 
The final recommendation for future studies is to increase the study sample size. Based 
on power analyses, a minimum of 10 subjects is necessary to detect potentially significant 
differences in GA between treatments. Studies investigating toe clearance treatment effects 
should include at least 38 subjects. Similarly, studies contrasting temporal parameters between 
treatments during treadmill walking should include a minimum of 25 post-stroke subjects. 
5.7 FUTURE STUDY 
Based on the results of this study, two hypotheses are suggested for potential future 
study:   
1) Ankle power during PS increases during WalkAide versus AFO ambulation on both level 
and inclined surfaces. 
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Such a study requires kinetic data and might include over ground walking with force plates 
(risk of subject fatigue and limited power due to restricted gait cycles) or incorporate a 
kinetically-instrumented treadmill.  Kinetic analysis might also reveal differences in gait 
symmetry during PS (and LR) that were not apparent during kinematic analysis.  Note that 
as the need for active push-off is reduced for declined walking, declined walking trials need 
not be included. 
2) Clinically programmed WalkAide heel sensor- versus tilt sensor-based stimulation results in 
improved stimulation reliability and more consistent timing during both level and non-level 
walking.   
Clinical heel sensor-based programming requires setting the specific sensor stimulation 
initiation/termination thresholds, the wait time, and the minimum/maximum stimulation 
duration.  Alternatively, the stimulation reliability and timing of the clinically programmed 
WalkAide (tilt sensor) and Bioness (heel sensor), randomly selected, might be contrasted 
after 8 weeks of neuroprosthesis acclimation. 
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CHAPTER 6: CONCLUSION 
 A common gait impairment for stroke survivors is the inability to dorsiflex the ankle 
during swing causing the foot to drag along the floor (i.e. foot drop); approximately 20% of the 
stroke survivors suffer from foot drop. This impairment limits mobility, increases instability, and 
increases the individual’s risk of tripping and falling.  
Foot drop is traditionally treated with an ankle-foot-orthosis (AFO), a solid or articulated 
plastic brace which holds the ankle in a neutral position during swing, preventing the foot from 
dragging along the ground. An alternative treatment is the WalkAide, a neuroprosthesis which 
electrically stimulates the peroneal nerve to activate the dorsiflexors during swing. Without 
structural constraints, the neuroprosthesis may increase ankle range of motion and improve gait 
symmetry and efficacy on both level and non-level surfaces when compared to an AFO, 
enhancing a person’s mobility and safety inside and outside the home.  
 This study used gait analysis to quantify the differences in temporal (SR, gait SI) and 
kinematic (GA) gait symmetry and efficacy (toe clearance) of eight post-stroke individuals 
suffering from foot drop during level and non-level ambulation using a WalkAide and an AFO.  
The neuroprosthesis stimulation reliability and timing were also contrasted for two programming 
options (clinically programmed tilt sensor, theoretical heel sensor programming).  
Research Hypothesis 1: The use of a neuroprosthesis for post-stroke individuals with 
drop foot will improve temporal and kinematic gait symmetry, as well as treatment efficacy on 
both level and non-level surfaces compared to an AFO.  No statistically significant differences in 
temporal symmetry (SR or SI) were observed between treatments, partially refuting this 
hypothesis. Additionally, no differences in knee GA were observed.  Trends (not statistically 
significant) of greater ankle GA during MS and TS with the AFO versus the WalkAide were 
observed. Statistically significant differences in ankle GA during IS between treatments were 
observed, supporting this hypothesis.  Greater (not statistically significant) mean and minimum 
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ankle GA during IS was found for AFO ambulation (all treadmill orientations) when compared to 
the WalkAide.  Significantly greater affected limb toe clearance was observed during level and 
inclined AFO ambulation when compared with the WalkAide, contrary to this hypothesis. 
However, greater toe clearance symmetry was observed during WalkAide ambulation, partially 
supporting this hypothesis. 
Research Hypothesis 2: Non-level walking will adversely affect the WalkAide tilt sensor-
based stimulation reliability and timing.  No statistically significant differences in tilt sensor-
based stimulation reliability were observed between level and non-level walking trials. However, 
four of the eight subjects demonstrated missed/extraneous stimulations (SR ≠ 1) during non-level 
walking, partially supporting this hypothesis; only three of eight subjects demonstrated 
missed/extraneous stimulations during level walking. StI timing occurred significantly closer to 
swing as the treadmill processed from declined to inclined orientations; no statistically significant 
differences in StT timing were observed between level and non-level walking. Although the 
observed changes in StI with level versus non-level ambulation support this hypothesis, these 
changes may be beneficial as StI closer to swing during inclined ambulation may allow for 
greater ankle plantar flexion during PS. 
Research Hypothesis 3: heel sensor versus tilt sensor stimulation control will improve 
stimulation reliability and exhibit more consistent stimulation timing during non-level 
ambulation.   No statistically significant differences stimulation reliability or timing were 
observed between tilt and theoretical heel sensor-based stimulation programming. However, more 
subjects (6/8) demonstrated optimal StR with theoretical heel sensor-based programming, 
supporting but not confirming this hypothesis. Stimulation variability decreased (not statistically 
significant) with the heel sensor-based stimulation, again supporting but not confirming this 
hypothesis. 
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Based on the current study, post-stroke individuals may exhibit increased kinematic ankle 
symmetry and possibly increased gait efficacy (toe clearance symmetry) during level and non-
level community ambulation with a WalkAide instead of an AFO. For post-stroke individuals 
who are household ambulators only and/or demonstrate an inconsistent gait pattern, an AFO is 
likely sufficient to minimize foot drop.  Heel sensor-based programming may provide more 
reliable and consistent dorsiflexion stimulation than tilt sensor-based programming. Additional 
clinical programming sessions may be required to allow increased plantar flexion needed during 
inclined walking. Community ambulators who commonly encounter inclines may benefit from tilt 
sensor-based stimulation. 
The current study also introduced a new measure to assess kinematic asymmetry (GA). 
Unlike previous measures of gait symmetry, SR or SI, the new GA measure also accounts for 
differences in kinematic motion sign (e.g. dorsiflexion versus plantar flexion). Since this measure 
normalizes the difference between limbs by the affected limb joint ROM, it facilitates comparison 
between subjects and joints.  This new GA measure provides a potentially valuable option for 
future comparisons of kinematic asymmetry due to different treatments and/or pathologies.  
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APPENDIX A: Fugl-Meyer Assessment Tasks (adapted from [50]) 
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APPENDIX B: GA for all phases of the gait cycle (swing and stance) 
  
  
  
Figure B1: GA of knee motion for all functional gait phases of all subjects during decline (top), level (middle), and inclined (bottom) 
treadmill walking. 
+, ++ denotes a statistically significant difference (0.05 and 0.01 levels, respectively) 
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Figure B2: GA of ankle motion for all functional gait phases of all subjects during decline (top), level (middle), and inclined (bottom) 
treadmill walking. 
+, ++ denotes a statistically significant difference (0.05 and 0.01 levels, respectively) 
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APPENDIX C: Individual ankle GA during IS, MS, and TS 
 
MS mean knee motion: 
 
 
 
Figure C1: Individual GA for mean knee motion during MS contrasting treatments for 
declined (top), level (middle), and inclined (bottom) walking. 
+, ++ denotes a statistically significant difference (0.05 and 0.01 levels, respectively) 
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TS mean knee motion: 
 
 
 
 
Figure C2: Individual GA for mean knee motion during TS contrasting treatments for 
declined (top), level (middle), and inclined (bottom) walking. 
+, ++ denotes a statistically significant difference (0.05 and 0.01 levels, respectively) 
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IS minimum and mean ankle motion: 
 
 
 
Figure C3: Individual GA for minimum ankle motion during IS contrasting treatments for 
declined (top), level (middle), and inclined (bottom) walking. 
+, ++ denotes a statistically significant difference (0.05 and 0.01 levels, respectively) 
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Figure C4: Individual GA for mean ankle motion during IS contrasting treatments for 
declined (top), level (middle), and inclined (bottom) walking. 
+, ++ denotes a statistically significant difference (0.05 and 0.01 levels, respectively) 
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MS mean and maximum ankle motion:  
 
 
 
Figure C5: Individual GA for mean ankle motion during MS contrasting treatments for 
declined (top), level (middle), and inclined (bottom) walking. 
+, ++ denotes a statistically significant difference (0.05 and 0.01 levels, respectively) 
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Figure C6: Individual GA for maximum ankle motion during MS contrasting treatments 
for declined (top), level (middle), and inclined (bottom) walking. 
+, ++ denotes a statistically significant difference (0.05 and 0.01 levels, respectively) 
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TS mean and maximum ankle motion:  
 
 
 
Figure C7: Individual GA for mean ankle motion during TS contrasting treatments for 
declined (top), level (middle), and inclined (bottom) walking. 
+, ++ denotes a statistically significant difference (0.05 and 0.01 levels, respectively) 
0
10
20
30
40
50
60
70
S2 S4 S5 S6 S7 S8 S1
0
S1
2 Al
l
Si
x
M
ea
n 
A
nk
le
 G
A
 
WalkAide AFO
0
20
40
60
80
100
120
140
S2 S4 S5 S6 S7 S8 S1
0
S1
2 Al
l
Si
x
M
ea
n 
A
nk
le
 G
A
 
WalkAide AFO
0
10
20
30
40
50
60
70
80
90
S2 S4 S5 S6 S7 S8 S1
0
S1
2 Al
l
Si
x
M
ea
n 
A
nk
le
 G
A
 
WalkAide AFO
Decline 
 
 
 
 
 
 
 
Level 
 
 
 
 
 
 
 
Incline 
187 
 
 
 
Figure C8: Individual GA for maximum ankle motion during TS contrasting treatments for 
declined (top), level (middle), and inclined (bottom) walking. 
+, ++ denotes a statistically significant difference (0.05 and 0.01 levels, respectively 
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APPENDIX D: F-scan insole versus WalkAide heel sensor 
 
 
 
Figure D1: Maximum (top) and mean (bottom) F-scan heel box plantar pressure versus 
WalkAide heel sensor loading data. 
 
Figure D2: F-scan heel load duration versus WalkAide heel sensor load duration. 
 
Figure D3: F-scan unloaded heel duration versus WalkAide heel sensor unloading duration. 
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